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Colorectal cancer (CRC) is currently the most prevalent malignancy in 
developed countries, accounting for over half a million deaths annually. The high 
mortality of CRC is largely due to late diagnosis and the lack of effective adjunctive 
treatment and preventive chemotherapeutics. Butyrate, a short-chain fatty acid 
produced during colonic bacteria fermentation of dietary fibre, has been shown to 
protect against CRC by inducing growth arrest, differentiation and apoptosis of cancer 
cells. In addition to regulating gene expression through its histone deacetylase 
inhibitor (HDACi) activities, butyrate has also been shown to directly affect the 
energy metabolism and apoptotic resistance in cancer cells. 
The mitochondrion has been shown to be a crucial player in the anti-neoplastic 
effects of butyrate, but the precise molecular pathways remain unclear. To determine 
the direct biochemical effects of butyrate on the mitochondria of colon cancer cells, 
we used a sub-proteomics approach to study the differential expression of 
mitochondrial proteins in HCT-116 human CRC cells treated with 5mM butyrate for 
24 hours. To accomplish this, mitochondrial fractions of the untreated and butyrate-
treated samples were compared by 2-dimensional difference gel electrophoresis (2-D 
DIGE). Subsequent tandem mass spectrometry (MS/MS) analysis identified 28 
butyrate-regulated proteins, out of which 18 were found to have mitochondrial 
functions based on published literature. These proteins include metabolic and redox 
enzymes; regulators of protein import, folding and assembly in the organelle; 
components of the mitochondrial translational apparatus; subunits of various 
respiratory complexes; as well as translocated proteins involved in apoptosis and cell 
death. This supports the association of the protective effects of butyrate with its 
biochemical effects on the mitochondria of cancer cells. 





In particular, one of the mitochondrial proteins found to be significantly down-
regulated by butyrate, was the mitochondrial heat shock protein 70 (mthsp70), which 
is also known as mortalin. This protein was recently reported to be overexpressed in 
colorectal adenocarcinomas and positively correlated with poor prognosis in CRC. 
The down-regulation of mortalin by the anti-cancer agent, butyrate, could be an 
important mechanism of chemoprotection by the latter.  
Using immunoassays, we characterised 5 mortalin isoforms (a, b, c, d, and e) 
and their specific regulation by butyrate, in the whole cell lysate and various 
subcellular fractions of HCT 116 cells. Most interestingly, two mortalin isoforms, d 
and e, were found to be significantly suppressed by butyrate in both the mitochondrial 
and nuclear fractions, but up-regulated in the whole cell lysate upon prolonged 
butyrate treatment. In addition, isoform d was found to be present specifically in the 
floating, apoptotic cell population of 72-hr butyrate-treated HCT 116 cells, further 
indicating the association between this mortalin isoform with butyrate-induced 
apoptosis. Furthermore, we also showed that these two mortalin isoforms were 
expressed in much lower levels in the subcellular fractions of HT-29 cells, a relatively 
more butyrate-resistant CRC cell line. This resulted in a different expression profile of 
mortalin upon butyrate perturbation. Hence, we suggest that the various mortalin 
isoforms may serve different functions in determining the susceptibility of CRC cells 
to butyrate treatment. 
 (495 words) 





LIST OF TABLES 
 
 
TABLE  PAGE 
1.1 Five-year survival for CRC according to the TNM stages 3 
3.1 Summary of protein spots identified in HCT 116 mitochondrial fraction 63 
3.2 List of mitochondrial proteins identified in HCT 116 mitochondrial fraction 64 
3.3 
Differentially expressed HCT 116 mitochondrial fraction proteins 
upon butyrate treatment, detected by DIGE, identified by MALDI-
TOF/TOF MS 
73 
3.4 Found or predicted phosphorylation sites by NetPhos, Scansite and 
recent literature 90 
3.5 Summary of the subcellular expression and butyrate regulation of 




































LIST OF FIGURES 
 
 
Figure.  PAGE 
1.1 Global and local rates of incidence and mortality of CRC. 2 
1.2 Molecular changes underlying the CRC carcinogenesis through ACS. 8 
1.3 Butyrate ion and its role as a SCFA in healthy colonic homeostasis. 16 
1.4 Regulation of gene transcription by chromatin modifications through the activities of HATs and HDACs. 18 
1.5 The HDAC family in humans. 21 
1.6 HDACi effects of butyrate on histone and non-histone proteins. 22 
1.7 Mechanisms of MOMP proposed by current literature. 29 
3.1 1-DE profile of whole cell lysates and mitochondrial fractions; and immunodetection of mitochondrial marker enrichment. 58 
3.2 DIGE comparison of the proteomes of HCT 116 crude whole cell lysate 
and mitochondria-enriched fraction. 61 
3.3 Mitochondrial proteins identified from the silver-stained 2-DE gel of HCT 116 mitochondria-enriched fraction. 62 
3.4 
Graph showing the subcellular distribution of the unique proteins 
identified through the preliminary survey of the HCT 116 mitochondrial 
fraction. 
63 
3.5  Rapid assessment of reproducibility among 3 independent harvestings. 67 
3.6 Representative 2-D DIGE image of control and butyrate-treated 
mitochondrial fractions of HCT 116 cells. 69 
3.7 Butyrate regulation of well-characterised mitochondrial proteins in HCT 116 mitochondrial fraction. 71 
3.8 Other butyrate-regulated proteins in HCT 116 mitochondrial fraction. 72 
3.9 2-DE profile of mortalin isoforms in HCT 116 whole cell lysate. 79 
3.10 2-DE profile of mortalin isoforms in HCT 116 mitochondrial fraction. 81 
3.11 Enrichment of mortalin isoforms and presence of additional isoforms in HCT 116 mitochondrial fraction, relative to whole cell lysate. 82 
3.12 Butyrate effects on the 2-DE profile of mortalin isoforms in HCT 116 
whole cell lysates. 84 





3.13 Butyrate effects on the 2-DE profile of mortalin isoforms in HCT 116 
mitochondrial fractions. 87 
3.14 In silico prediction of phosphorylation sites in mortalin protein 
sequence (UniProt accession no. P38646). 89 
3.15 Subcellular distribution of mortalin and its regulation by 24-hr butyrate treatment in HCT 116 cells. 92 
3.16 Expression of mortalin in HCT 116 nuclear and cytosolic fractions upon 24-hr butyrate treatment. 94 
3.17 Subcellular distribution of mortalin and its regulation by 24-hr butyrate treatment in HT-29 cells. 97 
3.18 Expression of mortalin in HT-29 whole-cell and subcellular fractions 
upon 24-hr butyrate treatment. 100 
4.1 Glutamate production by OAT and P5CDH. 110 
4.2 Summary of the multiple subcellular sites, binding partners and functions of mortalin. 119 
5.1 Summary of butyrate’s effects in HCT 116 mitochondrial proteome. 137 
 





ABBREVIATIONS AND SYMBOLS 
 
~ Approximately 
∆ψm Mitochondrial transmembrane potential 
1-D  One-dimensional 
2-DE Two-dimensional electrophoresis 
2-D DIGE Two-dimensional difference gel electrophoresis 
5AZA-dC 5-Aza-2’ deoxycytidine 
AAA ATPases associated with a number of cellular activities 
AJCC American Joint Committee on Cancer (AJCC) 
Acc. No. Accession number 
ACS Adenoma-carcinoma sequence 
ACN Acetonitrile 
AD Alzheimer’s Disease 
ANT Adenine-nucleotide translocase 
APC Adenomatous polyposis coli 
APOE Apolipoprotein E 
ATM Ataxia telangiectasia mutated 
ATP Adenosine triphosphate 
ATR ATM and Rad3-related 
Av. Ratio Average volume ratio 
Bcl-2 B-cell lymphoma 2 
BH3-only BH3 domains-only (proteins) 
BSA Bovine serum albumin 
CB Cathepsin B 
CDK Cyclin dependent kinase 
cDNA Complementary DNA 
CEA Carcinoembryonic antigen 
CHAPS 3-[(3-cholamidopropyl)dimethylammonio ]-2-hydroxy-1-propanesulfonate 





CHCA α-cyano-4-hydroxy-cinnamic acid 
CHIP Carboxyl terminus of Hsc70-Interactin protein with ubiquitous E3-ligase activity 
CIN Chromosomal instability 
Cl Chloride 
CoA Coenzyme A 
COX 2 Cyclooxygenase-2 
CRC Colorectal cancer 
CXCR C-X-C chemokine receptor 
CyDye Cyanine fluorescent dye 
cyt c Cytochrome c 
Da Dalton 
DCC Deleted in colon cancer (gene) 
DNA Deoxyribonucleic acid 
DTT Dithiothreitol 
E2F Elongation 2 factor 
EDTA Ethylenediaminetetraacetic acid 
EGFR Epidermal growth factor receptor 
EPIC European Prospective Investigation into Cancer and Nutrition 
ER Endoplasmic reticulum 
FADH Flavin adenine dinucleotide 
FAP Familial adenomatous polyposis 
FBS Fetal bovine serum 
FDA Food and Drug Administration 
g  Centrifugal force 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
GI Gastrointestinal 
GRP  Glucose-regulated protein  
GSH Glutathione 





H+ Hydrogen ion/ proton 
H2O2 Hydrogen peroxide 
HAT Histone acetyltransferase 
HCl Hydrochloric acid 
HDAC Histone deacetylase 
HDACi Histone deacetylase inhibitor 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HIF Hypoxia-inducible factor 
hmot Human mortalin 
HNPCC Hereditary nonpolyposis colon carcinoma 
hnRNP Heterogeneous ribonuclear protein 
hr Hour(s) 
HRP Horse radish peroxidase 
Hsp70 70-kD heat shock protein 
IAA Iodoacetamide 
ICAM Intracellular adhesion molecule 
ICAT Isotope-coded affinity tag 
id Identities 
IEF Isoelectric focusing 
IL Interleukin 
IM Inner (mitochondrial) membrane 
IPG Immobilized pH gradient 
LC-MS Liquid chromatography-mass spectrometry 
MALDI-
TOF/TOF MS 
Matrix-assisted laser desorption/ionization-tandem time-of-flight mass 
spectrometry 
MCC Mutated in colon cancer (gene) 
MCT Monocarboxylate transporters 
Met-Ox Methionine oxidation 
MHC Major histocompatibility complex 






MIN Microsatellite instability 
MMP Matrix metalloproteinase 
MMR Mismatch repair (genes) 
mot(-1 or -2) Mouse mortalin (variant 1 or 2) 
MOWSE Molecular Weight Search 
MOMP Mitochondrial outer membrane permeabilisation 
MPD Melavonate pyruvate decarboxylase 
Mr Molecular mass 
mRNA Messenger RNA 
MS Mass spectrometry 
MS/MS Tandem mass spectrometry 
mtDNA Mitochondrial DNA 
MTHFR Methylenetetrahydrofolate reductase 
mthsp70 Mitochondrial heat shock protein 70 
MW Molecular weight 
N’-acetyl N-terminal acetylation 
Na Sodium 
NaB Sodium butyrate 
NADH Nicotinamide adenine dinucleotide 
NCBI/nr National Center of Biotechnology Information non-redundant database 
nDNA Nuclear DNA 
NF-κB Nuclear factor-κB 
NH4HCO3 Ammonium bicarbonate 
NL Non-linear 
NSAID Nonsteriodal anti-inflammatory drugs 
OAT Ornithine Aminotransferase 
OM Outer (mitochondrial) membrane 





OXPHOS Oxidative phosphorylation 
P5CDH Delta-1-pyrroline-5-carboxylate dehydrogenase 
PBP Peptide-binding protein  
PBR Benzodiazepine receptor 
PBS Phosphate buffered saline 
PD Parkinson’s disease 
PDH Pyruvate dehydrogenase 
pI   Isoelectric point 
PKC Protein kinase C 
pmol Pico-mole (10-12) 
pRb Retinoblastoma protein 
pSer Phosphorylated serine residue 
psi Pounds per square inch 
pThr Phosphorylated threonine residue 
PTM Post-translational modification 
PTP Permeability transition pore 
pTyr Phosphorylated tyrosine residue 
ROS Reactive oxygen species 
RNA Ribonucleic acid 
rpm  Revolutions per minute 
RT PCR Reverse transciptase polymerase chain reaction 
SCFA Short chain fatty acid 
SDS-PAGE sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
Ser/Thr-phos Serine/Threonine phosphorylation 
SIPS Stress-induced prematire senescence 
siRNA Small interfering RNA 
STAT Signal Transducers and Activator of Transcription  
T Tween (for PBS-T and TBS-T) 





TBS Tris buffered saline 
TCA Tricarboxylic acid cycle 
TF Transcription factor 
TFA Trifluoroacetic acid 
TFC Transcription factor complex 
TIM Translocase of inner (mitochondrial) membrane 
TNF-α Tumour necrosis factor-α 
TNM Tumor, lymph node, distant metastasis 
TOM Translocase of outer (mitochondrial) membrane 
Tris tris(hydroxymethyl)aminomethane 
UniProt Universal Protein Resorce database (http://www.expasy.uniprot.org) 
UTR Untranslated region 
v/v Volume per volume 
VDAC Voltage-dependent anion channel 
w/v Weight per volume 
 
Introduction 




1.1. COLORECTAL CANCER (CRC) 
1.1.1. Epidemiology 
Colorectal cancer (CRC) forms in the tissues of the colon and rectum, and is 
currently the third most common cancer worldwide, ranking after lung and breast 
cancers (Kamangar et al., 2006). This malignancy alone accounts for over a million 
new cancer cases and over 500,000 cancer deaths annually (Figure 1.1). Its incidence 
concentrates in the developed countries, including North America, Australia, Western 
Europe and Japan, and generally increases with the mean age of the population 
(Parkin et al., 2005). The number of CRC cases in Singapore has tripled over the past 
two decades, making CRC the most prevalent cancer in the local population. On 
average, one in every 20 Singaporeans will suffer CRC in his/her lifetime. This risk is 
age-dependent, and will rise steeply beyond the age of 50 (Seow et al., 2004). In view 
of the aging population problem in Singapore, the prevention and clinical 
management of CRC stand out as critical healthcare issues for the nation. 
CRC develops through a number of well-characterized stages based on the 
degree of invasion which is the single most important determinant for survival at the 
point of diagnosis. The American Joint Committee on Cancer (AJCC) uses the TMN 
classification which stages CRC by the extent of wall invasion, nodal involvement 
and the presence of distant metastases (Table 1.1). When the cancer remains confined 
to the bowel wall (Stage I: T1-2; N0; M0), treatment is essentially curative with 5-
year survival rates of 90% or more. However, 50% of CRC patients normally present 
late (Rougier and Mitry, 2003). These patients usually succumb to tumour metastasis 
to distant organs within one year of diagnosis with a median survival not exceeding 
18 months, in spite of treatment (Ragnhammar et al., 2001; Serrano et al., 2004). 
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Figure 1.1: Global and local rates of incidence and mortality of CRC. 
Clockwise from top left corner: Worldwide annual number of cancer cases (dark brown bars) and 
deaths (pink bars) (Kamangar et al., 2006); picture of colon and rectum (from National Cancer 
Institute website: www.cancer.gov); CRC incidence (blue square) and death toll (red square) in 
Singapore (adapted from The Strait Times, Dec 9, 2004). 
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Table 1.1: Five-year survival for CRC according to the TNM stages 
Tumor (T) 
0 None evident 
Is In situ (limited to mucosa) 
1 Invasion of submucosa 
2 Invasion of muscularis propria 
3 Invasion of subserosa or nonperitonealized pericolic fat 
4 Invasion of contiguous structures 
Lymph Nodes (N) 
0 None evident 
1 1 to 3 positive pericolic nodes 
2 4 or more positive pericolic nodes 
3 Any positive node along a named blood vessel 
Distant Metastasis (M) 
0 None evident 
1 Any distant metastasis 
5-Year Survival Rates (%) 
Stage I T1   97 
 T2   90 
Stage II T3   78 
 T4   63 
Stage III Any T N1 M0 66 
 Any T N2 M0 37 
 Any T N3 M0 Data not avaliable 
Stage IV Any T Any N M1 4 
(Adapted from Crawford and Kumar, 2003) 
 
1.1.2.  Limits of current CRC diagnosis methods 
Approximately 90% of CRCs originate from benign polyps which are 
outgrowths of the colonic inner wall. These precancerous lesions, or adenomas, are 
estimated to take 5–15 years to evolve into invasive cancer (Watson, 2006). 
Substantial epidemiological and clinical trial data suggest that early detection and 
removal of these premalignant tumors can effectively prevent CRC (Winawer, 2005). 
Unfortunately, the development of these adenomas is largely asymptomatic thus 
requiring large-scale population screening procedures for detection. 
The current diagnostic methods are either limited in reliability—such as digital 
rectum examination, faecal occult blood test, and computed tomographic 
colonography; or invasive in nature—in the instances of double-contrast barium 
enema, flexible sigmoidoscopy, and colonoscopy. Screening for early-cancer 
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molecular markers in serum and stool samples represents a more efficient, and less 
uncomfortable, approach to regular screening (Osborn and Ahlquist, 2005). However, 
the search for robust diagnostic and risk markers is still in its infancy. The current 
serum marker of the disease, carcinoembryonic antigen (CEA), is low in sensitivity 
and specificity, and of little diagnostic value (Kahlenberg, et al. 2003).  
1.1.3.  Limits of current CRC treatment 
The first choice of treatment for CRC is surgical resection, involving wide 
resection of the affected colon segment, with at least 5 cm of normal bowel on either 
side of the tumor, along with its regional lymphatics and associated blood supply. 
End-to-end anastomosis is then performed, if possible, to rejoin the colon (Leong et 
al., 2004). Through this, over 90% of patients diagnosed at Stage I, may be cured, 
while majority of the patients with mestatasis at Stage III and IV, would die of disease 
relapse within five years of operation (Rougier & Mitry, 2003). Adjuvant 
chemotherapy with cytotoxic agents can be given postoperatively to decrease chances 
of recurrence and improve disease-free survival in Stage III patients, but only as 
palliative care for Stage IV patients. The mainstay for first-line chemotherapy is 5-
fluorouracil (Leong et al., 2004), which however can cause adverse effects of 
gastrointestinal (GI) epithelial damage, myelotoxicity, anaemia and cerebellar 
disturbances (Rang et al., 2003). 
The problems of emerging drug resistance in the rapidly evolving cancer cells, 
adverse side effects and poor prognosis of patients with advanced cancer, underscore 
the pressing need for novel therapeutic agents with higher efficacy and specificity. In 
recent years, studies on CRC-associated proteins has led to two new antibody 
therapeutics, Cetuximab (Erbitux) and Bevacizumab (Avastin), approved by the Food 
and Drug Administration (FDA) in recent years. These can prolong survival of 
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advanced CRC patients by around 5 months, in the hope that even better drugs may 
come along to help them (Ross, et al. 2004). 
1.1.4.  Grounds for modern cancer research 
The worldwide prevalence and fatality associated with CRC have driven the 
search of new technologies and treatment regimens to enable earlier diagnosis and 
higher survival rate of CRC patients. The current challenges in CRC cancer research 
can be summarised as follows:- 
(i) The search for early biomarkers, which are also more sensitive and specific, 
for the rapid diagnosis and subsequent prognosis of the disease. 
(ii) The discovery and optimisation of new chemotherapeutic drugs in the 
effective treatment of CRC with minimum side effects. 
(iii) The better classification of various sub-types of CRC, so as to administer the 
most effective therapy without inducing drug resistance in the rapidly evolving 
cancer cells. 
These converge in the newly emerging medical paradigm of “targeted 
therapies”—newly designed anti-cancer drugs which specifically target a 
macromolecule, usually a protein, found to be especially crucial to the cancer 
phenotype, but not the surrounding healthy tissues (Ross et al., 2004). The optimal 
cancer drug targets usually differ among various sub-types of the same cancer 
resulting in different degrees of tumour response to the same treatment (Igney and 
Krammer, 2002). Hence, the key to targeted therapy is customisation of treatment, 
where a diagnostic test would be performed prior to the administration of a drug, to 
consider the eligibility of the patient to receive the drug. An example of targeted 
therapy is Cetuximab, a blocker of the epidermal growth factor receptor (EGFR), 
initially developed to specifically treat EGFR overexpressing metastatic CRC (Ross et 
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al., 2004). This represents an early attempt in personalised medical care for cancer 
patients where the selection, dosage and route of administration of exisiting and new 
therapeutic agents would be tailor-made to enhance the recovery and quality of life of 
the individual. Such ideal forms of cancer therapy rely heavily on understanding the 
molecular mechanisms involved in carcinogenesis and the mechanism(s) of action of 
effective chemotherapeutic agents. 
1.1.5. Early cellular events in CRC carcinogenesis 
The intestinal epithelium is a rapidly renewing tissue in which cell homeostasis 
is regulated by a balance between proliferation, growth arrest, differentiation and 
apoptosis. Tumourigenesis is inititated upon the escape of the normal cell cycle 
controls, either through the over-proliferation of a mutated stem cell or the failure of 
damaged cells to undergo apoptosis (Potten et al., 1997). 
CRC develops through a multistage process phenotypically and genetically, 
commonly termed the adenoma-carcinoma sequence (ACS) (Figure 1.2) (Fearon and 
Vogelstein, 1990). In this sequence, the earliest identifiable lesion is an aberrant crypt 
focus which is dysplastic, usually containing mutations of the tumour suppressor gene 
adenomatous polyposis coli (APC) (Renehan et al., 2002). This expands over time to 
form macroscopically visible adenomatous polyps that transit from benign (adenoma) 
to early malignant growth (adenocarcinoma) which gains invasiveness, and progresses 
to form carcinoma and secondary metastases over time (Radtke and Clevers, 2005). 
Unfortunately, overtly invasive carcinomas are often the first clinical presentation of 
CRC. 
The Vogelstein’s genetic model proposes three prerequisites for the adenoma-
carcioma sequence: (i) CRC tumours arise from the mutational activation of 
oncogenes coupled with the mutational inactivation of tumour suppressor genes; (ii) 
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multiple gene mutations are required to produce malignancies; and (iii) genetic 
alterations may occur in a preferred sequence, but the accumulative effects of these 
mutations rather than order determines the clinical stage of the tumour (Fearon and 
Vogelstein, 1990). Hanahan and Weinberg (2000) further listed the essential 
characteristics the accumulated mutations must endow, in order for the cell to 
“succeed” in becoming cancerous: self-sufficiency in growth signals, insensitivity to 
growth-inhibitory signals, evasion of apoptosis, unlimited replicative potential, 
sustained angiogenesis, as well as tissue invasion and metastasis. In other words, for a 
pre-cancerous clone to succeed in achieving full-blown malignancy, it must acquire 
genomic instability which then dramatically accelerates the accumulation of strategic 



































1.1.6. Genetic models of CRC carcinogenesis 
About 5-10% of CRC cases are inherited in an autosomal-dominant fashion. 
Two distinct pathways of CRC development have been delineated through these 
hereditary models whose genetic changes also mirror those of the remaining 80-90% 
sporadic cancer (Fearon and Vogelstein, 1990).  
1.1.6.1.Chromosomal instability (CIN)  pathway 
Approximately 70-85% of CRCs develop via the more common CIN pathway 
and are distributed mostly in the distal colon. These are typically characterised by 
chromosomal translocations and aneuploidy. This phenomenon was discovered 
Figure 1.2: Molecular changes underlying the CRC carcinogenesis through ACS. 
Frequently targeted genes shown are K-ras; p53; APC; DCC; and MCC (adapted from Pandha and 
Sikora, 1997). 
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through the subset of hereditary CRC represented by familial adenomatous polyposis 
(FAP). FAP patients carry a germline mutation in one APC gene copy and, as a result, 
develop numerous adenomatous polyps in their colon which invariably progress into 
CRC around the age of 40 (Radtke and Clevers, 2005). Genetic lesions commonly 
implicated in the pathogenesis of CRC via CIN are mutation in APC or loss of 5q 
(APC gene), mutation of K-ras proto-oncogene, loss of 18q (where the deleted in 
colon cancer gene, DCC, resides), and lastly, deletion of 17p (which contains the 
important tumour suppressor p53 gene) (Figure 1.2). Not all CRCs possess the full 
complement of these genetic aberrations, as they may be bypassed by other genetic 
disruptions such as those in tumour suppressor genes mutated in colon cancer (MCC) 
and proto-oncogenes like B-cell lymphoma 2 (Bcl-2) (Worthley et al., 2007). 
1.1.6.2.  Microsatellite instability (MIN) pathway 
The other pathway of CRC development is less common (only in 20% CRCs) 
and exemplified by hereditary nonpolyposis colon carcinoma (HNPCC), or Lynch 
syndrome. This is characterised by diploid tumor cells with widespread microsatellite 
instability (repeats of short DNA sequences)—the hallmark of the MIN pathway. 60% 
of these cases are accounted by germline mutations in DNA mismatch repair genes 
(MMR), such as MSH2 and MLH1 (Worthley et al., 2007). Sporadic MIN tumours are 
almost exclusively found in the proximal colon, while the tumours in HNPCC are 
usually more evenly distributed. 
Besides oncogenes and tumour suppressor genes, a third class of cancer genes 
constitutes the stability genes or caretakers of genome integrity (Sieber et al., 2003). 
MMR belong to this gene class and function by removing nucleotides mispaired by 
DNA polymerases and insertion/deletion loops during
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MSH2 and MLH1 dramatically increase mutation rates with the accumulation of 
multiple different sized alleles as typified by MIN (Hoeijmakers, 2001). 
1.1.7.  Epigenetic pathway of CRC carcinogenesis via methylation 
Epigenetic changes refer to reversible heritable changes in gene function that 
occur without a change in the sequence, such as the silencing of genes via DNA 
methylation.  This happens via the action of DNA methyltransferases at cytosine 
bases of CpG sites (regions of DNA where a cytosine nucleotide occurs next to a 
guanine nucleotide) and is followed by the association of methyl-CpG binding 
proteins to the DNA. Subsequently, histone deacetylases (HDAC) and histone 
methyltransferases cause deacetylation and methylation of the associated histones, 
respectively. These post-translational modifications (PTMs) of histones then result in 
chromatin remodeling—the alteration in chromatin structure that affects the nuclease 
sensitivity of a region of chromatin. Such changes would then render the associated 
stretch of gene sequence inaccessible to transcription factors (TFs) and other 
regulators, thus shutting down the gene (Alberts et al., 2002).  
Although DNA methylation occurs naturally throughout the genome as in the 
case of genomic imprinting, the aberrant methylation of specific promoter sequences 
of tumor suppressor and caretaker genes can lead to pathologies like cancer. In CRC, 
genes commonly found inactivated via DNA methylation, include the MMR gene, 
MLH1, and cyclin dependent kinase (CDK) inhibitor gene, p16/INK4A (Worthley et 
al., 2007). It is also common for global DNA hypomethylation to happen via the non-
specific loss of 5-methylcytosine content in tumour cells, in turn promoting genomic 
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1.1.8. Risk factors of CRC 
Approximately 80-90% of CRC cases are sporadic in origin, most of which 
are characterised by somatic mutations of the APC gene and typically develop in the 
ACS (Figure 1.2). The complete process can take 10 to 15 years or more. During this 
period, the interplay of environmental factors and genetic susceptibility of the 
individual can potentially promote or abort carcinogenesis. Moreover, the colonic 
mucosa is constantly in contact with the bulk of indigestible food, intestinal 
microflora, bile salts and other chemicals in the intestinal lumen and thus, highly 
susceptible to perturbations of these contents. In fact, mucosal damage upon exposure 
to ingested carcinogens, pro-inflammatory molecules as well as toxic by-products of 
bacterial metabolism can directly result in carcinogenic mutations (Heavey and 
Rowland, 2004). 
1.1.8.1. Genetic risk factors 
Just like other forms of cancer, a positive family history of CRC and 
inflammatory bowel diseases has been closely associated with the lifetime occurrence 
of CRC in healthy individuals (Heavey et al., 2004). Besides the hallmark genes in 
hereditary CRC, there are polymorphic variants of certain enzymes, such as 
methylenetetrahydrofolate reductase (MTHFR) and N-acetyltransferases, which when 
coupled to other environmental risk factors, can render an individual more susceptible 
to CRC (Heavey et al., 2004). Adding to these, certain genetic syndromes also 
indirectly predispose a person to CRC via the phenotypes they impose. For example, 
substantial evidence indicates that hyperinsulinemia in obese people, or diabetic 
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1.1.8.2. Environmental risk factors 
Epidemiological findings have often labeled CRC as an “environmental 
disease” because 70-80% of CRC cases owe their appearance to culture and social 
practices of the affluent and industrialized nations (Boyle and Langman, 2000). These 
include a diet rich in fat and red meat, low intake of fibre, smoking, sedentary 
lifestyle, high body mass index, as well as, alcoholism. On the other hand, protective 
factors that can potentially prevent CRC have been identified to include vegetables, 
calcium, hormone replacement therapy, folate, nonsteriodal anti-inflammatory drugs 
(NSAIDs) and physical activity (Heavey et al., 2004). 
1.1.8.3. Chemopreventive role of dietary fibre 
Since prevention is better than cure, these findings raise the possibilities of 
lifestyle correction and dietary intervention as modes of CRC prevention. 
Chemoprevention is a fairly new paradigm in the clinical arsenal raised against 
cancer. Gustin and Brenner (2002) broadly defined it as the use of natural or synthetic 
compounds to block, reverse, and delay or prevent the development of invasive 
neoplasms. This modulation of cancer risk is often subtly effected through the cell 
metabolism consequently perturbing fundamental pathways on which the critical 
balance between apoptosis and cell proliferation is tilted. In contrast to cytotoxic 
chemotherapy, this therapy is usually longer-term and needs to be relatively free of 
side effects (Greenwald, 1996). Recent progress in this field focuses on the use of 
NSAIDs, like aspirin and celecoxib (a cyclooxygenase-2, COX 2, inhibitor, 
commercially named Vioxx), to treat CRC (Kohli et al., 2004). However, these drugs 
fail to fulfill the safety criteria: aspirin causes gastric bleeding, while Vioxx has been 
retracted for increasing cardiovascular disease risk. 
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On the other hand, dietary fibre attracted the most widespread attention as a 
natural and convenient prophylactic agent to lower the incidence of CRC. Recently 
the European Prospective Investigation into Cancer and Nutrition (EPIC) study, 
involving 520,000 participants from 10 European countries presented compelling 
evidence that a doubling of dietary fibre intake could actually reduce the risk of CRC 
by 40% (Bingham et al., 2003). 
1.1.8.4. Dietary fibre protects against CRC via SCFAs production 
To date, many hypotheses have been made for the beneficial effects of dietary 
fibre in preventing CRC. These include the stool bulking properties of roughage, 
promotion of bowel movement, reduction of colonic pH, alteration of bile acid 
metabolism, and the increase in the production of short chain fatty acids (SCFAs). 
These can minimise mucosal damage by carcinogens and toxic by-products of colonic 
bacterial fermentation (McIntyre et al., 1993). 
Among the speculations, the production of SCFAs through microflora 
fermentation of fibre has been the best supported protective mechanism against CRC. 
SCFAs have been shown to induce cell cycle arrest and apoptosis in CRC cells in 
vitro (Heerdt et al., 1997) and to significantly reduce colonic tumor mass in vivo 
(McIntyre et al., 1993). Although most normal human cells utilize glucose as the 
major source of energy, SCFAs — predominantly acetate, propionate, and butyrate — 
are metabolized via mitochondrial β-oxidation as the primary and preferred energy 
source of healthy colonocytes (Heerdt and Augenlicht, 1991). They are known to 
decrease colonic and faecal pH, and are important for the establishment and 
maintenance of the colonic mucosal homeostasis in both humans and rodents (Harig 
et al., 1989; Tappenden et al., 1997).  
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1.2. BUTYRATE AND CRC 
1.2.1. Butyrate as potential chemotherapeutic agent against CRC 
It has been highlighted that the type of fibre, and its resistance to fermentation, 
determines the amount, rate and composition of SCFAs produced, and in turn, 
determines the effectiveness of chemoprevention. McIntyre et al. (1993) had shown 
that it is the specific release of the four-carbon SCFA, butyrate, from the slow 
fermentation of cellulose-rich fibre such as wheat bran, which continues in the distal 
colon—where the colon is most cancer-prone—that confers protection against CRC.  
Following this, many studies have been performed to explore the applicability 
of butyrate as a potential chemotherapeutic agent to treat CRC (Scheppach and 
Weiler, 2004). Since it is a natural component of the gut and has been shown to be 
non-toxic to healthy colonocytes at physiological concentrations, butyrate also stands 
as a potential chemopreventive agent against CRC in high risk individuals (Myzak 
and Dashwood, 2006). Nevertheless, the successful design of clinical trials and 
therapeutic regimens for this cancer drug candidate will require a more thorough 
understanding of its role in tumorigenesis, as well as the host cell’s responses to its 
effects. 
1.2.2. Role of SCFA butyrate in colonic health and cancer 
1.2.2.1. Essential nutrient of the colon 
Butyrate is a four-carbon SCFA, preferred over propionate and acetate as the 
major substrate for oxidative metabolism in the large intestinal epithelium (McIntyre 
et al., 1993). It is present in milli-molar concentrations in the colonic lumen with an 
estimated daily production of over 200 mmol, most of which is absorbed (Sengupta et 
al., 2006). Butyrate absorption occurs via three main routes: diffusion of the 
undissociated form through the lipid membrane; paracellular diffusion of the anionic 
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form; and active transport mediated by ion pumps such as chloride/bicarbonate (Cl-
/HCO3-) exchangers, and monocarboxylate transporters (MCTs), such as MCT1 
(Borthakur et al., 2006). Butyrate is also known to stimulate water and NaCl 
absorption and regulate cell volume, via the recently characterised sodium-coupled 
MCT —SMCT1 (Diener and Scharrer, 1997; Gupta et al., 2006) (Figure 1.3). 
Interestingly, MCT1 expression has been found to be dramatically down-regulated 
during colon carcinogenesis. This was further demonstrated to suppress butyrate’s 
ability to induce cell-cycle arrest and differentiation in cancer cells (Cuff et al., 2005). 
1.2.2.2. Modulator of colonic cell growth and maturation 
Butyrate plays a unique physiological role in regulating the growth, 
maturation, and terminal differentiation of colon cells. Firstly, butyrate has been 
shown to be a natural promoter of colonic cell differentiation in vivo and in vitro 
(Heerdt et al., 1990). Secondly, butyrate can stimulate the growth of normal 
colonocytes (Sengupta et al., 2006). These effects have been linked to the role of 
butyrate as a major metabolic fuel for healthy colon cells (Boren et al., 2003). On the 
other hand, butyrate suppresses the growth of hyper-proliferative cells, such as those 
that are inflamed or stimulated by excessive bile salts or toxins (Sengupta et al., 
2006). It has been suggested that cells which lose the ability to metabolise butyrate 
efficiently and completely, are likely to be subjected to the negative effects of 
butyrate on growth and survival (Mariadason et al., 2001). This ability to metabolise 
butyrate is in turn positively linked to the differentiation status of the colonocyte, such 
that poorly differentiated cancer cells were noted to be poorer butyrate utilisers and 
thus more susceptible to its growth-inhibiting effects (Mariadason et al., 2001). As 
noted above, the down-regulation of butyrate transporter MCT1 is likely to be an 
adaptation by the tumour cells against growth arrest by butyrate. 
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1.2.2.3.Modulator of the gut inflammation and immunity 
Butyrate also plays important immunological roles in the gut. Firstly, it is an 
anti-inflammatory agent protecting against inflammatory bowel diseases like 
ulcerative colitis—another risk factor for CRC (Dove-Edwin and Thomas, 2001). 
Secondly, butyrate is also an enhancer of immunosurveillance through the 
upregulation of intracellular adhesion molecule (ICAM-1) (Scheppach and Weiler, 
2004) and activation of gut-associated immune cells (Gupta et al., 2006) (Figure 1.3). 
The latter finding has significant clinical implications because, to date, most 
Figure 1.3: Butyrate ion and its role as a SCFA in healthy colonic homeostasis.  
A. Chemical structure of butyrate ion. B. Colonic butyrate SCFA is produced from colonic 
bacterial fermentation of dietary fibre (I). Transport of SCFA into colonocyte can happen via a 
H+-coupled, electroneutral process by the MCT1 (II); and also via a sodium (Na+)-coupled, 
electrogenic process by the SMCT1 (III) which consequently stimulates Na+, chloride (Cl−), and 
water absorption. Absorbed butyrate functions as the primary metabolic energy source and 
promoters of cell differentiation in the colonocyte (IV). Butyrate can also modulate gut-associated 
immune function by acting as the endogenous agonists for G-protein-coupled receptors, GPR41 
and GPR43, upon exiting the basolateral membrane by a still unknown route (V). (Adapted from 
Gupta et al., 2006) 
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chemotherapeutics are critically immunosuppressive, often leaving the patient too 
weak to deal with any cancer cells not eliminated by chemotherapy (Rang et al., 
2003). 
1.2.2.4. Anti-cancer effects of butyrate 
A wealth of evidence supports the chemoprotective effects of butyrate. It has 
been demonstrated as a selective inducer of cancer cell growth arrest, cell 
differentiation and apoptosis in a variety of cancer cell lines and rodent models. For 
example, high-dose butyrate enema was shown to suppress an early carcinogenic 
event, the aberrant crypt formation, in otherwise healthy rats treated with a carcinogen 
(Wong et al., 2005). The effects of butyrate in these animal studies also provided 
clear evidence that it preferentially affects tumour cells, rather than causing general 
toxicity to individual organs or the whole organism (Marks et al., 2000). Among the 
many butyrate-mediated activities uncovered, the inhibition of HDACs is a keynote 
for the diverse anti-neoplastic properties of this fatty-acid molecule (Riagione et al., 
2001; Hinnebusch et al., 2002).  
 
1.2.3. Molecular mechanisms for butyrate anti-neoplastic effects 
1.2.3.1. Histone acetylation and deacetylation in gene expression 
Histone acetylation and deacetylation is a powerful form of epigenetic 
regulation. This PTM occurs on specific lysine residues of the specific histones in the 
nucleosomes which are fundamental units of the chromatin, comprising of about two 
turns of DNA wound around a histone octamer. Modifications often occur in the N-
terminal tails of histones, which extend away from the nucleosomal core. Histone 
acetyltransferases (HATs) transfer acetyl groups to lysine residues within the 
histones. This neutralises the positive charges of the lysine residues, in turn, causing 
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the histones to become less positively-charged and tightly bound to the negatively 
charged DNA phosphate backbone. As a result, a more ‘open’ chromatin 
conformation is generated where TFs and other transcriptional apparatus may have 
easy access to the gene sequence(s) associated with the histones (Figure 1.4).  
On the other hand, HDACs catalyse the removal of acetyl groups on the lysine 
residues of the histones. Consequently, the positive charges of the lysine residues are 
exposed and the histones become more positively-charged. These histones will then 
bind more tightly to the negatively-charged DNA in the nucleosome, leading to 
chromatin condensation. In this way, the DNA becomes inaccessible to transcriptional 
apparatus and transcription of the encoded gene is repressed (Figure 1.4). These 
opposing activities of HATs and HDACs can then tightly regulate gene expression 














Figure 1.4: Regulation of gene transcription by chromatin modifications through the 
activities of HATs and HDACs. A. The ‘open’ chromatin structure generated through HAT 
acetylation of the associated histones allows the access of the transcription factor complex (TFC) 
and the subsequent transactivation of the target gene. B. HDAC generates a ‘closed’ chromatin 
structure by removing the acetyl groups on the histone, cutting off the further access by TFC and 
thus, repressing of the target gene. (Adapted from Somech et al., 2004) 
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1.2.3.2. Role of HDAC in carcinogenesis 
Many lines of evidence indicate that HDACs play a fundamental role in 
maintaining the malignant cell phenotype. Aberrant recruitment and overexpression of 
HDAC have been recognised as alternatives to inactivating mutations of tumor 
suppressor and caretaker genes. For example, oncogenic DNA-binding fusion proteins 
produced from chromosomal translocations, or transcriptional repressors 
overexpressed in cancer cells, can recruit HDACs to promoter regions of important 
genes (Bolden et al., 2006). Since HDACs are also associated with methylated DNA, 
global changes in DNA methylation during carcinogenesis can also modulate the 
distribution and activities of HDACs in cancer cells (Oshiro et al., 2003).  
In general, acetylation of histone H3 and histone H4 tails is associated to 
actively transcribed genes (Minucci and Pelicci, 2006). The deacetylation of H4 has 
been recognised as a common hallmark of cancer (Fraga et al., 2005).  This global 
pattern can be due to the altered expression of individual HDACs, recently reported in 
tumor samples. Out of the 18 HDACs identified in humans, HDAC1, 2 and 3 are 
found to be overexpressed in CRC (Figure 1.5). Knocking down of these HDACs 
with short interfering RNA (siRNA) was shown to suppress growth and survival of 
CRC cell lines (Bolden et al., 2006). Taken together, these observations highlight the 
active role of HDACs in tumour pathogenesis and their potential as chemotherapeutic 
targets.  
1.2.3.3. Butyrate inhibition of HDAC 
Butyrate was initially proposed to selectively kill cancer cells by inducing 
cellular differentiation (Leder et al., 1975). Later, butyrate was discovered to promote 
histone hyperacetylation, in turn, reversing the silencing of strategic anti-cancer genes 
and restoring the latter’s activities to kill the transformed cell (Riggs et al., 1977). 
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Subsequently, a clear link between the suppression of cancer cell growth and the 
inhibition of HDAC activity by butyrate, or other HDAC inhibitors (HDACis), was 
established (Yoshida et al., 1990; Siavoshian et al., 2000). Unlike the non-specific 
actions of cytotoxic anti-cancer drugs, the actions of HDACis are highly specific. In 
fact, HDAC inhibition was noted to be at least 10-fold more significantly induced in 
cancer cells than normal cells (Bolden et al., 2006).  
To date, many specific HDACs targeted by butyrate have been delineated, 
from class I and Iia (Bolden et al., 2006) (Figure 1.5). Butyrate has also been noted to 
specifically induce the acetylation of histone monomers H3 and H4 (Kobayashi et al., 
2004). The overexpression of HDAC1, 2, and 3, as well as the hypoacetylation of 
histone H4 are associated with CRC (Bolden et al., 2006). Hence, butyrate is likely to 
strategically targets the specific epigenetic aberrations associated with the disease to 
bring about chemotherapy. 
Currently, butyrate is classified under a new class of HDACis investigated in 
clinical trials (phase I/II) for chemotherapy of various malignancies including CRC 
(Bolden et al., 2006; Minucci and Pelicci, 2006). Nevertheless, the effects of butyrate 
as an HDACi and epigenetic regulator could be considerably broader and more 
complicated than originally understood. Therefore, we need to better understand its 
anti-cancer mechanisms to optimise the development and application of this agent in 
the clinic, either by itself, or in combination with other anti-cancer drugs or 
treatments. We broadly categorise the proposed molecular mechanisms for anti-
neoplastic effects of butyrate into three general pathways for discussion: 
(i) Histone hyperacetylation via HDAC inhibition (Figure 1.6) 
(ii) Modification of HDAC non-histone substrates (Figure 1.6) 
(iii) Butyrate effects on  the mitochondria 
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Figure 1.5: The HDAC family in humans. 18 HDACs have been identified in humans, 
and they are subdivided into four classes based on their homology to yeast HDACs, their 
subcellular localisation and their enzymatic activities. Class I HDACs (1, 2, 3 and 8) are 
homologous to yeast RPD3 protein, and are expressed in the nucleus or ubiquitously. Class II 
HDACs (4, 5, 6, 7, 9, and 10) share homologies with yeast HdaI protein and can shuttle 
between nucleus and cytoplasm. The sub-class IIb HDACs (6 and 10) are found in the 
cytoplasm and contain 2 deacetylase domains. HDACs in class III are homologues of the yeast 
protein Sir2 (not shown). HDAC 11 is the only member of class IV HDACs. Structurally 
diverse HDACis, like butyrate (*), SAHA and despeptide, exert their inhibitory effects on 
different HDAC classes, or specific HDACs. Butyrate has been shown to inhibit the class I 
and IIa HDACs. (Adapted from Bolden et al., 2006.) 
Introduction 




























Figure 1.6: HDACi effects of butyrate on histone and non-histone proteins. 
A. HDAC acts on both histone and non-histone substrates. The latter can be TFs or 
proteins with different functions in the cell. As an HDACi, butyrate can affect gene 
expression directly through histone hyperacetylation; or indirectly through the 
regulation of the TFs. B. It can also directly induce the anti-tumour effects through the 
deacetylation of non-nuclear protein targets susceptible to modification by HDACs, 
such as tubulin and heat shock proteins. (Adapted from Bolden et al., 2006.) 
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1.2.3.4. Effects of butyrate mediated through histone hyperacetylation 
Early microarray gene expression studies have shown that butyrate can induce 
the expression of many genes through histone hyperacetylation mediated by HDAC 
inhibition in cancer cells. These include genes encoding colonocyte differentiation 
markers, like sucrase and alkaline phophatase; cell cycle inhibitors, p21 WAF1/CIP1 and 
Tob; pro-apoptotic genes, Bax and caspase 3; immune-associated proteins, like the 
major histocompatibility complex (MHC) class I and II; and co-stimulatory/adhesion 
molecules, such as CD40, CD80, CD86 and ICAM (Levy et al., 2003; Blottiere et al., 
2003; Ragione et al., 2001; Bolden et al., 2006). The induction of these genes sheds 
light on the various biological effects of butyrate, including promotion of 
differentiation, growth inhibition, apoptosis induction and enhancement of anti-
tumour immunity. 
In particular, the induction of tumor suppressor p21WAF1/CIP1 has been shown to 
be mandatory for butyrate-mediated G1/S cell cycle arrest (Hinnebusch et al., 2002). 
This CDK inhibitor prevents the hyperphosphorylation of the retinoblastoma protein 
(pRb) by cyclin D1/CDK 4, in turn, blocking the release of elongation 2 factor (E2F) 
bound by the unphosphorylated pRb. E2F is required for the transcription of genes 
encoding proteins needed for DNA replication and S-phase progression. Hinnebusch 
et al. (2002) showed that if p21WAF1/CIP1 is deleted, butyrate did not alter proliferation 
rate of HCT 116 colon cancer cells. Acetylation of histones H3 and H4 associated to 
the p21WAF1/CIP1 promoter region have been demonstrated as mechanisms through 
which butyrate activated transcription of p21WAF1/CIP1 (Kobayashi et al., 2004). 
Butyrate has also been shown to down-regulate cyclin B1 through the induction of 
p21WAF1/CIP1 (Archer et al., 2005). This shows that butyrate can also indirectly repress 
the expression of other genes via its primary targets. 
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1.2.3.5. Effects of butyrate through non-histone substrates of HDACs 
Gene expression studies performed at 48-72 hr post-treatment, when butyrate 
effects are maximal, indicate that only a relatively low percentage (~2%) of genes is 
regulated by butyrate, while most genes are unaffected by butyrate (Williams et al., 
2003). In addition, the number of genes that were found to be down-regulated 
approximated those that were found to be up-regulated. This is likely to be due to the 
multifactorial effects of HDAC inhibition which can also be mediated through non-
histone targets, such as TFs and non-nuclear proteins, not directly involved in 
transcriptional pathways (Bolden et al., 2006) (Figure 1.6). In support of this, 
proteomic analyses by Tan et al. (2002) and Tan et al. (2006) at an earlier time point 
(24 hr post-treatment), revealed protein targets that were previously not found to be 
transcriptionally regulated by butyrate. 
• TFs targeted by HDACs 
Besides histones, HDACs have been shown to deacetylate a wide array of 
non-histones proteins, of which a significant portion consists of TFs such as E2F1, 
p53, signal transducers and activator of transcription 1 (STAT1), STAT3, and nuclear 
factor-κB (NF-κB). The transcriptional activities of these can thus be altered by 
HDAC inhibition (Bolden et al., 2006). This is likely to account for the simultaneous 
down-regulation of several genes upon butyrate-induced HDAC inhibition, including 
antiapoptotic proteins, Bcl-2 and Bcl-XL; cell adhesion molecules, β1 integrin; 
oncoproteins, ras, c-myc and EGFR; pro-inflammatory mediators, like COX 2 and 
interleukin-1 (IL-1); pro-angiogenic factors, such as hypoxia-inducible factor-1α (HIF 
α) and C-X-C chemokine receptor (CXCR4); as well as metastasis facilitators, e.g. 
matrix metalloproteinases (MMPs) (Levy et al., 2003; Archer et al., 1998; Tong et al., 
2005; Bolden et al., 2006; Williams et al., 2003). Through the suppression of these 
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proteins, butyrate is likely to render the cancer cells more susceptible to drug-induced 
apoptosis, less proliferative, and less invasive.  
• Non-nuclear proteins modified by HDACs 
Besides regulating the transcription of specific genes, HDACs are found to act 
on a growing list of proteins not directly involved in gene transcription. These include 
Ku70, tubulin and Hsp90, and have been collectively termed the ‘acetylome’ 
(Minucci and Pelicci, 2006). In fact, reversible acetylation has been recognized as a 
regulatory PTM, like phosphorylation, which can impose important changes to the 
stability, interacting partners, localisation and DNA binding specificity of the target 
proteins (Minucci and Pelicci, 2006).  
For instance, acetylation can compete with ubiquitylation for the same lysine 
residues. By inhibition of a HDAC, butyrate can prevent the ubiquitylation of the 
HDAC substrates and their degradation by the ubiquitin proteasome. In addition, 
acetylation has been shown to impair the DNA-binding activities of enzymes involved 
in DNA metabolism and repair (Minucci and Pelicci, 2006). Butyrate can restore 
these functions to the relevant proteins via inhibiting HDAC activity and re-
establishing a variety of downstream signal cascades. Consistent with these, 
proteomics studies have identified a decline in the ubiquitin proteasome subunits (Tan 
et al., 2002), as well as, the cleavage and translocation of the mRNA-binding 
heterogeneous nuclear ribonucleoprotein hnRNP A1 (Tan et al., 2006), upon 24-hr 
butyrate treatment. In support of the second finding, hnRNP A1 has been recently 
identified as an oncoprotein in CRC tissues (Zhang et al., 2006), and thus, is likely to 
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1.3. BUTYRATE’S EFFECTS THROUGH THE MITOCHONDRIA IN 
CANCER 
1.3.1. The mitochondrial organelle as a key player in cell life and death 
Hengartner (2000) aptly described the mitochondrion as ‘the powerhouse and 
arsenal of the cell’, highlighting the pivotal role of this little organelle in both the life 
and death processes of a cell. Key functions of this organelle include adenosine 
triphosphate (ATP) production, global cellular regulation of calcium (Ca2+) fluxes and 
the redox state, together with being the center of control for pro- and anti-apoptotic 
signals. The many diverse roles of the mitochondria are inter-connected and inter-
dependent on each other. Mitochondrial dysfunction and mutations in mitochondrial 
DNA (mtDNA) are primary mechanisms underlying aging, as well as, many 
degenerative and metabolic diseases, including cancer (Verma et al., 2003). 
 
1.3.2. Mitochondria in cancer 
Kroemer (2006) noted that most cancer cells carry two predominant features: 
(i) Metabolic imbalances  
(ii) Enhanced resistance to death by the intrinsic mitochondrial pathway 
Since the mitochondrial organelle plays a central role in each of these aspects, 
it has been highlighted in many studies as a key target for cancer therapy (Don and 
Hogg, 2004; Galluzzi et al., 2006)  
1.3.2.1. Energy metabolism in cancer cells 
Cancer cells commonly manifest a metabolic shift to glycolysis as the primary 
route of energy (ATP) production despite the presence of oxygen—a phenomenon 
better known as the Warburg effect (Warburg, 1956). This requires a selective and 
high glucose uptake, and the concomitant suppression of the mitochondrial oxidative 
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phosphorylation (OXPHOS) (Moreno-Sanchez et al., 2007). By attenuating the 
oxygen (O2)-depleting mitochondrial respiratory chain activity, the tumour cells can 
readily adapt to hypoxic conditions as they grow further away from the blood supply 
(Kroemer, 2006). At the same time, this metabolic phenotype can confer aggressive 
characteristics to tumour growth, such as through the overproduction of the glycolytic 
by-product, lactate which is then secreted to lead to local acidification of the tumour 
microenvironment, causing it to be favourable for invasion (Mathupala et al., 2006). 
1.3.2.2. Apoptosis resistance in cancer cells 
Cancer cells have evolved numerous strategies to evade both the extrinsic 
death receptor and the intrinsic mitochondrial pathways of apoptotic cell death (Fulda 
and Debatin, 2006). The intrinsic mitochondrial pathway is primarily activated by 
stress stimuli such as chemotherapeutic drugs, DNA-damaging ionizing radiation, 
hypoxia, withdrawal of growth factors and oncoproteins (Hengartner, 2000). To 
survive the high amount of stress arising from their microenvironment and metabolic 
imbalances, most cancer cells share a common feature of enhanced resistance to 
induction of mitochondrial outer membrane permeabilisation (MOMP) (Kroemer, 
2006). 
• Intrinsic pathway of apoptosis via MOMP 
MOMP is also known as “the point of no return” in the intrinsic apoptotic 
pathway. It is usually triggered in a p53-dependent fashion, through the activation and 
translocation of the pro-apoptotic members of the BCL2 family, like Bax and Bak, as 
well as the BH3 domain-only (BH3-only) proteins like Bid, to the outer membrane 
(OM) of the mitochondria. Upon insertion into OM, Bax and Bak oligomerise to form 
a selective pore allowing small molecules, like cytochrome c, to exit from the 
intermembrane space. Bid, which is activated through truncation by caspases, can 
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enhance this process by inducing conformational changes in Bax and Bak, resulting in 
their full insertion into the OM and even greater poration of the latter (Galluzzi et al., 
2006) (Figure 1.7).  
Subsequently, both the outer and inner membranes (OM and IM) are 
permeabilised through the formation of the permeability transition pore (PTP) which 
is a non-specific pore consisting of the adenine-nucleotide translocase (ANT) in the 
IM and many OM proteins including the voltage-dependent anion channel (VDAC), 
benzodiazepine receptor (PBR) and Bax (Don and Hogg, 2004). MOMP results in the 
loss of OM barrier function and the mitochondrial transmembrane potential (∆ψm). 
These culminate in the release of procaspases, caspase activators like cytochrome c 
(cyt c) and second mitochondria-derived activator of caspases (Smac); as well as 
caspase-independent death factors like nucleases and proteases. cyt c then associates 
with the apoptotic peptidase activating factor (APAF1) and procaspase 9 to form the 
apoptosome which then proceeds to trigger a cascade of caspase activities to break 
down the cell and commit it to death. In addition, IM permeabilisation causes the 
mitochondria to lose vital metabolic and redox functions, thus hastening the death 
process (Galluzzi et al., 2006) (Figure 1.7). 
• Intrinsic resistance to MOMP in cancer cells 
Mitochondria isolated from cancer cells have been shown to be intrinsically 
resistant to MOMP, compared to those from normal cells (Brenner and Grimms, 
2006). This could be due to the overexpression of anti-apoptotic BCL2 members, Bcl-
2 and Bcl-XL, which act as barriers to MOMP on the OM. At the same time, 
inactivation of Bax, Bak and p53 are also commonly observed in cancer cells 
(Brenner and Grimms, 2006). Other possible factors contributing to MOMP resistance 
include alteration of the isoforms of the proteins in the PTP. For example, the VDAC 
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isoform 2 (VDAC2) can interact with Bak and prevent the latter’s activation (Brenner 



















1.3.2.3. Other characteristics of cancer cell mitochondria 
Besides difference in metabolic profile and resistance to MOMP, mitochondria 
of tumour cells also differ markedly from normal, in terms of mtDNA integrity 
(Chatterjee et al., 2006), mitochondrial gene expression (Heerdt et al., 1990), enzyme 
activity (Pelicano et al., 2006),  ∆ψm (Heerdt et al., 2005) and morphology (Alirol and 
Figure 1.7: Mechanisms of MOMP proposed by current literature.  
A. Proapoptotic Bax and Bak can first form a multimeric pore across OM. The process is 
enhanced by BH3-only proteins. The channel mediates the release from the intermembrane 
space (inter-mbr space) of apoptogenic factors e.g. cyt c. B. The PTP can also result in the 
permeabilisation of both OM and IM, water and solutes can then enter to result in matrix 
swelling and the bursting of OM. Opening and closing of the pore is regulated by a number 
of factors including the BCL2 family members Bax and Bcl-2. (Adapted from Fantin and 
Leder, 2006) 
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Martinou, 2006). These features have been demonstrated to regulate the cancerous 
characteristics of the cell.  
•  mtDNA deletions and mutations 
The mtDNA codes for essential subunits for OXPHOS and mtRNA 
translation. Oncogenic mtDNA mutations were shown to inhibit OXPHOS, increase 
reactive oxidative species (ROS) production, promote tumour cell proliferation and 
enhance adaptability to new microenvironments, in turn, facilitating invasion and 
metastasis (Brandon et al., 2006). mtDNA mutations have also been implicated in 
genome instability of CRC (Guleng et al., 2005). 
• Decreased mitochondrial gene expression 
Decreased mitochondrial gene expression is an early maker of CRC risk and 
tumorigenesis (Heerdt et al., 1990; Heerdt et al., 2003). The dysregulated expression 
of the mtDNA-encoded respiratory complex subunits can further handicap the 
assembly of the OXPHOS system and contribute to the Warburg phenomenon in CRC 
(Heerdt et al., 1991; Bianchini et al., 2006).  
•  Altered mitochondrial enzyme activities 
Recent proteomics studies of CRC tissues have reflected an enhanced 
expression of the glycolytic enzymes, and a parallel reduction of enzymes of the 
tricarboxylic acid cycle (TCA) cycle and fatty acid β-oxidation pathways (Mazzanti et 
al., 2006; Bi et al., 2006). The latter pathways are responsible for the production of 
reducing equivalents (nicotinamide adenine dinucleotide (NADH) and flavin adenine 
dinucleotide (FADH)) needed for OXPHOS. These are convincing evidences in 
support of the proposed explanation that the dysregulation of critical mitochondrial 
enzyme activities is a likely route for the progressive gain of glucose-metabolising 
capacity in cancer cells (Gottlieb and Tomlinson, 2005).  
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• Elevated ∆ψm 
The intrinsic mitochondrial ∆ψm is a key component of the electrochemical 
gradient generated across the IM as a consequence of electron transport through the 
respiratory complexes, coupled to the pumping of protons from the mitochondrial 
matrix to the intermembrane space. Ironically, despite the compromised state of 
OXPHOS in cancer cells, a higher ∆ψm was correlated to more invasive behaviour in 
CRC cancer cells and chemoresistance (Heerdt et al., 2005). This is supported by 
subsequent findings from the same research group showing that elevated ∆ψm allowed 
isogenic cells to be more resistant to apoptosis during hypoxia and loss of anchorage 
to the basement membrane (Heerdt et al., 2006). 
•  Differences in mitochondrial morphology 
Mitochondria exist in two interconverting forms; as small isolated particles, 
and as extended filaments where they are connected to each other through inter-
mitochondrial junctions to form, a so-called mitochondrial reticulum (Skulachev, 
2001). The mitochondrial network organisation has been shown to be directly related 
to the bioenergetic activities of the cell (Benard et al., 2007). Interestingly, cancer 
cells displaying the glycolytic phenotype have been found to harbour mainly 
fragmented mitochondria with expanded matrix, whereas the normal cells that major 
in respiratory energy production typically retained a well-interconnected 
mitochondrial network with enlarged cristae (Alirol and Martinou, 2006). 
Furthermore, such morphological changes of the mitochondria have been shown to 
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1.3.3. Butyrate effects through the cancer cell mitochondria 
Butyrate has also been proposed to affect the cancer cells through other 
cellular pathways where it usually involves two main outcomes: 
(i) Alteration of the cancer cell metabolic profile (Heerdt and Augenlicht, 
1991)  
(ii) Potentiation of intrinsic apoptosis via MOMP (Heerdt et al., 1997)  
These outcomes directly target the two main features shared among most 
cancer cells as discussed in the previous section, and are likely to have critical 
implications to the chemotherapeutic potential of butyrate. Since the mitochondrion is 
a key factor in both pathways, it is studied as a key target of butyrate’s effects in these 
aspects. 
1.3.3.1. Alteration of the metabolic profile of cancer cell 
In support of the Warburg’s effect as a main driving force and sustaining 
factor of carcinogenesis (Warburg, 1956), the disruption of the abnormal metabolic 
profile of the cancer cell has been recently proposed as an alternative route of 
chemotherapy (Moreno-Sanchez et al., 2007). Butyrate has been shown to alter the 
metabolic abnormalties of the cancer cells through a number of possible mechanisms. 
For example, butyrate treatment led to restored expression of genes encoding subunits 
of cyt c oxidase in the mitochondria, in turn enhancing activity of the overall 
respiratory complex III in HT-29 colonic adenocarcinoma cells (Heerdt and 
Augenlicht, 1991). In addition, butyrate has also been shown to inhibit glucose uptake 
and glycolysis in a dose-dependent manner in cancer cells (Boren et al., 2003). It 
remains unclear how butyrate induces such metabolic alterations in the cancer cells 
and how the HDACi activities of the SCFA can be involved. 
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1.3.3.2. Potentiation of intrinsic apoptosis via MOMP 
The therapeutic potential of butyrate stems from its capacity to selectively 
induce apoptosis in tumour cells. However, this is also the least understood effect of 
butyrate. Butyrate was demonstrated to sensitize cancer cells to the extrinsic pathway 
of apoptosis through the down-regulation of anti-apoptotic proteins (Natoni et al., 
2005) and the generation of reactive oxygen species (Giardina et al., 1999). However, 
signaling through death receptors may not be necessary for butyrate-induced 
apoptosis, because the SCFA, by itself, has been found to be capable of activating the 
intrinsic pathway of apoptosis via MOMP (Bolden et al., 2006). 
The precise mechanisms through which butyrate may trigger the mitochondria 
to undergo MOMP at the onset of apoptosis remain to be elucidated. Current findings 
can be summarised into three possible routes for the execution of cancer cell death 
through butyrate’s actions on the mitochondria: 
(i) Butyrate up-regulates proapoptotic proteins, Bax and Bak, possibly via 
up-stream HDAC inhibition (Chirakkal et al., 2006). This is often accompanied by a 
down-regulation of anti-apoptotic Bcl-2 and Bcl-XL, culminating in the 
destabilization of the OM and its permeabilisation (Levy et al., 2003). 
(ii) Butyrate leads to the acetylation of non-histone protein, p53, at lysine 
residues 320 and 373 which then give rise to the up-regulation of p53-regulated 
proapoptotic genes, PIG3 and NOXA (Terui et al., 2003). 
(iii) Butyrate targets ANT in the mitochondrial OM to induce opening of 
the PTP, mitochondrial swelling and MOMP, as demonstrated in isolated 
mitochondria and ANT proteoliposomes (Heerdt et al., 2003; Jan et al., 2002).  
Augenlicht’s laboratory has futher delineated the direct induction of MOMP 
by butyrate in (iii) to be independent of p53, but dependent on the mitochondrial 
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electron transport functions and the dissipation of an intact ∆ψm (Heerdt et al., 1997; 
Heerdt et al., 1998).  
In short, butyrate appears to mediate intrinsic apoptosis through more than one 
way in cancer cells.  It would be interesting to understand how these pathways may 
interplay and whether if one mode of butyrate-induced apoptosis is likely to 
predominate, depending on the cancer cell’s specific metabolic profile and 
susceptibility to apoptosis. Further study into the effects of butyrate on the cancer cell 
mitochondria is likely to aid in the elucidation of the precise molecular pathways by 
which butyrate induces death in tumour cells selectively. In addition, the specific 
mitochodrial targets of butyrate in the cancer cell may also shed light on the 
differential sensitivities of various cancer cell types to butyrate’s action (Galfi et al., 
2002). 
 
1.4. THE PROTEOMICS APPROACH 
1.4.1. Why proteomics? 
To date, most studies of butyrate-mediated gene expression patterns have been 
performed at the mRNA level through the use of complementary DNA (cDNA) 
microarrays. However, proteins are the primary workhorses of the cell in carrying out 
the biological functions encoded by gene transcripts. Therefore, it is pertinent to also 
study the effects of butyrate regulation at the protein level. In addition, butyrate has 
also been shown to induce non-transcriptional changes, through the non-histone 
substrates of HDACs. Hence the study of protein changes upon butyrate perturbation, 
will not only reflect actual phenotypic changes executed by the protein end-product of 
each mRNA transcript, but also give a more complete picture to the sum of butyrate 
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actions involving the alterations in both gene transcription as well as other cellular 
pathways. 
1.4.1.1. The dynamic proteome 
The earliest definition of a proteome is the protein complement expressed by 
the genome of an organism, tissue or cell (Wilkins et al., 1996). Proteomics is the 
large-scale study of the proteome as a complement to genomics and functional 
genomics. However, unlike the genome which is normally static, the transcriptome 
(the mRNA complement), and the proteome are highly dynamic, defined by the 
contexts of tissue, cell-type and cell-stage specificites, as well as the extracellular 
milieu. This discrepancy is very much more pronounced for the proteome which 
constitutes the outcome of the complex interplay of multiple genes, proteins and other 
molecules, in addition to extracellular influences. Therefore, the current definition of 
a proteome specifies that it is the protein complement of a given biological sample at 
a specified time or physiological state, including all the protein isoforms and modified 
products of the biological processes involved (de Hoog and Mann, 2004). 
Very often, the level of transcription of a gene does not correlate to the 
resultant functional activity of the encoded protein. This is because proteins are highly 
heterogeneous in structure and are subjected to numerous forms of regulation through 
post-transcriptional controls and PTMs, like phosphorylation, acetylation, 
sumoylation and oxidation. Consequently, the functional activity of a protein can be 
fine-tuned through the modulation of its stability, subcellular localisation and binding 
specificities (Seo and Lee, 2004).  
Besides PTMs, regulation can also occur at the post-transcriptional level to 
determine the outcome of gene expression. These include alternative splicing, editing, 
localisation, interaction and stabilisation of the mRNA transcripts by the 3’ 
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untranslated regions (UTRs). For example, alternative splicing has been recently 
found to occur for about 60% of all human gene products, in a cell-specific or 
developmental-specific manner (Modrek and Lee, 2002). This mode of regulation 
involves the combination of mRNA transcripts at different splice junctions to give rise 
to multiple structurally and functionally unique proteins, as a result, greatly 
multiplying the coding capacity of each DNA-coded gene (Modrek and Lee, 2002). 
Nevertheless, due to the fact that most gene arrays comprise of pre-selected 
oligonucleotide sequences of interest, unless the unique regions differentiating the 
splice variants are targeted specifically, these important nuances are usually 
overlooked. 
1.4.1.2. Proteomics as a discovery tool 
Proteomics is a discovery tool through which we can examine global changes 
at protein levels and forms of expression under various environmental conditions. 
While the current gene expression studies are insufficient to fully elucidate the diverse 
proteins involved in cellular health and disease, proteomics offers a direct means to 
capture proteins in their various isoforms and modifications. In this way, complex 
physiological changes can be monitored to discover novel protein isoforms and new 
modes of regulation for important players. Since proteins are also the cellular targets 
of therapeutic agents like butyrate, a proteomics approach in studying the effects of 
butyrate can potentially uncover novel targets of butyrate treatment and new insights 
into its anti-cancer mechanisms.  
1.4.2. Technologies in proteomics 
Proteins, unlike DNA and mRNA, cannot be easily amplified through reverse 
transcriptase polymerase chain reaction (RT PCR) and automated cycle sequencing. 
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Enrichment and detection methods of high sensitivities are needed to study important 
drug-induced changes in the cellular proteome.  
1.4.2.1. Two-dimensional gel electrophoresis / mass spectrometry 
approach  (2-DE/MS) 
The 2-DE technique marks the beginning of proteomics and is the standard 
method to resolve and array authentic proteins from biological samples over the past 
30 years (Anderson et al., 2001). It separates proteins by their isoelectric points (pIs), 
in the first dimension of isoelectric focusing (IEF); then by their relative molecular 
mass (Mr), in the second dimension of sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE). Upon protein visualization with appropriate detection 
methods, the resultant 2-DE gel provides a global “snapshot” of the state of thousands 
of proteins from a single sample. These proteins can then be identified through mass 
spectrometry (MS). In the past decade, advances in MS technologies, mainly in 
tandem MS (MS/MS) sequencing, has facilitated the high-throughput identification 
and characterisation of proteins at sensitivities below 1 pmol (Godovac-Zimmermann 
and Brown, 2001).  
The main strength of 2-DE is its capacity to resolve proteins into individual 
spots for semi-quantitative analysis, and to study protein modifications that give rise 
to protein isofoms of differing pIs and/or Mr (Rabilloud, 2002). Despite the 
automation and high sensitivities offered by technologies of liquid chromatography-
mass spectrometry (LC-MS), this traditional method continues to be an important tool 
in expression proteomics to study the complex molecular pathways in diseases, such 
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1.4.2.2. Two-dimensional difference gel electrophoresis (2-D DIGE) 
The two-dimensional difference gel electrophoresis (2-D DIGE) circumvents 
the problems of inter-gel variability and the narrow linear range of 2-DE spot 
detection methods, for better quantitation of differential protein expression. As many 
as three different samples can be pre-labeled with spectrally resolvable fluorescent 
cyanine dyes—Cy2, 3 and 5. These can then be pooled in equal quantities and 
resolved on the same 2-DE gel. The gel is then scanned at the three different 
excitation/emission wavelengths of the respective dyes and differences in dye 
intensities can be quantitated via statistical analytical software. The Cy2-labeled 
sample usually consists of a pooled mix from the samples of every batch and serves as 
an internal standard present in every 2-D DIGE gel, thus allowing cross-gel analysis 
of multiple pairs of samples to identify true biological changes (Patton, 2002). Hence, 
through the innovation of 2-D DIGE, protein expression of samples that are perturbed 
by drugs or candidate drugs, like butyrate, can be compared to the controls, for the 
quantitative analysis of significant drug-induced changes. 
1.4.3. Subproteomics—when less is more 
There is enormous diversity in the expression level, physical properties and 
stability among the proteins in a cell, such that it is impossible to achieve fair 
representation of the complete proteome using any single method of proteomics. To 
illustrate this, the dynamic range for detection of protein abundance in 2-DE,  is in 
magnitudes of 104, however the disparity in expression level of cellular proteins can 
range from 108 actin molecules to only 100 cell surface receptor molecules 
(Rabilloud, 2002). Hence, the low-abundance proteins would often be masked by the 
high-abundance housekeeping proteins, which would also be saturated and not 
suitable for quantitation on 2-DE gels. There is a real need for the enrichment of 
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specific classes of proteins, according to certain unique physical properties that they 
share, allowing them to be purified as a separate entity from the rest of the proteins in 
the cell. Such a subset of proteins in the cell is commonly referred to as a 
‘subproteome’ of the cell. 
An example of subproteomics is organellar proteomics which usually employs 
differential and gradient centrifugation techniques to purify for subproteomes of 
specific organelles in the cell. In addition to reducing sample complexity with the 
concurrent enrichment of the protein subsets of interest, valuable information can be 
yielded from the newly observed subcellular localisation of certain proteins. This is 
because the functions of most proteins are dependent on their location and interaction 
partners, rather than just relative abundances (Taylor et al., 2003).  
1.4.3.1. Mitochondrial proteomics 
The endosymbiotic origins of mitochondria are preserved in their double 
membrane structure, unique circular genome (mtDNA) and their own transcription, 
translation and protein assembly system. The mtDNA encodes for 13 essential 
mitochondrial polypeptides which include components of the OXPHOS system and 
the mitochondrial translation machinery. The rest of the proteins residing in the 
organelle, estimated to be around 1000 to 2000 in number (McDonald and Eyk, 
2003), are derived from the nuclear genome (nDNA), and imported through the highly 
regulated functions of the chaperone proteins, and translocases of the inner and outer 
membrane (TIM and TOM) (Lopez and Melov, 2001). 
Proteomics is suitable for the large-scale and unbiased study of crucial players 
in the multiple survival and death processes controlled by the mitochondrial organelle. 
Mitochondrial proteomics directly addresses the many PTMs, as well as 
translocations of proteins in the multifactorial biological processes involving the 
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mitochondria, such as tumorigensis and apoptosis. Currently, the attempts in defining 
the complete mitochondrial proteome so as to elucidate the workings of this complex 
organelle, has culminated in the characterisation of close to 700 human mitochondrial 
proteins (Gibson, 2005). Most of these proteins can be found in the mitochondrial 
protein databases like MITOP (http://ihg.gsf.de/mitop2) (Prokisch et al., 2006). Over 
800 putative mitochondrial proteins have also been listed in the MitoProteome 
database (http://www.mitoproteome.org) (Cotter et al., 2004). 
1.4.3.2. Study of the effects of butyrate on the mitochondrial proteome 
The effects of the HDACi, butyrate, on the metabolism and intrinsic apoptotic 
resistance of the cancer cells are likely to be linked to the mitochondrial proteome and 
functions. By studying the effects of butyrate on the mitochondrial proteome, we can 
possibly reveal the molecular targets of butyrate in the mitochondria and shed light on 
the mechanisms through which butyrate induces its chemotherapeutic effects through 
the organelle. These insights may also allow us to understand why butyrate can act 
more efficaciously in certain cancer cells and not others. These clinically relevant data 
can then possibly contribute to the better targeting of this drug candidate to the right 
subset of CRCs in therapy, as well as, in the design of clinical regiments that enhance 
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1.5. PROJECT AIMS 
Recently, much work has been devoted into the delineation of butyrate’s 
effects on cancer cells, so as to propel the development of this promising drug 
candidate for targeted therapy in cancer. However, relatively little conclusive data has 
been obtained on the effect of butyrate through the mitochondrion, despite the latter’s 
integral role in the survival and death of the cancer cell. In particular, systematic 
investigation of the mitochondrial proteins directly regulated by butyrate has yet been 
reported. In this project, we employ a proteomics approach to study the effect of 
butyrate on the mitochondrial proteins of colon cancer cells, so as to better address the 
various biochemical changes this anti-cancer agent can induce on and through the 
organelle. 
The three main aims of this project can be summarized as following:- 
(i) Enrichment of mitochondrial proteome of HCT 116 cells for 2-D DIGE 
analysis of butyrate-induced changes in protein expression. 
(ii) Identification of differentially expressed proteins in the mitochondrial 
proteome of HCT 116 cells upon butyrate treatment, through 2-D DIGE 
analysis. 
(iii) Characterisation of the subcellular expression of mortalin, a mitochondrial 
protein found regulated by butyrate in our study; and its potential role in 
the chemotherapeutic actions of butyrate and differential susceptibilities of 
two cancer cell lines, HCT 116 and HT-29, to butyrate. 
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2. MATERIALS AND METHODS 
2.1. CELL LINES AND CELL CULTURE 
Human colon cancer cell lines HCT 116 and HT-29 (American Type Culture 
Collection, Rockville, MD) were cultured in McCoy’s 5A media (Sigma, St Louis, 
MO) supplemented with 10% fetal bovine serum (Gibco, Green Island, NY) and 
antimycotic antibiotics (Sigma). The cells were maintained in a humidified incubator 
at 37 ºC, 5% CO2.  
 
2.2. SAMPLE PREPARATION 
2.2.1. Butyrate treatment and harvesting of cells 
The HCT-116 cells were seeded in 175 cm2 tissue culture flasks (Nalgene 
Nunc, Roskilde, Denmark). Upon reaching 60% confluency, the media was replaced 
with fresh standard media or media containing 5 mM sodium butyrate (NaB) (Sigma). 
Both adherent and floating cells were harvested at appropriate time points after 
butyrate treatment (24 hr for subcellular fractions and HT-29 whole cell lysates; 24, 
48 and 72 hr for HCT 116 whole cell lysates). Floating cells were collected in the 
media while adherent cells were rinsed with phosphate buffered saline (PBS) and 
trypsinised with a solution of 0.5 g/L trypsin and 0.2 g/L ethylenediaminetetraacetic 
acid disodium salt (EDTA) (Gibco) and incubated at 37 ºC. The resultant cell 
suspension and the corresponding floating cells were centrifuged at 100 g for 5 min at 
4 ºC. After discarding supernatant, the cells were resuspended in ice-cold PBS and 
rinsed thrice at 100 g for 5 min at 4 ºC. Since there was a significant proportion of 
floating versus adherent HCT 116 cells at 72 hr post butyrate treatment, two 
additional samples were collected by harvesting of the floating and adherent cells as 
separate populations.  
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2.2.2. Whole cell lysates 
All procedures were performed on ice, unless otherwise stated. Harvested 
control and butyrate-treated HCT 116 and HT-29 were separately disrupted in 2-DE 
sample lysis buffer—cocktail solution containing 7 M urea (USB, Cleveland, USA), 
2M thiourea (Fluka, Buchs, Switzerland), 4% (w/v) 3-[(3-
cholamidopropyl)dimethylammonio]-2-hydroxy-1-propanesulfonate (CHAPS) (USB), 40 
mM Tris[hydroxymethyl] aminomethane (Tris) (J.T. Baker, Phillipsburg, USA) and 1 
mM phenylmethylsulphonyl fluoride (PMSF) (Sigma), 50 µg/mL Dnase 1 and Rnase 
A (Roche Diagnostic, Mannherim, Germany). The cell lysates were incubated at room 
temperature for 30 min and subsequently centrifuged at 14,000 g, 4 °C for 45 min to 
obtain the supernatants as whole cell lysates for analyses. 
2.2.3. Subcellular fractions 
For the subcellular fractions, harvested control and butyrate-treated HCT 116 
and HT-29 cell pellets, containing around 2 × 108 cells each, were separately 
resuspended in 10 mL of extraction buffer, containing 10 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) (Sigma) pH 7.5, 200 mM mannitol (Sigma), 
70 mM sucrose (Bio-Rad, Hercules, CA, USA), 1 mM EGTA (Sigma), 1 × Halt 
Protease Inhibitor Cocktail (Pierce, Rockford, IL) and 2 mg/mL bovine serum 
albumin (BSA) (Sigma). A nitrogen cell disruption bomb, model 4639 (Parr 
Instrument Company, Moline, USA) was pre-cooled to 4 ºC and used to burst the 
control and treated cells, separately. Each resuspended cell pellet was placed inside 
the nitrogen cell bomb and put under the pressure of 700 psi for 30 min, with 
magnetic stirring. All procedures were performed on ice, including the incubation of 
the cells in the nitrogen cell bomb. At the end of the incubation, the cells were lysed 
by releasing them through the bomb delivery valve. The lysates collected contained 
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the cytosolic contents of the cells, as well as unlysed mitochondria and nuclei for 
subsequent fractionation. 
2.2.3.1. Mitochondrial enrichment 
The collected cell lysates were spun at 1,000 g for 5 min at 4 ºC. The 
supernatants contained the mitochondria/cytosol/membranes while the pellet enclosed 
the nucleus. The mitochondrial fractions were pelleted by centrifugation at 3,500 g for 
10 min at 4 ºC. The supernatants now contained the cytosol and membranes. 
The mitochondria-containing pellets were each resuspended in 2 mL of the 
extraction buffer (as previously described, but not containing BSA). The two 
centrifugation steps were repeated to achieve purer mitochondrial samples. The final 
mitochondrial pellets were disrupted separately with sample lysis buffer (as 
previously described, but not containing Rnase A). After 30 min incubation at room 
temperature, the mitochondrial lysates were centrifuged at 14,000 g for 5 min at 4 ºC, 
and the final supernatants were obtained for analyses.  
2.2.3.2. Cytosol enrichment 
The supernatants were further centrifuged at 8,800 g for 20 min at 4 ºC to 
purify for the cytosol. The pellets were discarded and the supernatants were 
centrifuged at 75,000 g for 60 min at 4 ºC to pellet down remaining membranes and 
debris. The supernatants contained the cytosol. These were desalted and precipitated 
using the 2-D Clean-Up Kit (GE Healthcare, formerly known as Amersham 
Biosciences, Uppsala, Sweden). The final pellets were resolubilised in the sample 
lysis buffer (as previously described, but without Dnase 1 and Rnase A) for analyses. 
2.2.3.3. Nuclear enrichment 
The pellets containing the nuclei were suspended in 5 mL PBS and centrifuged 
at 1,500 g for 2 min at 4 ºC. Each pellet was suspended in 1 mL of NB buffer, 
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containing 10 mM HEPES pH 7.4, 10 mM KCl (Merck), 2 mM MgCl2 (Sigma), 1 
mM DTT (Bio-Rad) and 1 × Halt Protease Inhibitor Cocktail, and incubated for 1 hr 
on ice, subsequently homogenised with 30 strokes of the Dounce homogeniser and 
applied to 10 mL 30% (w/v) sucrose in NB buffer. After centrifuging at 700 g for 10 
min at 4 °C, each pellet was washed twice with 6 mL NB buffer, centrifuged as 
above, suspended in 1 mL NB buffer, and centrifuged again at 10,000 g for 10 min at 
4 °C. The final nuclear pellets were then disrupted with sample lysis buffer (as 
described previously, containing both Dnase 1 and Rnase A). Upon 30 min incubation 
at room temperature, the nuclear suspensions were centrifuged at 20,800 g for 10 min 
at 4 °C, and the supernatants were kept for analyses. 
 
2.3. PROTEIN ASSAY 
Protein concentration was measured at 595 nm absorbance, using the 
Coomassie Plus protein assay reagent kit (Pierce) with BSA as standard. 
 
2.4. 2-D DIGE 
For statistically significant analysis, duplicates for three independently 
harvested batches of HCT 116 mitochondrial samples (24 hr butyrate treatment and 
control) were analysed.    
2.4.1. CyDye labeling 
Protein labeling for 2-D DIGE was performed according to the protocol in the 
Ettan DIGE User Manual (GE Healthcare). Cy3 and Cy5 were used to label the 
control and butyrate-treated sample, respectively. For each 2-D DIGE gel, a total of 
400 pmol of each dye was added to 50 µg of protein contributed by each of the control 
and treated mitochondrial fraction. An equal amount of Cy2 was added to a mixture 
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pooled from equimolar of the control and treated samples from all three batches (each 
contributing 8.33 µg which is one-sixth of the 50 µg), to act as internal standard for 
image matching and cross-gel statistical analysis. 
2.4.2. IEF 
Immobilized pH Gradient (IPG) strips (GE Healthcare) (18 cm, pH 3-10, non-
linear (NL)) were rehydrated passively over-night with rehydration buffer consisting 
of 7 M urea, 2 M thiourea, 4% (w/v) CHAPS, 20 mM DTT, 0.2% (v/v) of appropriate 
IPG buffer (GE Healthcare), trace amount of bromophenol blue (Merck). Labeled 
samples containing 20 mM DTT and 0.5% (v/v) IPG buffer were then loaded using a 
sample loading cup on a universal strip holder, and focused on the IPGphor IEF unit 
(GE Healthcare). Isoelectric focusing was then performed with the following 
parameters: (i) 100 V, 100 Vhr; (ii) 200 V, 400 Vhr; (iii) 500 V, 500 Vhr; (iv) 1000 
V, 500 Vhr; (v) 1000-8000 V, 2250 Vhr; (vi) 8000 V, 36000 Vhr achieving a total of 
39750 Vhr in 9.5 hr (maximum current of 50 µA per strip, 20 °C). 
2.4.3. 2-DE 
Prior to the second dimensional separation by sodium dodecyl sulphate-
polyacylamide gel electrophoresis (SDS-PAGE), the focused IPG strips were 
subjected to a two-step equilibration: 15 min of reduction in 50 mM Tris-HCl 
(pH6.8), 6 M urea, 30% glycerol (BHD, Poole, England), 1% (w/v) DTT, 2% (w/v) 
SDS and trace amount of bromophenol blue; followed by 15 min of alkylation with 
2.5% (w/v) iodoacetamide (IAA) (Fluka) buffered at pH 8.8. 2-DE was performed as 
described in Liang et al. (2005). The 18-cm IPG strips were then loaded onto 18.3cm 
x 19.3cm, 1.0-mm, 12.5% polyacrylamide gels and sealed in place with 0.75% 
agarose dissolved in Tris/Glycine/SDS electrophoresis buffer with trace amount of 
bromophenol blue. Tris/Glycine/SDS electrophoresis buffer used was 25 mM Tris, 
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192 mM glycine (Bio-Rad) and 0.1% SDS. SDS-PAGE was performed at a constant 
current of 15 mA /gel for 20min followed by 30 mA /gel for 5-6 hr, using a 
PROTEAN II XL cell electrophoresis unit (Bio-Rad) cooled to 10ºC. Broad range 
molecular weight standards (Bio-Rad), applied on sample application strips (GE 
Healthcare) were electrophoresed concurrently. 
2.4.4. Fluorescence scanning and protein visualisation ?   
The Cy2 (mixed standard), Cy3 (control) and Cy5 (treated) components of each 
2-D DIGE gel were individually scanned using mutually exclusive 
excitation/emission wavelengths at 488/520 nm for Cy2, 532/580 nm for Cy3 and 
633/670 nm for Cy5, by Typhoon Variable Mode Imager 9400 (GE Healthcare). The 
resultant fluorescent gel images were viewed using ImageQuant v5.0 (Molecular 
Dynamics, Sunnyvale, CA, USA).  
2.4.5. DeCyder image analysis 
Computerised evaluations of the 2D-DIGE gel patterns were performed using 
DeCyder image analysis software v5.02 (GE Healthcare) as described in the Ettan 
DIGE User Manual. These allow simultaneous comparison of abundance changes 
across the three batches of control/treated samples which give a total of six DIGE gels 
including duplicates. Briefly, the DeCyder differential in-gel analysis (DIA) module 
was used to merge the Cy2, Cy3 and Cy5 images in each gel for spot detection and 
definition. Differences in protein abundance between the control/treated samples were 
then quantitated with respect to the internal standard present on the same gel. This is 
measured in terms of volume ratio (defined as the change in sum of pixel intensities 
within each spot boundary, between the two images). Next, the DeCyder biological 
variation analysis (BVA) module was then used to match all protein-spot maps from 
the six gels to an assigned master image (the 2-DE spot map with the most number of 
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spots). Manual checking and “landmarking” were done to make sure the matching 
was authentic. BVA then calculated the average volume ratios, as well as the paired 
student’s t-test p-values for the variance of the ratio of each differentially regulated 
protein spot in the three batches. A threshold limit of 1.4 fold difference was set as a 
significant quantitative change in this study. Student’s t-test at 95% statistical 
confidence (significance level, p < 0.05) was set. Only spots found in at least 5 out of 
6 gels, and with significant regulation in at least 2 out of the 3 batches, were selected. 
These were viewed using the three-dimensional (3-D) simulation of protein intensities 
to further confirm the list of significantly regulated spots to be excised.  
2.4.6. Vorum Silver Staining 
After SDS-PAGE and fluorescence image acquisition, the gels were fixed and 
silver stained according to the Vorum Silver Staining protocol (Mortz et al., 2001). 
Fixing of the gels was done in 50% (v/v) methanol (Merck), 12% (v/v) acetic acid 
(Merck) and 0.05% (v/v) formalin (Merck) for at least 2 hr. The gels were then 
washed in 35% (v/v) ethanol (Merck) thrice for 20 min and subsequently sensitized in 
0.02% (w/v) sodium thiosulphate (Merck) for 2 min. After each gel was rinsed thrice 
with double-distilled water for 5 min, they were incubated in 0.2% (w/v) silver nitrate 
(Merck) and 0.076% (v/v) formalin in water for 20min. The silver nitrate solution was 
discarded and the gels were washed in water twice, 1 min each time. Development 
was next done in 6% (w/v) sodium carbonate (Merck), 0.004% (w/v) sodium 
thiosulphate (Merck) and 0.05% (v/v) formalin. The developer was removed upon 
attaining the desired intensity and 1.46% (w/v) sodium EDTA (Bio-Rad) was added 
for 20 min to stop the reaction. Finally, each gel was washed thrice with water, 5 min 
per washing. Every step was conducted with constant shaking. The images of the 
Materials and Methods 
49   
 
 
silver stained gels were scanned and saved for analysis with the Image Master Lab 
Scan v3.01 software (GE Healthcare).  
 
2.5. MASS SPECTROMETRY (MS) 
2.5.1. Enzymatic digestion of protein spots 
In-gel tryptic digestion of differentially expressed protein spots was carried 
out as described in Neo et al. (2005). Previously selected spots were manually excised 
from the silver stained 2-D DIGE gels and transferred to 96-well polypropylene 
microtitre plates (Nalge Nunc) using a self-made plunger. Each gel plug was 
incubated in 150 µL of washing buffer consisting of 50% (v/v) acetonitrile (Applied 
Biosystems, Foster City, USA) and 2.5 mM ammonium bicarbonate (NH4HCO3) 
(Sigma) for at least 24 hr at 4 ºC.  
Following that, the washing buffer was refreshed, and the plate incubated at 37 
ºC for 10 min with constant shaking. The solution was then removed and the gel spots 
dried in a Savant Automatic Environmental Speed Vac AE2010 centrifugal 
concentrator (Holbrook, NY, USA) for 10 min. Each dried gel piece was then reduced 
by 20 µL of 10 mM DTT in 100 mM NH4HCO3, for 1 hr at 56 ºC. Following that, 
DTT solution was replaced with 20 µL of 55 mM IAA in 100 mM NH4HCO3, and the 
alkylation was done in the dark at room temperature, for 45 min. Subsequently, IAA 
was discarded and the protein spots were each equilibrated in 100 µL of 100 mM 
NH4HCO3 for 10 min at 37 ºC. Each gel spot was then dehydrated with in 100 µL of 
ACN, for 10 min. The two incubation steps with NH4HCO3 and ACN were repeated.  
Subsequently, enzymatic digestion was performed by incubating the spots 
with 10 µL of trypsin solution (20 µg/mL of sequence grade modified trypsin 
(Promega, Madison, USA); 25 mM NH4HCO3; 5 mM acetic acid) at 37 ºC for 16 hr. 
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Tryptic peptides from each gel spot was extracted with 10 µL of 0.1% trifluoroacetic 
acid (TFA) (Applied Biosystems) in 50% (v/v) ACN and 15 min sonication in an 
ultrasonic water bath (Crest Ultrasonics, Trenton, NJ, USA). 
2.5.2.  MS and database searching 
Peptides extracted from each gel spot were analysed by matrix-assisted laser 
desorption/ionization-tandem time-of-flight mass spectrometry (MALDI-TOF/TOF 
MS). The peptide digest from each gel spot was concentrated with Speed Vac. A 
volume of 0.5 µL of the concentrate was spotted onto a MALDI stainless steel plate, 
overlaid with equal volume of freshly prepared α-cyano-4-hydroxy-cinnamic acid 
(CHCA) matrix solution (10 mg/mL CHCA, 0.1% (v/v) TFA, 50% (v/v) ACN, 12 
µg/mL ammonium citrate (Sigma)). Upon crystallisation, the peptide fragments were 
analysed on a 4700 Proteomics Analyser mass spectrometer (MALDI-TOF/TOF MS) 
(Applied Biosystems). Peptide mass spectra were automatically acquired with a typsin 
autodigest exclusion list and the five most intense ions were selected for MS/MS. Up 
to 10,000 shots were accumulated for each spectrum. The collision gas was 
atmospheric air and the laser energy was 1 kV. Internal calibration was performed 
with 4700 Cal Mix (Applied Biosystems) composing of des-Arginine-Bradykinin 
904.468Da, Angiotensin I 1296.685Da, Glutamine-Fibrinopeptide B 1570.677Da, 
adrenocorticotropic hormone (ACTH) (1-17 clip) 2093.087Da, ACTH (18-39 clip) 
2465.199Da, and ACTH (7-38 clip) 3657.929Da. 
Interpretation of the MS data was carried out by the GPS Explorer software 
(Applied Biosystems) and database searching was done using the in-house MASCOT 
program (www.matrixscience.com; Matrix Science, London, UK). Both combined 
MS-MS/MS and MS/MS only searches were conducted with the following settings: 
UniProtKB/SWISSPROT (http://www.expasy.org/sprot/), or MSDB database 
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(http://csc-fserve.hh.med.ic.ac.uk/msdb.htm),  all entries, peptide tolerance at 200 
ppm, MS/MS tolerance at 0.3 Da, carbamidomethylation of cysteine (fixed 
modification), phosphorylation at serine, threonine and tyrosine (variable 
modifications), methionine oxidation (variable modification) and N-terminus 
acetylation (variable modification).  
Subsequently, UNIPROT (http://www.expasy.com) and NCBI/nr 
(http://www.ncbi.nlm.nih.gov/) non-redundant databases were manually searched to 
verify high-scoring protein identifications. The theoretical Mr and pI of each 
identified protein were compared with the gel region from which the protein was 
excised (experimental Mr and pI). An in-house 2-DE spot analysis program, ClickMe 
v3.11, designed by Jason Neo, was utilised to measure the experimental Mr and pI of 
the gel spots of interest. Subcellular localisations of the confirmed butyrate-regulated 
proteins in our mitochondrial fractions were studied through the afore-mentioned 
databases and current literature findings. 
  
2.6. SDS-PAGE / WESTERN BLOT  
2.6.1. 1-Dimensional (1-D) SDS-PAGE 
 5 µg of protein from the whole cell lysates of control and 24 hr butyrate-
treated HCT 116, or HT-29, and the corresponding subcellular fractions, were 
denatured at 95 ºC for 5 min, in sample loading buffer consisting of 0.125 M Tris-HCl 
(pH 6.8), 4% SDS, 10% DTT (Bio-Rad), 10% glycerol (Merck) and trace amount of 
bromophenol blue. The samples were then electrophoresed on a 1.0-mm 
polyacrylamide gel at a constant current of 15 mA/gel until the tracking dye front 
migrated to within 3 mm from the bottom of the gel, using Mini-Protean III gel 
apparatus (Bio-Rad). Acrylamide: bisacrylamide ratios of 12.5% and 10% were used 
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for gels in the preliminary assay of HCT 116 mitochondrial enrichment and the 
subsequent 1-DE profiles of mortalin subcellular expression in HCT 116 and HT-29, 
respectively. Precision Plus Protein dual colour standards (Bio-Rad) were 
electrophoresed concurrently in the Tris/Glycine/SDS electrophoresis buffer (as 
described previously).  
2.6.2. 1-D western immunodetection 
After electrophoresis, proteins were transferred onto 0.45 µm nitrocellulose 
membranes (Bio-Rad) in transfer buffer (Towbin buffer, consisting of 20% methanol, 
25 mM Tris, 192 mM glycine and 0.1% SDS).  
For the preliminary assessment of HCT 116 mitochondrial enrichment, the 
proteins were transferred electrophoretically using a Hoefer TE 70 Series Semi-Phor 
Semi-dry Transfer Unit (GE Healthcare). After western blotting, the nitrocellulose 
membrane was blocked with 5 % non-fat milk in PBS-T (PBS and 0.1% (v/v) Tween 
20 (USB)) at 4 ºC over-night. Mouse anti-pyruvate dehydrogenase PDH E1α 
monoclonal IgG (Molecular Probes, Eugene, OR) and goat horse radish peroxidase 
(HRP)-conjugated anti-mouse IgG antibodies (Santa Cruz Biotechnology, Santa Cruz, 
CA, USA) were used at dilutions of 1:500 and 1:2,500 in PBS-T with 1% (w/v) non-
fat milk, respectively. Reference actin controls were probed with rabbit anti-actin 
polyclonal IgG (Sigma) and goat HRP-conjugated anti-rabbit IgG antibodies (Santa 
Cruz Biotechnology) at dilutions of 1:2,000 and 1:2,500 in PBS-T with 1% (w/v) non-
fat milk, respectively. Three washes in PBS-T were performed after every 1-hr 
antibody incubation. 
For the detection of mortalin expression in subcellular fractions of HCT 116 
and HT-29 upon 24-hr butyrate treatment, the proteins were transferred 
electrophoretically using the Mini Trans-Blot Electrophoretic Transfer Cell (Bio-
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Rad). After western blotting, the nitrocellulose membranes were blocked with 5% 
BSA in TBS-T (20 mM Tris-HCl, 137 mM NaCl, 0.1% (v/v) Tween 20, pH 7.5) at 4 
ºC overnight. For mortalin detection, mouse anti-Grp75 IgG monoclonal antibody 
(Stressgen, Victoria, Canada) and sheep HRP-conjugated anti-mouse IgG antibody 
(GE Healthcare) were used at dilutions of 1:1,000 and 1:5,000 in TBS-T with 1% 
(w/v) BSA, respectively. Nuclear marker (Lamin B) was probed with mouse (clone 
101-B7) anti-Lamin B monoclonal IgG (Calbiochem, Darmstadt, Germany) and sheep 
HRP-conjugated anti-mouse IgG antibody at dilutions of 1:200 and 1:5,000, 
respectively. Mitochondrial marker (PDH E1α) was detected with mouse anti- PDH 
E1α IgG and sheep HRP-conjugated anti-mouse IgG antibody at dilutions of 1:500 
and 1:5,000, respectively. Lastly, cytosol marker (glyceraldehyde-3-phosphate 
dehydrogenase, GAPDH) was probed with rabbit anti-GAPDH (full-length) 
polyclonal IgG (Santa Cruz Biotechnology) and goat HRP-conjugated anti-rabbit IgG 
antibodies (Pierce) at dilutions of  1:1,000 and 1:5,000, respectively. Similarly three 
washes in TBS-T were performed after each 1-hr antibody incubation. 
2.6.3. 2-D western immunodetection 
 For the detection of various mortalin isoforms and the presence of 
phosphorylated serine (pSer) and tyrosine (pTyr) residues, 120 µg of proteins from 
HCT 116 and HT-29 control and butyrate-treated whole cell lysates, and subcellular 
fractions, were focused on 18-cm pH 3-10 NL IPG strip using the protocol: (i) 200V, 
400Vhr; (ii) 500V, 500Vhr; (iii) 1000V, 500Vhr; (iv) 1000-8000V, 2250Vhr; (v) 
8000V, 36000Vhr achieving a total of 39650Vhr in 8.5 hr. 
In the second dimension, separation was done in 10% polyacrylamide gels, 
where the dye front was allowed to migrate past the bottom gel boundary, so that the 
75-66 kD region of the gel was at least 4.5 cm in length. This was done by constantly 
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monitoring the Precision Plus Protein dual colour standards electrophoresced 
concurrently. In this way, the 74 kD mortalin isoforms can be resolved from the other 
proteins present above and below it in the 2-DE gel. 
After 2-DE, proteins were transferred electrophoretically onto nitrocellulose 
membrane using the Trans-Blot® Electrophoretic Transfer Cell (Bio-Rad). The post-
transfer nitrocellulose membranes were blocked overnight with 5 % (w/v) BSA in 
TBS-T at 4 ºC, and detected for mortalin as previously described. Immunodetection of 
pSer and pTyr in the 2-DE blot of HCT 116 mitochondrial fractions were conducted 
using mouse anti-phosphotyrosine IgG2b PY20 (BD Biosciences, Franklin Lakes, NJ, 
US) and mouse anti-phosphoserine IgM (Calbiochem) at 1:1,000 and 1:200 dilutions 
TBS-T with 1% BSA, respectively. The anti-pSer and anti-pTyr blots were than 
subsequently probed with goat anti-mouse IgM, µ chain specific (Pierce) and IgG, 
whole molecule (Sigma) HRP-conjugated antibodies, at dilutions 1:2,500 and 1: 
2,000, respectively.  
2.6.4. Visualisation of immunoreactive proteins 
The immunoblots were than soaked in enhanced chemiluminescence (ECL) or 
ECL-Advance Western blotting detection reagents (GE Healthcare) for 3 min. 
Membranes were then exposed to Kodak Biomax MR Film (Kodak, Rochester, NY). 
SuperSignal West Dura Extended Duration Substrate (Pierce) was also applied to 
achieve stronger and more specific signals in some cases. 
2.6.5. MS/MS confirmation of mortalin isoforms  
After immunodetection, equal transfer was ascertained by subjecting the 
immunoblots to colloidal silver staining, using a mixture of 40% (w/v) sodium citrate 
(Merck), 20% (w/v) iron II sulfate heptahydrate (Merck), and 20% (w/v) silver 
nitrate, added sequentially. The colloidal stained blots of HCT 116 whole cell lysates 
Materials and Methods 
55   
 
 
and mitochondrial fractions were then matched to silver stained 2-DE gels of the 
samples run parallel during 2-DE.  The immunodetected mortalin spots were 
identified and excised from the 2-DE gels for further verification through MALDI-
TOF/TOF MS identification. 
In-gel trypsin digestion was performed as described. The peptide digests from 
each gel spot were completely dried by Speed Vac and recovered in 1.2 µl CHCA 
matrix solution (5 mg/mL CHCA in 0.1% (v/v) TFA, 50% (v/v) ACN, 12 µg/mL 
ammonium citrate). About 1 µl of the peptide-matrix mixture was spotted onto the 
appropriate MALDI sample plate for analysis by the ABI 4800 Proteomics Analyser 
mass spectrometer (MALDI-TOF/TOF MS) (Applied Biosystems). MS data were 
typically acquired with around 500 shots per sample well, with the five most intense 
ions selected for MS/MS. The peptides were subsequently subjected to MS/MS 
analyses using air with collision energy of 2 kV and collision gas pressure of 2 x 10-6 
Torr. Stop conditions were implemented so that 2000 to 3000 shots were accumulated 
depending on the quality of the tandem mass spectra. Interpretation was carried out 
using the GPS Explorer software and MASCOT search engine. The International 
Protein Index (IPI) human database Version 3.18 (Kersey et al., 2004) was used for 
the search of tryptic peptides. The search parameters only allowed N-terminal 
acetylation, cysteine C-terminal carbamidomethylation and methionine oxidation. 
Peptide mass tolerance and fragment mass tolerance were set to 150 ppm and ± 0.4 
Da respectively. The apparent pIs of the differently charged mortalin isoforms were 
estimated following the instructions and using the pH gradient graphs given in the 
Immobiline DryStrip Visualisation of pH Gradients manual (GE Healthcare). 
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2.7. BIOINFORMATIC PREDICTIONS 
2.7.1. Phosphorylation sites prediction via NetPhos 
The amino acid sequence of human mortalin, available at the UniProt database 
entry of accession number P38646 (http://au.expasy.org/uniprot/P38646), was 
submitted at the NetPhos 2.0 Server (http://www.cbs.dtu.dk/services/NetPhos) (Blom 
et al., 1999) for the prediction of phosphorylation sites of all three available 
residues—tyrosine, serine, and threonine.     
2.7.2. Phosphorylation sites prediction via Scansite 
 The UniProt accession number of mortalin (P38646) was submitted to the 
Motif Scanner available on Scansite (http://scansite.mit.edu/) (Obenauer et al., 2003), 
with the search parameters set to find all motifs and groups, at medium stringency, 
and to show predicted domains in sequence. 
Prediction results were subsequently cross-compared and compiled, together 













3.1. ENRICHMENT OF HCT 116 MITOCHONDRIAL PROTEOME 
3.1.1. Enrichment of mitochondrial marker upon subcellular 
fractionation 
 
 Four independent batches of HCT 116 mitochondrial fractions were harvested 
as previously described. These were then compared to two independent crude, i.e. un-
fractionated, HCT 116 whole cell lysates on a 1-D SDS-PAGE gel (Figure 3.1A). 
Differences in the 1-DE protein band patterns were observed upon enrichment, such 
as the more intensified banding at the 40-20 kD molecular weight region of the gel 
(note boxed regions in Figure 3.1A). 
 More specifically, we performed western immunodetection of the 
mitochondrial matrix protein, pyruvate dehydrogenase E1 alpha subunit (PDH E1α), 
among the mitochondrial fractions and crude lysates. Significant mitochondrial 
enrichment was shown in Figure 3.1B where PDH E1α could be detected in the 
mitochondrial fractions but not the whole cell lysates. The colloidal stained image of 
the nitrocellose membrane used for immunodetection in Figure 3.1C showed uniform 
transfer of proteins among the mitochondrial and crude fractions, and hence reflected 
true enrichment of the mitochondrial marker protein. 
Results 



















































Figure 3.1: 1-DE profile of whole 
cell lysates and mitochondrial 
fractions and immunodetection 
of mitochondrial marker 
enrichment. 
A. 1-D SDS-PAGE was performed to 
compare the expression profiles of 
mitochondrial fractions (lanes 3-6) 
and crude whole cell lysates (lanes 1-
2). Boxes indicate areas of differences 
between the crude (green) and 
mitochondrial (red) fractions. 5 µg of 
protein was loaded in each lane. 
B. Immunodetection of mitochondrial 
matrix protein, pyruvate 
dehydrogenase E1α (PDH E1α) in the 
mitochondria-enriched fractions (3-6). 
Actin was co-detected as loading 
control.  
C. Colloidal silver-stained 
nitrocellulose membrane post 
immunodetection showed uniform 
transfer of proteins across fractions. 
 
Untreated and butyrate-treated whole cell 
lysates (Lane 1 and 2); untreated 
mitochondrial fraction (Lane 3, 4 and 6); 
butyrate-treated mitochondrial fraction 
(Lane 5); Biorad prestained molecular 
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3.1.2. 2-DE profile of HCT 116 mitochondrial proteome 
To assess the effective enrichment of proteins from the various compartments of 
the mitochondrial organelle, the mitochondria-enriched sample was further compared 
to the whole cell lysate using 2-D DIGE (Figure 3.2). Equal amounts of whole cell 
lysate (Cy3-labeled) and mitochondrial fraction (Cy5-labeled) were resolved and 
visualised on a 2-DE gel. We observed the significant enrichment of many proteins 
(~202 red spots), simultaneous reduction of several others (~204 green spots), as well 
as the maintained expression of the rest (~65 yellow spots) in the mitochondrial 
fraction compared to the crude whole cell lysate. Hence, we have achieved significant 
reduction of sample complexity in our mitochondrial fraction and the enrichment of 
previously masked lower-abundance mitochondrial proteins. 
The red and yellow spots were then excised from a corresponding silver-
stained gel (Figure 3.3). MALDI-TOF/TOF MS and MASCOT data-mining of the 
UniProt and NCBI/nr database were next performed to identify the various protein 
spots. These spots are labeled ‘R’, ‘Y’ and ‘N’ respectively, in Figure 3.3. Out of the 
299 spots analysed, 145 spots were positively identified—with a probability score 
calculated higher than 70 and a minimum of two matching peptides sequenced. Most 
of the spot positions in the 2-DE map correlated well with the theoretical Mr and pI 
values of the identified proteins.  
As surveyed in Table 3.1, 69 (~49%) of the identified spots were 
mitochondrial proteins, most of which were detected as being enriched in the 
mitochondrial fraction (Refer to Table 3.2 for list of mitochondrial protein spot 
identities (ids)). The successful separation and identification of mitochondrial proteins 
from all four different compartments of the mitochondrial organelle—matrix, inner 
membrane, inter-membrane space and outer membrane—signifies that the nitrogen 
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cell disruption method and isolation protocol are gentle enough for the isolation of 
intact mitochondria. 
Many proteins were represented by two or more distinct spots on the 2-DE gel, 
indicating the presence of multiple isoforms with different masses and charges 
(Figure 3.3, Table 3.2). This phenomenon is especially prominent for mitochondrial 
proteins which are known to be subjected to many forms of regulation and PTMs 
(Fountoulakis et al., 2002). For instance, mortalin was represented by 5 different 2-
DE spots (Y27, Y28, R41, R57, and R58 in Figure 3.3) in our study. Altogether, 90 
unique proteins were identified from the 141 2-DE spots of the HCT 116 
mitochondrial fraction, excluding 4 BSA spots, which were likely to be contaminants 
from the mitochondria extraction media used. 
As summarised in Figure 3.4, of the 90 unique proteins identified, 37 (41%) 
are well-characterised mitochondrial proteins; on the other hand, 39 (43%) are known 
to be cytoplasmic, nuclear or membrane associated; while 9 (10%) are known to 
localise in the endoplasmic reticulum (ER) and Golgi network; and the remaining 5 
(6%) have no available subcellular localisation information. Although, a portion of 
the proteins identified have no reported mitochondrial origins, to date, it is highly 
likely that they could be localised in the mitochondria, associated with the 
mitochondrial membrane, or interacting with other proteins that translocate to the 
mitochondria in HCT 116 cells. Alternatively, they may be contaminants from the 
mitochondrial enrichment process. In short, our mitochondrial fractionation protocol 
has effectively enriched the HCT 116 mitochondrial proteome for 2-DE gel analysis. 
With close to 50% protein spots confirmed to be mitochondrial in origin, our method 
is comparable to those of recent studies in terms of specific enrichment and detection 
of mitochondrial proteins (Fudaka et al., 2004; Jiang et al., 2005). This is especially 
Results 
61   
 
 

























Figure 3.2: DIGE comparison of the proteomes of HCT 116 crude whole cell 
lysate and mitochondria-enriched fraction. Equal amounts of Cy3-labeled whole 
cell lysate (shown as green) and Cy5-labeled mitochondrial fraction (red) were 
combined and resolved on a pH 3-10 and 12.5% polyacrylamide gel and visualised via 
fluorescence scanning. Spots that are red and orange represent proteins that were 
significantly enriched while green spots signify proteins that were decreased or 
removed, upon subcellular fractionation. Yellow spots indicate proteins of equal 
abundance in both crude and mitochondrial fractions. 
pH 3 pH 10 
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Figure 3.3: Mitochondrial proteins identified from the silver-stained 2-DE gel of 
HCT 116 mitochondria-enriched fraction. Spots circled in blue represent proteins 
successfully identified through MALDI-TOF/TOF MS (refer to Table 3.1 for 
identities). Spots annotated with “R” correspond to red (i.e. enriched) spots in Figure 
3.2, while those with “Y” correspond to yellow (i.e. equally expressed) spots. Spots 
annotated with “N” represent “new” spots that were found on the silver-stained gel 
map but not the 2-D DIGE map. 
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between whole cell lysate 
and mito fraction) 
Red 
(specifically enriched 
in mito fraction) 
New 
(not found in previous 
DIGE gel image, but 
present in 2-DE profile) 
 Total no. of spots identified 33 101 11 
No. of mitochondrial proteins 
identified 6 58 5 
Matrix 3 18 4 
Inner membrane 2 18 1 
Outer membrane - 2 - 
Inter-membrane 





Unspecified* 1 18 - 
Cytosolic; 




6 3 - 
Plasma Membrane 3 7 - 
Nuclear - 1 1 
Other proteins # 
Unknown - 4 1 
BSA (from extraction media) - 4 - 
Percentage of Mitochondrial 
proteins among identified proteins, 
excluding BSA spots (%) 
(6/141×100%=) 4.3 (58/141×100%=) 41.1 (5/141×100%=) 3.5 
‘*’—Mitochondrial proteins have not/yet to be localized in one specific compartment of the mitochondrial organelle, so are not assigned a sub-
organellular  localisation.  
‘# ’—Identified proteins with other reported subcellular localisations and have not been characterised to be mitochondrial in origin. 





























Figure 3.4: Graph showing the subcellular distribution of the unique proteins identified 
through the preliminary survey of the HCT 116 mitochondrial fraction. Out of the 145 
spots identified, 69 were of known mitochondrial proteins. These represented 37 different 
proteins and 41% of the total number of unique proteins identified. 
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Table 3.2: List of mitochondrial proteins identified in HCT 116 mitochondrial fraction 












Mr (Da) / pI 
Y27 263  70676.60 / 5.38 
Y28 337 70008.51 / 5.45 
R41 86 95395.74 / 6.53 
R57 385 72012.77 / 5.54 




R58 237 72680.85 / 5.64 
Y33 181 60621.95 / 5.17 
Y34 512 60365.85 / 5.23 
R198 792  60555.56 / 5.30 
2 60 kDa heat shock protein, 
mitochondrial, chaperonin P10809 Matrix 
61187 /  
5.70  
R199 395 60814.81 / 5.37 
Y47 459 52682.93 / 5.03 
R108 378 63666.67 / 6.51 
R113 375 53037.04 / 5.09 
3 ATP synthase beta chain P06576 Inner 
membrane 
56525 /  
5.26  





P13995   37468 / 8.86  Y64 176 
38903.23 / 
7.83 
R49 76 92055.32 / 7.28 
R53 303 79361.70 / 5.39 5 
NADH-ubiquinone 




80491 /  
5.89 





R75 216 85374.47 / 5.98 
R76 176 88714.89 / 5.98 
6 Mitochondrial inner 
membrane protein, Mitofilin Q16891 
Inner 
membrane 
84026 /  
6.08  
R77 196 85374.47 / 6.07 
7 Aconitase 2 Q8TAQ6   86252 / 7.62 R90 57 
86042.55 / 
7.48 
R94 305 77357.45 / 6.33 
R101 290 72012.77 / 6.41 
R102 300 72012.77 / 6.47 
8 Heat shock protein 75 kDa, 
mitochondrial  Q12931   
80246 / 
8.05  
R103 280 71344.68 / 6.54 
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72692 /  
7.06  R105 95 
67336.17 / 
6.39 
R106 60 65222.22 / 6.41 
R122 309 49148.15 / 5.51 10 
Ubiquinol-cytochrome-c 
reductase complex core 





R126 233 49148.15 / 5.61 
R131 74 55629.63 / 5.83 











12 Aldehyde dehydrogenase P05091 Matrix 56859 / 6.63  R132 80 
55629.63 / 
5.87 




R139 155 55111.11 / 6.19 14 Mitochondrial processing peptidase alpha subunit Q10713 Matrix             





R143 431 58481.48 / 7.05 15 Dihydrolipoyl dehydrogenase P09622 Matrix 
54686 / 
7.59  R144 121  58481.48 / 7.30 
16 SAM50-like protein CGI-51 Q9Y512 Outer 
membrane     
52328 / 
6.44  R145 151 
55888.89 / 
6.75 
R149 294  54074.07 / 7.24 17 Glutamate dehydrogenase 1 P00367 Matrix 61701 / 7.66  R150 217 54333.33 / 7.48 
18 Succinyl-CoA ligase [ADP-forming] beta-chain Q9P2R7   
50331 / 
7.05  R152 112 
44885.25 / 
5.79 
19 Mitochondrial processing peptidase beta subunit O75439 Matrix             
55073 /  
6.38  R154 367 
 49666.67 / 
6.03 
R157 341  46555.56 / 6.21 20 Ornithine aminotransferase P04181 Matrix 48847 / 6.57  R158 128 46555.56 / 6.34 
R159 575 45518.52 / 6.67 21 Elongation factor Tu P49411   49542 /  7.26  
R160 531 45518.52 / 6.90 
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Mr (Da) / pI 
22 Fumarate hydratase P07954   54773 / 8.85 R162 56 
46814.81 / 
7.60 
R167 258 42016.39 / 6.34 23 Mitochondrial 28S 
ribosomal protein S22 P82650   
41425 / 
7.70  R169 72 42131.15 / 6.52 
24 Acyl-CoA dehydrogenase, 
short-chain specific P16219 Matrix  
44611 / 
8.13  R168 68 
42131.15 / 
6.43 






8.59  R173 442 40639.34 / 7.58 
26 Delta3,5-delta2,4-dienoyl-CoA isomerase Q13011  
36314 /  
6.61  R177 102 
34672.13 / 
6.23 
27 Electron transfer flavoprotein alpha-subunit P13804 Matrix  
35400 / 
8.62  R179 81 
 34557.38 / 
7.52 
28 Voltage-dependent anion-




6.32  R181 167 
36049.18 / 
7.80 
29 Prohibitin P35232 Inner 
membrane 
29843 / 
5.57  R184 462 
32032.79 / 
5.45 
30 Enoyl-CoA hydratase P30084 Matrix 31807 / 8.34  R188 129 
 30371.90 / 
6.03 
31 3,2-trans-enoyl-CoA isomerase P42126 Matrix 
33080 / 
8.80  R189 140 
31459.02 / 
6.15 
R191 311 28173.55 / 6.07 32 Thioredoxin-dependent peroxide reductase P30048   
28017 / 
7.68  R192 163 28330.58 / 6.33 
33 Single-stranded DNA-binding protein Q04837   
17249 /  




Complement component 1, 
Q subcomponent binding 
protein 
Q07021 Matrix 31742 / 4.74  N12 114 
35819.67 / 
3.83 
35 Ubiquinol-cytochrome c 
reductase iron-sulfur subunit  P47985 
Inner 
membrane 
29918 /  
8.55  N17 132 
29194.21 / 
6.49 
36 Superoxide dismutase [Mn] P04179 Matrix 24878 / 8.35  N18 90 
26524.79 / 
7.33 
N31 268  10115.70 / 9.14 37 10 kDa heat shock protein P61604 Matrix 10794 /  8.91  
N32 68  10272.73 / 9.42 
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3.2.  MITOCHONDRIAL PROTEOMICS OF BUTYRATE-TREATED 
HCT 116 CELLS 
3.2.1. Batch-to-batch reproducibility among mitochondrial fractions 
Three independent batches of control and butyrate-treated mitochondrial fractions 
were harvested and shown to be highly similar in their 2-DE profiles (Figure 3.5), 


























































Figure 3.5: Rapid assessment of reproducibility amongst 3 independent 
harvestings. A. Control and butyrate-treated HCT 116 mitochondrial fractions of 
Batch 1; B. Batch 2; and C. Batch 3, displayed highly similar 2-DE spot patterns 
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3.2.2. 2-D DIGE analysis of HCT 116 mitochondrial proteome changes 
upon butyrate treatment 
Mitochondrial dysfunction and apoptosis have been implicated in the 
chemotherapeutic effects of butyrate but the exact mechanisms by which butyrate 
causes them are not clear. Upon establishing significant enrichment in our 
mitochondrial fractions, we proceeded to do functional proteomics analysis of the 
HCT 116 mitochondria upon 24-hr 5-mM butyrate treatment. To ensure that the 
proteome alterations were not due to biological or technical variation, the three 
independent batches of control and butyrate-treated mitochondrial samples (as 
previewed in Figure 3.5) were analysed using DIGE, in duplicates—making up a total 
of six gels. An internal standard—pooled from equal amounts of the six samples—
was present in every gel.  
Control and treated samples from each experimental batch were pre-labeled 
with Cy3 and Cy5 respectively, while the internal standard, with Cy2. Figure 3.6 
shows a representative 2-D DIGE image of one of the gels. By overlaying the Cy3 
and Cy5 fluorescently-scanned images, differential expression of individual protein 
spots were detected via ImageQuant and quantitated with the DeCyder software (red 
and green spots represent proteins up-regulated and down-regulated by butyrate 
respectively). We noted that majority of the spots on the 2-DE gel were yellow, i.e. 
not regulated. This implied that butyrate treatment modulated the expression of a 
small number of specific protein targets in the mitochondrial proteome of HCT 116 
cells rather than causing extreme perturbation resulting in disruption or destruction of 
the mitochondrial proteome. Confirming this, analysis by DeCyder BVA yielded 92 
significantly regulated spots (student’s t-test p<0.05) at 1.4 fold and above, out of the 
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Figure 3.6: Representative 2-D DIGE image of control and butyrate-treated 
mitochondrial fractions of HCT 116 cells. Cy3-labeled control (green) and Cy5-
labeled treated (red) proteome images were overlaid to display the differences in protein 
expression (up-regulated spots, red; down-regulated spots, green; unregulated, yellow). 
75 µg each of control, treated and internal standard (Cy2-labeled; not shown) were 
combined into a total of 150 µg of proteins and separated via first dimension IEF on a 
18-cm pH3-10 NL IPG strip, and second dimension gel electrophoresis on a 12.5% 
polyacrylamide gel. 
pH 3 pH 10 
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3.2.3. Proteome alterations in the HCT 116 mitochondria upon butyrate 
treatment 
In our study, we used the available information on the UniProt and NCBI/nr 
databases, as well as published research findings, to ascertain the mitochondrial origin 
of the proteins. Of the differentially expressed spots analysed, 47 were successfully 
identified through MALDI-TOF/TOF MS. These accounted for 28 unique proteins, 
with the presence of multiple isoforms for certain proteins—possibly arising from 
different forms of regulation, PTMs and proteolysis initiated by butyrate. Out of 
these, 18 protein ids (25 spots) are proteins with well-characterised mitochondrial 
functions in databases and published literature (Figure 3.7). These include enzymes 
with metabolic and redox functions; components of the respiratory complexes; 
regulators of protein import and folding; members of the mitochondrial RNA 
translation system, and proteins implicated in apoptosis, or cell death.  
Four of the differentially expressed mitochondrial proteins are well-known 
residents of subcellular compartments other than mitochondria, but have also been 
reported to be found in the mitochondria in later studies. They are catalase; 
heterogenous nuclear ribonucleoproteins (hnRNPs) hnRNP C1/C2, and hnRNP K; as 
well as cathepsin B. In addition, we have identified 15 differentially expressed 
proteins (18 spots) which have yet to be reported to be localised in the mitochondria 
(Figure 3.8, Table 3.3). Most of these were up-regulated in the mitochondrial fraction 
upon butyrate treatment, possibly indicating a butyrate-induced translocation to the 
mitochondria. Nevertheless, these could also arise from differential contamination of 
the mitochondrial fractions by other organelles. However, in view of the 
reproducibility of our samples (Figure 3.5) and the statistical stringency of the DIGE 
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analysis, these proteome changes were more likely to be significantly induced by 
























Figure 3.7: Butyrate regulation of well-characterised mitochondrial proteins in 
HCT 116 mitochondrial fraction. 2-D DIGE gel of HCT 116 mitochondrial fractions 
was stained with silver and differentially protein spots were excised for MS/MS 
identification. Identified spots are annotated with spot numbers and protein identities. 
↓ represents down-regulated and ↑ represents up-regulated.  





























































Figure 3.8: Other butyrate-regulated proteins in HCT 116 mitochondrial fraction. 
2-D DIGE gel showing differentially expressed spots identified to be proteins currently 
not documented to be localised in the mitochondrial yet. These are nevertheless 
interesting candidates for further investigation of novel localisation in the HCT 116 
mitochondrial and possible association/dissociation with the organelle upon butyrate 

































pH 3.0 pH 10.0 
Results 
73 
Table 3.3: Differentially expressed HCT 116 mitochondrial fraction proteins upon butyrate treatment, detected by DIGE, identified by MALDI-TOF/TOF MS 
N.B.: DIGE data are presented in terms of average ratio (Av. Ratio)—a measure of protein spot intensity in the treated samples relative to the control samples. 
DIGE Resultsa MALDI-TOF/TOF MS Protein Identification Resultsb 
Spot 
no. 





Expt Mr / 
pI 
Theor. 
Mr / pI 
Subcell. 
Loc. 
Mitochondrial proteins (Metabolism & Redox) 




6.37 Mito matrix 
Catalase P04040 38-46, 354-362, 365-379, 431-443, 444-455 48 194 64090.91 / 8.09 59816 / 6.95 Mito / Perox  
1640 3.40E-05 1.54 Delta-1-pyrroline-5-
carboxylate dehydrogenase 
(P5CDH) 
P30038 32-47, 305-310, 319-325, 403-408 36 75 64090.91 / 8.09 62169 / 8.25 Mito matrix 
2256 0.00067 1.77 33-46, 50-64, 67-76, 78-96, 114-129, 170-180, 156-161, 275-292, 332-351, 363-372, 387-392 47 629 
46636.36 / 
6.40 
2211 1.50E-05 1.85 
Ornithine 
Aminotransferase (OAT) P04181 33-46, 50-64, 67-76, 156-161, 170-180, 363-372, 
387-392 48 369 
47727.27 / 
6.65 
48846 / 6.57 Mito matrix 




P11310  47-53, 58-69, 70-79, 179-189, 218-235, 249-256, 260-271, 280-294, 340-348, 350-358, 396-408 35 410 
46090.91 / 
8.15 47015 / 8.61 Mito matrix 
2546 1.10E-04 1.61 71-88, 160-170, 171-189, 257-269, 270-284, 285-294, 348-355, 409-426 42 485 
42570.25 / 
6.03 





160-170, 257-269, 270-284, 285-294, 348-355 41 184 42570.25 / 6.25 
47797 / 6.53 Mito matrix 
2181* 0.00054 1.41 
Pyruvate dehydrogenase 
E1 alpha subunit (PDH 
E1α) 
P08559 46-58, 120-127, 227-235, 245-253, 246-253, 278-288, 289-302, 303-311 41 288 48545.45 / 7.11 43952 / 8.35 Mito matrix. 
2555 0.0014 -1.61 
185-202, 203-220, 251-262, 302-314, 333-347, 
333-347(1 Ser/Thr-phos), 383-388, 392-401, 405-
413, 439-447 
55 397 41644.63 / 7.57 
2556 8.50E-05 -2.02 
110-126, 184-202, 251-262, 318-328, 353-359, 
360-370, 383-388, 392-401, 405-413, 427-438, 
439-447 
53 634 41644.63 / 8.11 
2561 0.0026 -1.64 
Coproporphyrinogen III 
oxidase (CPO) P36551 
110-126, 203-220, 251-262, 302-314, 383-388, 
392-401, 405-413, 427-438, 439-447 55 531 41760.33 / 7.87 













Expt Mr / 
pI 
Theor. 
Mr / pI 
Subcell. 
Loc. 
Mitochondrial proteins (Oxidative Phosphorylation; Respiratory Chain Complexes) 
2480 0.00016 -1.69 
NADH-ubiquinone 
oxidoreductase 42 kDa 
subunit 
O95299 117-122, 131-139, 229-242, 327-332 42 128 42685.95 / 8.26 41067 / 8.67 Mito matrix 
1265θ 0.0049 -1.51 
NADH-ubiquinone 
oxidoreductase 75 kDa 
subunit 
P28331 63-68, 185-200, 361-382, 409-417, 451-467, 471-483, 519-538, 593-602, 625-643 55 537 
83584.00 / 
5.57 80491 / 5.89 
Mito inner 
membrane 
4415* 0.023 -1.51 ATP synthase D (δ subunit) P30049 137-150, 151-156 19 70 16594.26 / 4.07 17479 / 5.38 
Mito inner 
membrane 
Mitochondrial proteins (Protein Import & Folding) 
1346θ 0.00097 -1.64 
Stress-70 protein 
(Mortalin) P38646 
77-85, 86-99, 127-135, 188-202, 207-218, 266-
284, 349-360, 378-391, 378-391(1 Met-Ox), 395-
405, 499-513, 568-574 
49 832 79188.00 / 5.58 73920 / 5.87 
Mito inner 
membrane 
3065* 0.0077 -2.26 84-93, 106-117, 134-143 19 85 34008.26 / 5.58 
3101 0.011 -1.73 36-41, 84-93, 106-117, 134-143, 187-195, 220-239 49 305 33082.64 / 5.57 
3196 0.045 1.51 84-93, 106-117, 134-143, 187-195, 240-253, 241-253 37 196 
32851.24 / 
5.35 
3214* 0.00039 -1.58 
Prohibitin P35232 
12-35, 36-41, 84-93, 94-105, 106-117, 134-143, 
187-195, 220-239, 240-253 54 745 
31694.21 / 
5.57 
29843 / 5.57 Mito inner 
membrane 
2359* 0.046 -1.51 
Probable mitochondrial 
import receptor subunit 
TOM40 homolog 
O96008 92-102, 92-102(1 Met-Ox), 185-195, 240-253, 240-253(1 Met-Ox), 278-293, 316-330 25 183 
44537.19 / 




Mitochondrial proteins (RNA Translation) 
4358 0.0051 -1.56 Mitochondrial 39S 
ribosomal protein L49 Q13405 12-35, 38-50, 63-76, 77-87, 135-148 51 229 
17061.48 / 
8.31 19243 / 9.47 Mito matrix 
1589* 0.042 2.02 70-86, 306-316 32 128 66628.00 / 5.16 
1604* 0.024 -2.31 
Heterogeneous nuclear 
ribonucleoprotein K  
(hnRNP K) 
P61978 
22-35, 70-86, 180-191, 192-201, 306-316, 317-
325, 423-433,  33 271 
66000.00 / 
5.23 










Expt Mr / 
pI 
Theor. 
Mr / pI 
Subcell. 
Loc. 
Mitochondrial proteins (Apoptosis / Cell Death) 




P07910 51-61, 143-151 18 74 41413.22 / 5.20 33725 / 4.95 
Mito / Cyto / 
Nu 
3157 0.018 1.46 Cathepsin B P07858 224-237, 315-331 28 94 33545.45 / 5.25 38752 / 5.88 
Lyso / Cell 
surface / 
Mito 
Proteins of unconfirmed mitochondrial origin 
730 0.0076 1.52 150 kDa oxygen-regulated protein (ORP150) Q9Y4L1 
107-119, 120-131, 159-170, 171-185, 252-262, 
252-262(1 Met-Ox), 283-291, 346-358, 439-451, 
481-486, 541-555, 754-768, 804-811 
51 622 137777.78 / 5.21 
111494 / 
5.16 ER 
1244 0.034 1.52 51-60, 209-216, 241-249, 281-296, 472-482, 628-644 43 191 
83584.00 / 
8.15 
1602* 0.019 -1.55 
Lamin A/C P02545 
29-41, 209-216, 250-261, 281-296 35 167 65454.55 / 6.67 
74380 / 6.57 Nu 
1676 89.20E-07 4 
T-complex protein 1, alpha 
subunit (TCP-1α) P17987 1-11(1 N’-acetyl), 131-145, 299-309 26 115 
63272.73 / 
6.25 60819 / 5.80 Cyto 
1696 0.032 -1.58 T-complex protein 1, 
epsilon subunit (TCP-1ε) P48643 
43-49, 133-142, 203-210, 248-261, 345-352, 371-
378, 401-410, 515-525 46 467 
62727.27 / 
5.56 60089 / 5.45 Cyto 




P12268 137-149, 182-195, 196-203, 209-224, 243-259, 312-322, 350-355, 357-375, 494-511 45 390 
60000.00 / 
7.46 
56226 /  
6.44 -- 
1190* 0.038 -2.09 
Lamina-associated 
polypeptide 2 isoform 
alpha 
P42166 17-32, 253-263, 416-426, 500-510 23 121 87352.00 / 8.41 75885 / 7.80 Nu 
2323 0.021 1.5 19-28, 85-95, 96-113, 197-206, 239-254, 292-312, 329-335, 360-372,  45 462 
45545.45 / 
5.50 
2353 0.0021 1.49 19-28, 85-95, 96-113, 197-206, 239-254, 292-312, 329-335, 360-372, 292-312 (1 Met-Ox) 57 559 
44884.30 / 
5.41 
2345* 0.03 1.51 




19-28, 96-113, 197-206, 292-312, 239-254, 329-
335, 360-372 45 546 
44884.30 / 
5.36 










Expt Mr / 
pI 
Theor. 
Mr / pI 
Subcell. 
Loc. 
2396 0.024 1.51 8-24, 25-32, 25-32, 112-118, 126-138, 151-159,169-176, 216-226, 254-264,266-274 58 250 
44305.79 / 
5.65 
3590 0.0059 1.83 8 -24, 25-32, 112-118, 126-138, 151-159, 167-176, 177-187, 217-226 15 562 
28352.46 / 
5.57 
4117 0.009 1.75 
Keratin, type I cytoskeletal 
19 (Cytokeratin 19) P08727 
126-138, 151-159, 167-176, 169-176, 217-226 40 188 20799.18 / 4.85 
44079 / 5.05 Cyto 




P50453 144-158, 171-181, 214-223 27 85 43611.57 / 5.70 43004 / 5.61 Cyto 
2362 0.033 1.5 Selenide, water dikinase 1 (SPS 1) P49903 5-16, 33-40, 64-76, 284-298, 345-359 29 171 
44537.19 / 
5.75 43396 / 5.65 -- 
2219 0.0085 1.6 137-148, 149-157, 253-260, 301-313 38 223 47727.27 / 5.85 
2264 0.0028 1.48 137-148, 149-157, 175-185, 253-260 19 71 46909.09 / 5.82 
3441 0.0011 3.43 
Keratin, type I cytoskeletal 
18 (Cytokeratin 18) P05783 
6-13, 90-96, 124-130, 131-136, 137-148, 149-157, 
158-164, 165-174, 167-174, 175-185 34 437 
29676.23 / 
7.35 
47897 / 5.34 Cyto/ Peri-Nu 
2719 0.019 -1.53 Annexin A2 (Annexin II) P07355 
10-27, 28-36, 49-62, 68-76, 119-134, 135-144, 
157-168, 178-195, 179-195, 196-203, 212-219, 
220-226, 233-244, 273-278, 313-323 
64 1090 39214.88 / 8.76 38677 / 7.56 Cell surface 
2820 0.033 1.56 60S acidic ribosomal protein P0 P05388 17-26, 27-38, 67-77, 84-92, 135-146, 215-220 33 229 
38983.47 / 
6.14 34423 / 5.72 Ribo 
1465* 0.048 1.61 T-plastin O88818 166-178, 245-253, 264-272, 318-333, 516-527 45 165 71652.00 / 5.65 70888 / 5.52 Cyto 
2963 0.00087 -1.73 Uncharacterised protein C20orf72 Q9BQP7 
40-51, 87-94, 96-108, 156-166, 167-177, 179-194, 
203-214, 334-344 53 358 
36553.72 / 
7.30 39795 / 7.58 -- 
a
 
“Av. Ratio”- Average volume ratio and student’s t-test p value were derived from DeCyder analysis. A positive Av. Ratio signifies up-regulation and a negative value signifies down-regulation in terms of fold 
differences. Results are averaged over 3 independent experiments, unless otherwise stated. b “Acc. No.” represents accession numbers from UniProt database; Experimental Mr (Expt Mr) and theoretical Mr (Theor. Mr) 
are in Da. “Subcell. Loc.” Represents subcellular localisation documented in database and literature—“Mito”, for mitochondrial; “Perox”, peroxisomal; “Nu”, nuclear; “cyto”, cytosolic; “ER”, endoplasmic reticulum;  
“Ribo”, ribosomal; “Lyso”, lysosomal; “Cell Surface”, plasma membrane; “—”, unknown or yet to be specified. 
*Decyder results from 2 out of 3 batches, but expression trend is supported by another independent batch (4th) of DIGE analysis. θ Decyder results from 2 out of 3 batches. 
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3.3. BUTYRATE REGULATION OF MORTALIN EXPRESSION IN CRC 
CELLS  
One of the proteins which was significantly down-regulated by 24-hr, 5-mM 
butyrate treatment, in the mitochondrial fraction of HCT 116 cells, was mortalin, a 
mitochondrial chaperone (Spot no. 1346 in Figure 3.7; down-regulated 1.64 fold upon 
butyrate treatment with p value of 0.00097). An increased level of this protein has 
been reported in a variety of immortalised and tumour-derived cells and tissues, 
including colorectal adenocarcinomas and carcinomas (Dundas et al., 2005; Wadhwa 
et al., 2006; Widodo et al., 2007). Its contributing role to carcinogenesis is further 
highlighted by the fact that overexpression of mortalin could lead to increased 
malignancy of breast cancer cells (Wadhwa et al., 2006); while knocking it down 
resulted in senescence-like growth arrest in human immortalised cells (Wadhwa et al., 
2003a; Wadhwa et al., 2004). 
To elucidate the involvement of mortalin in butyrate-induced growth arrest 
and apoptosis of colorectal cancer cells in the third section of this study, we did the 
following:- 
(i) Characterisation of the mortalin isoforms expressed in HCT 116 whole-
cell and mitochondrial fractions 
(ii) Study of the effects of butyrate in the expression of HCT 116 mortalin 
isoforms. 
(iii) Study of butyrate regulation of mortalin in HT-29 — a cell line previously 
shown to be more resistant to butyrate anti-cancer effects, compared to 





3.3.1. Characterisation of mortalin isoforms in HCT 116 whole cell and 
mitochondrial fractions 
3.3.1.1. Mortalin isoforms detected at HCT 116 whole cell level 
Through the use of a commercially available monoclonal antibody raised 
specifically against mortalin, also known as 75 kD glucose regulated protein (GRP 
75),  we detected three mortalin isoforms (a, b, and c) on the 2-DE map of the HCT 
116 unfractionated whole cell lysate (Figure 3.9). The ids of these 3 protein spots 
were confirmed as mortalin by MS identification (data not shown). The pIs of the 
mortalin isoform a, b, and c were estimated—using the pH gradient graphs 
accompanying the IPG strips from GE Healthcare—to be approximately 5.5, 5.6 and 
5.7, respectively. They shared a common Mr of around 74 kD. According to the 
UniProt database, the theoretical values of Mr and pI of mortalin are 73.92 kD and 
5.87, respectively. Therefore, even though their Mr was close to the theoretical value, 
the HCT 116 mortalin isoforms had significantly more acidic pIs compared to the 
unmodified form of mortalin. These charge deviations possibly reflect post-
translational modifications such as varying degrees of phosphorylation of mortalin. 
In addition to the three mortalin spots, the commercial antibody had also 
detected other protein spots with a fainter signal (Figure 3.9C). These were verified 
by MS/MS to be not mortalin, but rather consisted mainly of other heat shock proteins 





































Figure 3.9: 2-DE profile of mortalin isoforms in HCT 116 whole cell lysate. 
A. Silver-stained 2-DE map of (untreated) HCT 116 whole cell lysate. 120 µg of proteins 
was focused on a pH 3-10 NL IPG strip before being separated on a 10% polyacrylamide 
gel. B. Zoomed-in area where the mortalin isoforms (depicted by blue arrow heads) were 
found on the 2-DE gel. C. The three differently charged isoforms of mortalin (a, b, and c) 
were transferred from the 2-DE gel area (enclosed by blue rectangle) and immunodetected 






3.3.1.2. Mortalin isoforms detected in HCT 116 mitochondrial fraction 
Western blotting of HCT 116 mitochondrial fractions detected at least five 
isoforms of mortalin (a, b, c, d, and e) in the same 2-DE gel region as the HCT 116 
whole cell lysates, where protein Mr was around 74 kD and pI, between 5.0 to 6.0 
(Figure 3.10). These have estimated pIs of 5.4 (d), 5.5 (a), 5.6 (b), 5.7 (c), and 5.8 (e). 
The ids of these five protein spots were confirmed as mortalin by MS identification 
(data not shown). Therefore, upon mitochondria enrichment, we detected at least two 
additional isoforms of mortalin, d and e, with pIs of 5.4 and 5.8, respectively (Figure 
3.11). There was also a concurrent significant enrichment of the isoforms a, b and c, 
as compared to the whole cell lysate fractions. 
As a side-note, many of the non-specific spots co-detected with mortalin 
previously in the whole cell lysate (Figure 3.9C), were noted to be enriched in the 
mitochondrial fraction (Figure 3.10C). These were verified by MS/MS and 
bioinformatics searches to be mitochondrial heat shock proteins such as chaperonin 
(mitochondrial HSP60) and mitochondrial associated cytoskeletal proteins such as 
keratin II cytoskeletal 8—predicted by PSORT to be mainly mitochondrial associated 








































Figure 3.10: 2-DE profile of mortalin isoforms in HCT 116 mitochondrial fraction. 
A. Silver-stained 2-DE map of (untreated) HCT 116 mitochondrial fraction. 120 µg of 
proteins was focused on a pH 3-10 NL IPG strip before being separated on a 10% 
polyacrylamide gel. B. Zoomed-in area where the mortalin isoforms (depicted by red arrow 
heads) were found on the 2-DE gel. C. The five differently charged isoforms of mortalin (a, 
b, c, d, and e) were transferred from the 2-DE gel area (enclosed by red rectangle) and 





























Figure 3.11: Enrichment of mortalin isoforms and presence of additional isoforms in 
HCT 116 mitochondrial fraction, relative to whole cell lysate. 
(From left to right) The three mortalin isoforms, a, b, and c were detectable in HCT 116 
whole cell lysate. These three isoforms were detected in higher abundance in the 
mitochondrial fraction where two additonal mortalin isoforms, d and e, were also present, 
flanking the original three. All five mortalin isoforms were visualised at the 74-kD region of 
the 2-DE HCT 116 mitochondrial proteome map as a horizontal trail. 
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3.3.2. Butyrate-induced changes in mortalin expression in HCT 116  
3.3.2.1. Butyrate regulation of mortalin isoforms at whole cell level 
The expression of mortalin isoforms in HCT 116 whole cell lysates showed 
detectable changes only at 48 hr butyrate treatment and beyond (Figure 3.12), 
contrary to that previously observed in the 2-D DIGE analyses of the mitochondrial 
fractions where butyrate induced significant down-regulation of at least one mortalin 
isoform within 24 hr treatment. There were also no significant down-regulation of the 
mortalin isoforms a, b, and c, at the whole cell level. In fact, observable changes at 48 
hr butyrate treatment showed the up-regulation of the extreme-pI isoforms, d and e, 
previously found only to be present in the mitochondrial fraction of HCT 116 cells. 
Hence, the previous trend of down-regulation of mortalin through 2-D DIGE is likely 
to only apply for the mitochondrial fraction, and does not indicate an overall decrease 
of mortalin level in the cell. 
At 72 hr butyrate treatment, over 50% of the HCT 116 cells were detached 
from the culture flask—a phenomenon associated with non-proliferating, apoptotic 
colonocytes experiencing loss of plasma membrane integrity (Clarke et al., 2000). To 
account for the difference in mortalin expression between these floating cells 
belonging to a later apoptotic phase, and those that were still attached to the flask, we 
harvested them as separate populations—‘floating’ and ‘adherent’. We noted that 
upon 72 hr incubation, mortalin isoform e was invariably up-regulated in control cells 
(mostly adherent) and the adherent population of butyrate-treated cells. Hence, it is 
likely that isoform e corresponded to a less specific stress response to the prolonged 
incubation of the cells with or without butyrate. 
On the other hand, we observed that the most negatively-charged mortalin 
isoform d was specifically up-regulated upon prolonged butyrate treatment and was 
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found in the apoptotic floating population. We hypothesise that this isoform was 

























Figure 3.12: Butyrate effects on the 2-DE profile of mortalin isoforms in HCT 116 
whole cell lysates. 
Immunoblots showing the 2-DE profiles of HCT 116 whole cell lysates of increasing 
periods of butyrate (NaB) treatment, in the region where the previously characterised 
mortalin isoforms were found (74 kD, pI 5.0-6.0). Differentially regulated mortalin 
isoforms are annotated with arrows.  
a b c a b c 
a b c a b c 
a b c a b c 
a b c a b c 
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3.3.2.2. Butyrate regulation of HCT 116 mitochondrial mortalin 
isoforms 
In contrast to butyrate regulation of mortalin in the whole cell lysates, there 
was an apparent down-regulation of all the mortalin isoforms in HCT 116 
mitochondrial fractions upon 24 hr of butyrate treatment, in particular, the isoforms d 
and e (Figure 3.13A). Since these isoforms coincide with those that were up-regulated 
in the whole-cell lysates upon prolonged treatment, they were most probably released 
from the mitochondria into the whole cell in response to butyrate and/or prolonged 
incubation stress. However, these two isoforms are likely to constitute a very small 
percentage of the total mortalin of the cell, such that their extra-mitochondrial build-
up in the whole cell lysates was only obvious at either 48 hr butyrate treatment, or 72 
hr incubation (Figure 3.12). These results were consistently reproduced in three 
independent experimental batches. Therefore, 24 hr butyrate treatment led to the 
overall decrease in mortalin expression in the HCT 116 mitochondrial compartment. 
Interestingly, the most drastic decrease was observed for mortalin isoform d which 
was previously associated with butyrate-induced apoptosis in the whole cell lysate 
fractions. 
3.3.2.3. Detection of serine and tyrosine phosphorylation in butyrate-
regulated mitochondrial mortalin isoforms 
We next used commercially available antibodies to ascertain the presence of 
phosphorylated serine (pSer) and tyrosine (pTyr) residues in the HCT-116 mortalin 
isoforms, so as to account for their more acidic pIs from that of the unmodified 
precursor. We detected the presence of pSer in mortalin isoforms a, b, c and, very 
minimally, in e (Figure 3:13B). In addition, there was a siginificant reduction of 
serine phosphorylation in isoforms a, c, and e, upon butyrate treatment. We also 
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detected the presence of pTyr in mortalin isoforms a, b, and c; and significant loss of 
tyrosine phosphorylation in these isoforms upon butyrate treatment (Figure 3:13C). 
Surprisingly the most negatively-charged isoform d did not seem to have any pSer 
and pTyr detectable by our assay. This can explained by two possibilities: (i) the 
negative charges on d are due largely to threonine phosphorylation (not included in 
our assay); (ii) other forms of regulation and modifications are responsible for its 
acidic pI. In summary, serine and tyrosine phosphorylation may have contributed in 
part to the horizontal migration of the mortalin isoform spots, but there could also be 



























Figure 3.13: Butyrate effects on the 2-DE profile of mortalin isoforms in HCT-116 
mitochondrial fractions 
 A. Immunoblots showing the 2-DE profiles of mortalin expressed in the HCT 116 
mitochondrial fractions 24 hr butyrate (NaB) treatment and control, in the region where 
these previously characterised isoforms were found (74 kD, pI 5.0-6.0). B. Immunoblots of 
HCT-116 mitochondrial fractions probed for phosphorylated serine residues (pSer). C. 
Immunoblots of HCT-116 mitochondrial fractions probed for phosphorylated tyrosine 
residues (pTyr). Regulated isoforms are annotated with arrows; red arrows indicate position 





3.3.2.4. Prediction of phosphorylation sites in mortalin 
Phosphorylation in mortalin has been detected in many studies and postulated 
to be a key mode of regulation of its functional activity and specificity (Mizzen et al., 
1991; Mizukoshi et al., 2001; Kanai et al., 2007). However, to date, only a small 
number of phosphorylation sites has been specifically characterised for this protein. In 
order to gain a better picture of the extent of alteration this protein can undergo 
through phosphorylation, we performed in silico prediction of the putative 
phosphorylation sites using the algorithms available on Scansite 
(http://scansite.mit.edu) and NetPhos (www.cbs.dtu.dk/services/NetPhos/).  
Scansite predictions showed 14 phosphorylation sites (Figure 3.14A), of 
which serine residue 200 (S200) has already been confirmed as a true phosphorylation 
site of DNA damage-triggered protein kinase ATR (Matsuoka et al., 2007). On the 
other hand, NetPhos predicted 29 serine, threonine and tyrosine phosphorylation sites, 
of which five were in common with Scansite’s, including S200. The predicted sites, as 
well as the empirically proven ones (S200, S65 and threonine 62—T62) are listed in 
Table 3.6. In total, there were 18 predicted pSer sites and 2 known ones; 10 predicted 
pThr and a known one; 7 predicted pTyr sites in the precursor (unprocessed) sequence 
of mortalin; as well as 3 other putative sites at isoleucine, valine and leucine residues. 
These could serve as potential sites for future investigation of possible regulatory 
phosphorylation accounting for the differently charged HCT 116 mortalin isoforms, 
































Figure 3.14: In silico prediction of phosphorylation sites in mortalin protein sequence 
(UniProt accession no. P38646). 
A. Scansite Motif Scan graphical output showing known domains (coloured rectangles with 
names labeled below) in mortalin, and motifs for putative phosphorylation sites (above). 
Underneath is a plot of the predicted accessibility at each residue (which is relative to the 
hydrophobicity of the regional amino acid sequence). B. NetPhos output showing mortalin 







Table 3.4 Found or predicted phosphorylation sites by NetPhos, Scansite                          




(NP#/SC*) Motif Group Name Prediction source / Reference 
Found / Predicted Phosphorylated Serine Residues (pSer) 
S29 0.794#  NetPhos 
S34 0.791#  NetPhos 
S42 0.996#  NetPhos 
S65 -- Mps1 kinase Kanai et al., 2007 




DNA damage kinase  
ATM kinase 
NetPhos; Scanscite;  
Matsuoka et al., 2007 
S321 0.768#  NetPhos 
S376 0.962#  NetPhos 
S378 0.956#  NetPhos 
S408 0.819#  NetPhos 
S469 0.786#  NetPhos 
S533 0.988#  NetPhos 
S550 0.613#  NetPhos 
S554 0.996#  NetPhos 
S627 0.863#  NetPhos 




Basophilic Ser/Thr kinase 
 (PKC δ) 
NetPhos; Scansite 
S657 0.996#  NetPhos 
S662 0.990#  NetPhos 
S664 0.926#  NetPhos 
Found / Predicted Phosphorylated Threonine Residues (pThr) 
T62 -- Mps1 kinase Kanai et al., 2007 




Basophilic Ser/Thr kinase 
(Calmodulin dependent kinase 2) 
NetPhos; Scansite 
T294 0.854#  NetPhos 
T347 0.4745* Basophilic Ser/Thr kinase 
 (PKC µ) 
NetPhos; Scansite 
T462 0.872#  NetPhos 
T463 0.5089* Basophilic Ser/Thr kinase (Calmodulin dependent kinase 2) 
Scansite 
T504 0.4309* Basophilic Ser/Thr kinase  (PKC µ) 
Scansite 




Acidophilic Ser/Thr kinase 
(Casein Kinase 2) 
NetPhos; Scansite 
T667 0.5279* DNA damage kinase  (DNA PK) 
Scansite 
Found / Predicted Phosphorylated Tyrosine Residues (pTyr) 
Y46 0.876#  NetPhos 
Y118 0.757#  NetPhos 
Y128 0.4713* Src homology 2  (Nck SH2) Scansite 
Y196 0.5409* Src homology 2  (Grb2 SH2) Scansite 
Y196 0.5771* Phosphotyrosine binding  (Shc PTB) Scansite 
Y568 0.954#  NetPhos 






(NP#/SC*) Motif Group Name Prediction source / Reference 
Other Predicted Phosphorylated Residues  
I58 0.6654* Kinase binding site  (Erk D-domain) Scansite 
V133 0.6688* Kinase binding site  (Erk D-domain) Scansite 
L298 0.6589* Kinase binding site  (Erk D-domain) Scansite 
#
 Scoring of putative site by NetPhos (NP); above 0.50 is significant 
*Scoring of putative site by Scansite (SC); scores closer to 0.00 reflect less divergence from optimal motif 
predicted 
Motif group names for are only given for Scansite predicted sites. 
‘S’-serine; ‘T’-threonine; ‘Y’-tyrosine; ‘I’-isoleucine; ‘V’-valine; ‘L’-leucine 
Residues in bold denote empirically proven phosphorylation sites to date. 
 
3.3.2.5. Butyrate effects on  mortalin level in HCT 116 subcellular 
fractions 
As noted, the significant decrease in mortalin isoforms d and e in the 
mitochondrial fractions were accompanied by their novel appearance in the whole cell 
lysates of HCT-116 cells, albeit with a time lapse of at least 24 hr. Thus, we 
hypothesise that these mortalin isoforms were translocated, rather than degraded, into 
other subcellular departments, possibly the nuclear or cytosolic, upon perturbation by 
butyrate. We next investigated butyrate regulation of mortalin in various subcellular 
compartments of HCT 116 cells, to better understand the effects of butyrate on the 
intracellular distribution of mortalin. 
Subcellular expression of mortalin was most significantly down-regulated in 
the HCT 116 nuclear fractions, as compared to the mitochondrial, cytosolic and whole 
cell lysates (Figure 3.15). As a side-note, the 74-kD mortalin was most abundantly 
expressed in the mitochondrial fraction of HCT 116 colon cancer cells, followed by 
the nuclear fraction where there was a significant enrichment of the mortalin band 
relative to the whole cell lysates. On the contrary, very little mortalin was detected in 
the HCT 116 cytosolic fraction. The purity of the HCT 116 nuclear and cytosolic 
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Figure 3.15: Subcellular distribution of mortalin and its regulation by 24 hr 
butyrate treatment in HCT 116 cells. 1-DE immunoblot showing the relative 
abundance of mortalin (74-kD) in the various subcelluar fractions of HCT-116. 5 µg of 
proteins were loaded per fraction and resolved on a 10% polyacrylamide, 8 cm by 6 cm, 
15-well, 1-D gel; proteins were then transferred onto a nitrocellulose membrane for 
probing with the antibodies against mortalin and the subcellular markers to show 
enrichment. Mr for target proteins are labeled. 
 WCL: whole cell lysates; MITO: mitochondrial; NU: nuclear; CYTO: cytosolic; C: control; T: treated. 
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3.3.2.6. Regulation of mortalin isoforms in HCT 116 nuclear fraction 
2-DE profile of the HCT-116 nuclear fractions (Figure 3.16A) showed similar 
distribution of the five mortalin isoforms, a, b, c, d, and e, to the mitochondrial 
fractions (Figure 3.13), rather than to the whole cell lysate (Figure 3.12). More 
importantly, there was a parallel trend of down-regulation of mortalin isoforms a, d, 
and e in the nuclear fraction upon butyrate treatment, with the most significant 
reduction in d and e. In fact, as in the case of the mitochondrial fraction, mortalin 
isoform d was no longer detectable in the nuclear fraction upon butyrate perturbation.  
3.3.2.7. Regulation of mortalin isoforms in HCT 116 cytosolic fraction 
2-DE profile of the HCT-116 cytosolic fractions (Figure 3.16B) showed the 
distinct pre-dominance of mortalin isoform b present in HCT 116 cytoplasm, unlike 
the previous fractions. We also noted that mortalin isoforms a, b and c were also 
significantly down-regulated upon butyrate treatment, in these fractions. Therefore, 
butyrate treatment was shown to down-regulate specific mortalin isoforms in the 
mitochondrial, nuclear, and cytosolic subcellular fractions; despite the consistent level 



























Figure 3.16: Expression of mortalin in HCT 116 nuclear and cytosolic fractions upon 
24 hr butyrate treatment.  
A. Immunoblots showing the 2-DE profiles of characterised mortalin isoforms in HCT 116 
nuclear fractions — 24 hr butyrate (NaB) treatment and control, in the region these isoforms 
were previously found (74 kD, pI 5.0-6.0). B. Immunoblots showing the 2-DE profiles of 
characterised mortalin isoforms in HCT 116 cytosolic fractions in the same region. 
Differentially regulated mortalin isoforms are annotated with arrows. For each fraction, 120 
µg of proteins were focused on a pH 3-10 NL IPG strip before being separated on a 10% 
polyacrylamide gel. Differentially regulated isoforms are annotated with arrows; red arrows 




3.3.3. Butyrate-induced changes in mortalin expression in HT-29 
3.3.3.1. Butyrate regulation on mortalin level in HT-29 subcellular 
fractions 
Paradoxical to its contributory role to carcinogenesis upon overexpression 
(Wadhwa et al., 2006); mortalin was later found to be highly expressed in cancer cells 
sensitive to drug-induced apoptosis, and to be a determinant for the outcome of 
treatment with various chemotherapeutic agents (Wadhwa et al., 2000; Um et al., 
2003; Widodo et al., 2007; Deocaris et al., 2007). In order to better understand the 
potential role of mortalin as a determinant of butyrate sensitivity in colon cancer cells, 
we studied the effects of butyrate on HT-29 colon adenocarcinoma cells—a cell line 
with a higher differentiation status than HCT 116 carcinoma—previously shown to be 
less sensitive to butyrate-induced apoptosis (Tan et al., 2002) and to gain chemo-
resistance upon prolonged incubation with butyrate (Kucerova et al., 2002). 
Interestingly, there were more pronounced alterations in mortalin levels of the 
various subcellular fractions of HT-29 upon 24 hr butyrate treatment (Figure 3.17). 
Similar to HCT 116, butyrate perturbation led to a common trend of decrease in 
mortalin abundance in the mitochondrial, nuclear and cytosolic fractions (in 
descending order of magnitude); and a corresponding increase of mortalin in the 
whole cell lysate (this time observable at 24 hr time-point). Significant enrichment of 
the HT-29 mitochondrial, nuclear and cytosolic fractions was demonstrated through 
the enrichment of PDH, lamin B and GAPDH respectively. It is noted that the nuclear 
fractions contained significant amounts of the mitochondrial marker, but nevertheless 




Upon butyrate treatment, intracellular distribution of mortalin changed 
similarly in both HCT 116 and HT-29 (from mitochondrial/ nuclear/ cytosolic to 
whole-cell, possibly ER); however these alterations occurred at greater magnitude in 
HT-29 which was supposedly less susceptible to the anti-cancer effect of butyrate. We 
next studied butyrate regulation of individual mortalin isoforms in HT-29 using 2-DE, 
so as to better ascertain the differences in mortalin expression between the two cell 






















Figure 3.17: Subcellular distribution of mortalin and its regulation by 24 hr 
butyrate treatment in HT-29 cells. 1-DE immunoblot showing the relative abundance 
of mortalin (74-kD) in the various subcelluar fractions of HT-29. 5 µg of proteins were 
loaded per fraction and resolved on a 10% polyacrylamide, 8 cm by 6 cm, 15-well, 1-D 
gel; proteins were then transferred onto a nitrocellulose membrane for probing with the 
antibodies against mortalin and the subcellular markers to show enrichment. Mr for  
target proteins are labeled. 




3.3.3.2. Butyrate-induced changes at HT-29 whole cell level 
The 2-DE profile of HT-29 whole cell lysates (Figure 3.18A) showed similar 
expression of the three mortalin isoforms a, b, and c, as compared to HCT 116 whole 
cell lysates (Figure 3.12). However, all three isoforms were up-regulated in HT-29 
upon 24 hr butyrate exposure, in contrast to HCT 116 where there was no significant 
up-regulation of mortalin isoforms until 48 hr treatment. Moreover, the significantly 
up-regulated isoforms in HCT-116 whole cell lysate after 48 hr butyrate treatment, 
were d and e, rather than a, b, and c. Therefore, butyrate induced the up-regulation of 
different mortalin isoforms in the two cell lines, at whole cell level. 
3.3.3.3. Butyrate-induced changes in HT-29 mitochondrial fraction 
HT-29 mitochondrial 2-DE proteome (Figure 3.18B) did not display the same 
distribution of the five differently charged mortalin isoforms a, b, c, d, and e, as HCT 
116 mitochondrial 2-DE proteome (Figure 3.13). The three mortalin isoforms a, b, 
and c were significantly enriched in HT-29 mitochondrial fractions, however there 
was only a slight trace of isoform e, while isoform d was not detected at all. 
Therefore, with respect to HCT 116, HT 29 mitochondria significantly lacked 
mortalin isoforms e and d, which were previously associated to prolonged incubation 
and butyrate-induced apoptosis, respectively. 
In addition, butyrate appeared to down-regulate mortalin isoforms a, b, and c 
more extensively in HT-29 mitochondrial fraction than in HCT-116. This observation 
was confirmed by a second independent experimental batch. In summary, HT-29 
mitochondrial fraction were found to predominantly express the mortalin isoforms, a, 





3.3.3.4. Butyrate-induced changes in HT-29 nuclear fraction 
Similar to HT-29 mitochondrial fraction, there was a significant lack in 
isoforms d and e in HT-29 nuclear fractions (Figure 3.18C), as compared to that of 
HCT 116 nuclear fractions (Figure 3.16A). Isoforms a, b, and c were all subjected to 
significant down-regulation by butyrate treatment, while the trace amount of isoform 
d completely disappeared. Therefore butyrate treatment very significantly down-
regulated the three dominant mortalin isoforms a, b, and c found in HT-29 nuclear 
fraction, just as in the case of HT-29 mitochondrial fraction (Figure 3.18B). 
HT-29 nuclear fraction expressed mortalin isoforms a, b, and c, as well as, a 
barely detectable amount of isoform d, rather than e. Even though mortalin isoforms d 
and e are co-expressed in both nuclear and mitochondrial compartments, as in the case 
of HCT 116; their exclusive localisation in HT-29 implies that d is likely to be more 
closely associated to the nucleus while e, to the mitochondria.  
3.3.3.5. Butyrate-induced changes in HT-29 cytosolic fraction 
Lastly, mortalin isoform b, as well as a trace amount of a, was detected in HT-
29 cytosolic fraction (Figure 3.18D). The predominance of b was reminiscent of 
HCT-116 cytosolic fraction (Figure 3.16B), thus this isoform could primarily reside in 
the cytoplasm and represent a cytosolic intermediate en-route to ER, or be involved in 
the retrograde movement of processed proteins between the cytosol and mitochondria, 
as suggested by Ran et al. (2000). Upon butyrate treatment, isoform b was very 
































Figure 3.18: Expression of mortalin in HT-29 whole-cell and subcellular fractions 
upon 24 hr butyrate treatment.  
Immunoblots showing the 2-DE profiles of characterised mortalin isoforms in HT-29 upon 
24 hr butyrate (NaB) treatment and control, in the region these isoforms were previously 
found (74 kD, pI 5.0-6.0): A. whole cell lysates; B. mitochondrial fractions; C. nuclear 
fractions; and D. cytosolic fractions. For each fraction, 120 µg of proteins was focused on a 
pH 3-10 NL IPG strip before being separated on a 10% polyacrylamide gel. Differentially 
regulated isoforms are annotated with arrows; red arrows indicate position of isoforms 
missing upon butyrate treatment. The results of the whole cell and mitochondrial fractions 







3.3.4. Differential regulation of mortalin isoforms in HCT 116 and HT-
29 upon butyrate treatment 
Hence, mortalin isoforms were down-regulated in all three subcellular 
fractions, namely mitochondrial, nuclear and cytosolic, of HCT 116 and HT-29; with 
a parallel, albeit not proportional, increase of these isoforms in the whole cell lysates. 
These changes occurred in greater magnitude in HT-29 than HCT 116 (Table 3.7). 
However, the mortalin isoforms d and e initially linked to the prolonged incubation 
stress and butyrate-induced apoptosis, respectively, were essentially missing in HT-
29. These differences in mortalin expression are possible factors underlying the 
difference in susceptibility of the two cell lines to butyrate’s anti-proliferative and 




















Table 3.5: Summary of the subcellular expression and butyrate regulation of mortalin isoforms in HCT 116 and HT-29 
HCT 116 colon carcinoma cells HT-29 colon adenocarcinoma cells 
WCL Mito Nu Cyto WCL Mito Nu Cyto Mortalin isoforms 
C T C T C T C T C T C T C T C T 
a (pI 5.5) ++ ++ +++ + ++ + + - + ++ ++ + +++ ++ + - 
b (pI 5.6) +++ +++ +++++ ++++ ++++ ++++ ++++ +++ +++ +++ ++++ +++ ++++ +++ ++++ ++ 
c (pI 5.7) ++ ++ ++++ +++ +++ +++ + - + ++ +++ ++ +++ ++ - - 
d (pI 5.4) - * ++ - + - - - - - - - + - - - 
e (pI 5.8) - * ++ + ++ + - - - - + - - - - - 
‘+’ is arbitrary unit denoting varying degree of mortalin expression : 
‘+’ – low expression; ‘++’ – significant expression; ‘+++’ –moderate expression; ‘++++’ – high expression; ‘+++++’ – very high expression 
‘-’ – absence 
‘*’ – expression upon longer incubation 
 WCL—whole cell lysates; Mito—mitochondrial; Nu—nuclear; Cyto—cytosolic; C—control; T—butyrate treatment 
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4.1. HCT 116 MTIOCHONDRIAL PROTEOME  
In our study, mitochondria from HCT 116 control and butyrate-treated cells 
were rapidly isolated through nitrogen disruption of the cells and two rounds of 
differential centrifugation. The nitrogen decompression technique employed, first 
saturated the cells with pressurized nitrogen before releasing the pressure to cause the 
nitrogen in the cells to come out of solution, forming bubbles that stretched and 
ruptured the plasma membrane (Brown et al., 2004). Unlike conventional 
homogenisation methods which often damaged the mitochondrial OM, this method 
was shown to be gentle; applicable to large sample volumes without generating heat 
or oxidation damage; and exposing the cells to the uniform disruptive action only 
once (Meisenholder, 2000). Our preliminary results (Table 3.1) indicated that this 
method was gentle enough to isolate intact mitochondria for subproteomics. 
4.1.1. Enrichment of mitochondrial proteome 
To assess the enrichment of the HCT 116 mitochondrial proteome, we 
monitored the enrichment of the PDH E1α subunit in our mitochondrial fractions as 
compared to the whole cell lysates (Figure 3.1). Since the PDH complex is present in 
low abundance in the mitochondrial matrix (estimated at 1 copy for every 200 copies 
of the respiratory-chain complex III in the human heart mitochondria) (Taylor et al., 
2003), it served as a specific marker for mitochondrial enrichment in our study. 
Secondly, our preliminary 2-D DIGE comparison of the Cy5-labelled 
mitochondrial fraction (red) and Cy3-labelled whole cell lysate (green) reflected 
significant reduction in sample complexity (Figure 3.2).  Many high-abundance 
proteins were removed from the whole cell lysate (~204 green spots), while many 
lower-abundance proteins were unmasked and enriched in the mitochondrial fraction 
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(~202 red spots). Subsequently, MS/MS analyses showed that 58 out of 69 2-DE red 
spots were mitochondrial in origin (Table 3.1). In addition, specific enrichment of 
low-abundance mitochondrial proteins was achieved in our fractions (Table 3.1). 
Overall, our enrichment achieved close to 50% specificity in terms of percentage of 
protein spots in the 2-DE profile identified to be well-characterised mitochondrial 
proteins (Table 3.2). This percentage is comparable to that of current 2-DE 
mitochondrial proteome studies (Gibson, 2005).  
 The use of a comparative proteomics tool to differentiate proteins which are 
selectively enriched in a subfraction from non-specific co-contaminants, has been 
applied in recent organellar proteomics studies through another technique in 
proteomics—isotope-coded affinity tag (ICAT) (Dunkley et al., 2004; Jiang et al., 
2005). Using ICAT, where samples were differentially labeled with isotope tags and 
analysed via LC-MS/MS, various research teams were able to assign proteins to 
specific organellar locations without having to obtain pure organelles. This was done 
by labeling the two subproteomes—either two different organellar proteomes that 
cross-contaminate each other (Dunkley et al., 2004), or a crude fraction versus a more 
purified one (Jiang et al., 2005)—with the respective isotope tags, and comparing the 
relative abundances of each protein in the fractions. In principle, proteins that are 
truly present in the organelle would be significantly enriched compared to the crude 
or cross-contaminating fraction, and thus, distinguishable from non-specific 
contaminants by statistical and bioinformatic tools (Andersen and Mann, 2006). 
 Our study demonstrated the feasibility of using 2-D DIGE, as an alternative to 
ICAT, in showing specific enrichment of proteins in a subcellular fraction, with 
respect to the crude fraction. Furthermore, the use of 2-DE also revealed the specific 
protein isoforms differentially expressed in each fraction. This is a significant 
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innovation in organellar proteomics because protein constituents of most organelles 
are in constant exchange with the rest of the cell and perturbation of the cell might 
change the subproteome within an organelle (Andersen and Mann, 2006). 
Nevertheless, the unequivocal localisation of a protein in an organelle should be 
demonstrated by follow-up studies using in situ detection methods like 
immunofluorescence and fluorescence tagging. 
4.1.2. 2-DE/MS/MS survey of HCT 116 mitochondrial proteome 
To our knowledge, this is the first 2-DE profiling performed for the 
mitochondrial proteome of HCT 116 colon cancer cell line. We found that many 
proteins in the HCT 116 mitochondrial proteome existed in multiple isoforms, such 
that the 90 distinct mitochondrial proteins identified in the fraction were actually 
represented by 141 different 2-DE spots (Figure 3.3; Table 3.2). This observation is 
consistent with the notion that the over 1000 mitochondrial proteins predicted from 
the human genome (MacDonald and Van Eyk, 2003) are likely to be even more 
diverse in structures and functional activities, as a result of differential regulation 
during transcription, translation and post-translational modifications (Fountoulakis et 
al., 2002). Since post-translationally modified targets would not be detected in a 
microarray, or be easily distinguishable in a shotgun LC-MS/MS analysis, 2-DE 
protein expression profiling is essential to identify and characterise such alterations to 
the mitochondrial proteins during perturbations, such as treatment with butyrate. 
Mitochondria play a central role in cancer cell metabolism and apoptosis. 
Given that proteins are the main workhorses to bring about the functional role of this 
crucial organelle in carcinogenesis, our survey of HCT-116 mitochondrial proteome 
could provide significant information of mitochondrial proteins associated with the 
metabolic imbalances and apoptosis resistance of colonic cancer cells. For example, 
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the presence of multiple isoforms of heat shock proteins, like chaperonin HSP60, 
mortalin mthsp70, and mitochondrial HSP75 (Table 3.2), indicated the likelihood of 
the overexpression of stress proteins during malignancy, to sustain mitochondrial 
metabolism and redox status in the midst of high cellular and environmental stress 
(Salvioli et al., 2003). In addition, the expression of VDAC isoform 2 (VDAC2) (Spot 
R181 Figure 3.3), an endogenous inhibitor of Bak activation and mediation of MOMP 
(Galluzzi et al., 2006), could be a mechanism by which HCT 116 cancer cells evade 
the intrinsic pathway of apoptosis. 
 
4.2. MITOCHONDRIAL PROTEOMICS OF BUTYRATE-TREATED  
HCT 116 
4.2.1. 2-D DIGE analysis of HCT 116 mitochondrial proteome changes 
upon butyrate treatment 
HCT 116 colon cancer cells carry K-ras mutation and are derived from 
primary human colonic carcinoma. This cell line is undifferentiated, CEA-expressing 
when established in vitro (Brattain et al., 1999) and has been a common model used 
to study carcinogenesis (Mohr and Illmer, 2005). These cancer cells have been shown 
to be tumourigenic in nude mice, with high metastatic potential (Brattain et al., 1981). 
HCT 116 cell cultures are also commonly used to study chemotherapeutic agents, 
such as HDACis (Tan et al., 2006). Particularly, these cells were shown to be highly 
susceptible to butyrate-induced growth arrest and apoptosis (Tan et al., 2002), with 
significant changes in the whole-cell and heparin-bound proteomes at just 24 hr post 
treatment (Tan et al., 2006). In addition, apoptosis of HCT 116 cells was 
demonstrated to be highly dependent on the mitochondrial pathway, such that 
inhibition of caspase 9 was sufficient to abrogate apoptosis initially triggered by death 
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receptors via the extrinsic apoptotic pathway in these cells (Ozoren and El-Deiry, 
2002). 
In this study, we analyzed the differential expression of mitochondrial proteins 
upon 5 mM butyrate treatment of HCT-116 colorectal carcinoma cells at 24 hr post-
treatment. Previous work by our lab has established the treatment duration of 24 hr as 
an early time point, before massive apoptosis takes place, so that we can detect 
changes in pathways involved rather than study endpoints of butyrate effects (Tan et 
al., 2002). The concentration of 5mM butyrate used is physiologically relevant and 
established for the study of anti-proliferative and differentiating effects of butyrate 
(Williams et al., 2003). This is the first time an unbiased, large-scale profiling is 
performed on the butyrate-perturbed colon cancer cell mitochondrial proteome. 
Butyrate-treated and control mitochondrial fractions from each experimental 
batch were labeled with spectrally resolvable dyes, and resolved on the same 2-DE gel 
for differential expression analysis by 2-D DIGE (Figure 3.6). Over 2000 
fluorescently labeled protein spots were detected by the DeCyder software. Ninety-
two spots were shown to be significantly regulated at 1.4 fold and above (student’s t-
test p<0.05) across three independent experimental batches. This low percentage 
(~5%) of modified proteins, consistent with our previous work (Tan et al., 2006), 
reflected the specificity of butyrate’s actions.  
According to our DeCyder analysis, there were 30 up-regulated protein spots 
compared to 62 down-regulated protein spots in the butyrate-treated HCT 116 
mitochondrial proteome (Figure 3.6). This reflected a predominant decreasing trend in 
the mitochondrial protein expression levels. This is contrary to the previous findings 
of Heerdt et al. (1996) who showed an elevation of the steady-state levels of 
mitochondrial mRNA species in HT-29 colon cancer cells upon prolonged butyrate 
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treatment. This thus highlighted the importance of proteomics, as a complementary 
approach, in the study of drug-induced changes in cancer cells. 
4.2.2. Butyrate-regulated mitochondrial proteins in HCT 116  
The 18 mitochondrial proteins found to be significantly regulated by butyrate 
(constituting 25 spots in Figure 3.7) include i) enzymes responsible for the metabolic, 
redox and OXPHOS activities in the organelle; ii) players of mitochondrial protein 
import and folding; iii) proteins facilitating mtRNA translation; and iv) proteins 
implicated in cell death (Table 3.3). The various proteome alterations reflect the 
multi-facet effects of butyrate on the HCT 116 mitochondria to bring about growth 
arrest and apoptosis; as well as the self-protective response of the cancer cell against 
this anti-cancer assault. We categorised them into functional groups so as to discuss 
the biological significance of their regulation by butyrate and lay ground for further 
studies. 
4.2.2.1. Oxidative metabolic enzymes 
Our 2-D DIGE analysis indicated that nearly half of the proteins altered upon 
butyrate treatment were metabolic and redox enzymes. These include players of the 
TCA cycle, fatty acid β-oxidation, amino acid metabolism, as well as redox regulation 
in the HCT 116 mitochondria. In general, the results support other findings that 
butyrate is capable of inducing extensive metabolic changes in cancer cells (Boren et 
al., 2003).  
For example, there was a general up-regulation of enzymes involved in 
producing the necessary reducing equivalents, NADH and FADH, needed for 
OXPHOS, upon 24 hr butyrate treatment. These include players of the TCA cycle, 
such as pyruvate carboxylase (PC), pyruvate dehydrogenase (PDH), pyrroline-5-
carboxylate dehydrogenase (P5CDH); proteins involved in β-oxidation of fatty acids 
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(e.g. short/branch-chain specific acyl-CoA dehydrogenase (SBCAD)); as well as, 
proteins playing a role in amino acid metabolism (e.g. ornithine aminotransferase 
(OAT)) (Spots 872, 2181, 1640, 2546 and 2549, as well as 2211 and 2256, 
respectively, Figure 3.7; Table 3.3). Recent proteomic studies showed the abnormally 
low expression of these enzymes in CRC tissues, compared to those involved in 
glycolysis which were increased (Mazzanti et al., 2006; Bi et al., 2006). Our data thus 
supports the notion that dysregulation of mitochondrial metabolic enzymes is a 
possible cause for the glycolytic metabolic profile of transformed cells which could in 
turn be reversed by butyrate. This metabolic correction could possibly attenuate 
tumour growth and invasion previously promoted by the Warburg’s effect (Kroemer, 
2006). 
4.2.2.2. Redox enzymes 
Our results also corroborate with literature supporting that butyrate induces 
oxidative stress through its effects on the metabolism of the cancer cell mitochondria 
(Giardina and Inan, 1998; Giardina et al., 1999). By modulating the expression of the 
various mitochondrial metabolic enzymes in HCT 116 cells, butyrate could, in turn, 
induce acute oxidative stress on the cancer cells and sensitise them to a variety of 
death signals. For instance, our DIGE data showed the up-regulation of two enzymes, 
P5CDH (1.54 fold) and OAT (1.77 and 1.85 fold) (Spots 1640, 2256 and 2211, 
respectively, Figure 3.7), whose combined actions are needed for the production of 
glutamate which can be subsequently converted to the TCA intermediate, α-
ketoglutarate (Figure 4.1). As indicated in Figure 4.1, the amino acid product, 
glutamate, can also lead to ROS production via the inhibition of antioxidant 
glutathione (GSH) uptake by the tumour mitochondria (Carretero et al., 2000). In vivo 
studies have shown that the selective depletion of mitochondrial GSH (mtGSH) 
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content in the cancer cells, but not normal cells, consequently rendered the tumour 
cells more susceptible to oxidative stress and tumour necrosis factor-α (TNF-α)-
induced cytotoxicity (Carretero et al., 2000; Obrador et al., 2001).  
Furthermore, butyrate has been reported to increase cellular peroxide (H2O2) 
generation in CRC cells upon its absorption and metabolism (Giardina and Inan, 
1998). Intracellular H2O2 accumulation caused by butyrate was subsequently shown to 
sensitise the host cells to apoptosis by the extrinsic pathway (Giardina et al., 1999). 
Interestingly, our data also showed the up-regulation of catalase (1.54 fold) (Spot 
1640, Figure 3.7) in the mitochondrial fraction. This antioxidant enzyme is usually 
found in the peroxisome but has been increasingly reported to be found in the 
mitochondria of tissues with high metabolic requirements and ROS production (Radi 
et al., 1991; Salvi et al., 2007). Hence the increase of catalase in the HCT 116 













Figure 4.1: Glutamate production by OAT and P5CDH 
The up-regulation of both OAT and P5CDH can lead to the concerted production of 
glutamate which can in turn be converted to TCA intermediate, α-ketoglutarate, or 
accumulate and cause mitochondrial GSH (mtGSH) depletion in the cancer cells. 
(Adapted from Haslett et al., 2004) 
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4.2.2.3. Respiratory chain complex subunits 
Even though we noted that butyrate treatment up-regulated metabolic enzymes 
needed for the production of OXPHOS substrates, the drug also concurrently down-
regulated various subunits of the OXPHOS respiratory complexes in the HCT 116 
mitochondrial proteome. In particular, we observed that butyrate down-regulated the 
largest subunit of the NADH-ubiquinone oxidoreductase, p75, by 1.51 fold (Spot 
1265, Figure 3.7). This subunit binds the iron-sulfur rings and is crucial for the 
functioning of the complex in NADH oxidation. The selective cleavage of p75 by 
caspases can lead to the disruption of the OXPHOS electron transport chain, loss of 
∆ψm, decline in ATP levels, H2O2 production and eventually, the loss of mitochondrial 
structural integrity (Ricci et al., 2004). In fact, cells expressing the noncleavable 
mutant p75 were resistant to ∆ψm dissipation and apoptotsis (Ricci et al., 2004). 
Hence, the down-regulation of p75 by butyrate may be a crucial player inducing HCT 
116 cell death via the intrinsic pathway of apoptosis.  
4.2.2.4. Players of apoptosis and cell death 
At 24-hr post butyrate treatment, we noted the elevated levels of hnRNP 
C1/C2, as well as a possibly truncated form of cathepsin B (CB) in the HCT 116 
mitochondrial fractions (Spots 2584 and 3157, respectively, Figure 3.7). Both of these 
proteins do not naturally occur in the mitochondria, but have been noted to be 
specifically translocated to the mitochondrial at the onset of apoptosis, or cell death 
(Thiede et al., 2002; Lee et al., 2004; Baici et al., 2006). In particular, CB was 
represented by the up-regulated Spot 3157 (Figure 3.7). This spot was estimated to 
have an Mr of 33 kD and pI of 5.3. These values correspond with the truncated form 
of CB that is specifically targeted to the mitochondria (Mr 32 kD; pI 5.48); rather than 
the original procathepsin B found in ER (Mr 39 kD; pI 5.88) (Mutener et al., 2004). 
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Unlike the normal CB, this isoform which is a product of alternate splicing of the 
mRNA transcript, is unfolded and carries no enzymatic activity. However, it is known 
to trigger nuclear fragmentation and cell death in human immortalised and cancer 
cells (Muntener et al., 2003). Hence, butyrate could possibly cause cell death through 
the up-regulation of these death-promoting factors in the mitochondrial proteome of 
HCT 116 cells. 
4.2.2.5. Members of the mitochondrial translation system 
Our comparative proteomic analysis of the HCT 116 mitochondrial proteome 
showed that butyrate also regulated proteins involved in the translation of 
mitochondrial proteins. These include the mitochondrial 39S ribosomal protein L49 
(MRP-L49) and hnRNP K (Spots 4358, and 1589 and 1604, respectively, Figure 3.7). 
Of greater interest is hnRNP K, a nucleic acid-binding protein recently shown to 
associate with multiple mitochondrial mRNA within the mitochondrial organelle 
(Ostrowski et al., 2002) and to be needed for insulin-induced expression of 
mitochondrial proteins (Ostrowski et al., 2004). Our DIGE data showed that hnRNP 
K was down-regulated at Spot 1604 (Mr 66 kD; pI 5.23) and correspondingly up-
regulated at Spot 1589 (Mr 67 kD; pI 5.16) which is more negatively charged (Figure 
3.7). This is a likely consequence of PTMs such as phosphorylation. Upon 
phosphorylation, hnRNP K has been demonstrated to lose its affinity to poly(C), 
which are cytosine ribonucleotide repeats, and be deactivated (Ostrowski et al., 2002). 
This in turn may modulate the translation of proteins controlled by this transducer, 
thus affecting the overall synthesis of mitochondrial proteins. 
4.2.2.6. Regulators of mitochondrial protein import and folding 
Another functional group of mitochondrial proteins most significantly 
regulated by butyrate, were those involved in the import and folding of newly 
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synthesised proteins into the organelle. These include mortalin (stress 70 
protein/mthsp70/GRP 75/PBP74), prohibitin, and the core subunit of the 
mitochondrial import receptor, translocase of outer membrane (TOM40)—all of 
which were down-regulated in the butyrate-treated mitochondrial proteome (Spots 
1346; 3065, 3101, 3196, and 3214; and 2359, Figure 3.7, respectively). For prohibitin, 
we observed the general down-regulation of 3 isoforms differing in masses (Spots 
3065, 3101, and 3214), accompanied by the up-regulation of another more negatively-
charged isoform (Spot 3196). These were likely to have resulted from PTMs induced 
by butyrate. 
Most mitochondrial proteins are encoded by the nuclear DNA, and synthesised 
in the cytosol, then targeted to the organelle by an N-terminal signal sequence. These 
are imported in an unfolded state into the mitochondrial matrix via the TOM and TIM 
complexes which form the contact sites for the mitochondrial OM and IM. 
Mitochondrial chaperones like mortalin (mthsp70), chaperonin (HSP60) and 
prohibitin are then involved in the folding and assembly of these nuclear-encoded 
proteins into mitochondrial complexes (Bourges et al., 2004). Prohibitin also forms 
part of the membrane-bound ring complex which functions as a quality check, 
delivering excess proteins to the AAA (ATPases associated with a number of cellular 
activities) proteases for degradation (Langer et al., 2001). Therefore, butyrate-induced 
changes in these key proteins are likely to impair the import and stabilization of newly 
synthesized mitochondrial proteins, in turn, causing mitochondrial destabilisation and 









4.3. BUTYRATE REGULATION OF MORTALIN EXPRESSION IN CRC 
CELLS 
One of the proteins significantly down-regulated by butyrate, in the HCT 116 
mitchondrial fractions, was mortalin (1.64 fold, p value of 0.00097, Table 3.3; Spot 
no. 1346 in Figure 3.7). Mortalin is a heat non-inducible homolog of the HSP70 
family of chaperone proteins and has been identified as the mitochondrial heat shock 
protein 70kD (mthsp70) (Wadhwa et al., 2002), peptide binding protein (PBP74) 
(Domanico et al., 1993), and glucose regulated protein (GRP75) (Webster et al., 
1994).  
Most importantly, the overexpression of human mortalin (hmot) has been 
consistently found in different cancers, especially CRC (Wadhwa et al., 2006). In 
fact, mortalin has not only been shown to be over-expressed by colorectal 
adenocarcinomas in tissue microarray studies, but its degree of over-expression has 
also been found to correlate positively with poor prognosis in the respective patients 
(Dundas et al., 2005). One of the most convincing evidences for the contributing role 
of mortalin to carcinogenesis was recently demonstrated by Wadhwa et al. (2006) 
who showed that the overexpression of mortalin was sufficient to increase the 
malignancy of breast carcinoma cells. 
Through our 2-D DIGE analysis, we showed that mortalin was down-
regulated in the mitochondrial fraction of the 24-hr 5-mM butyrate-treated HCT 116 
colon cancer cells. Butyrate is well-known for its anti-neoplastic actions and has been 
shown to act on the mitochondria to attenuate growth and survival of cancer cells 
(Heerdt et al., 1997). Hence, butyrate down-regulation of mortalin in the 
mitochondria could be an important mechanism of chemoprotection by this anti-
cancer agent. This novel finding is also clinically relevant and warrants further study 
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as mortalin had been discovered to be a prognostic marker for CRC patient survival 
(Dundas et al., 2005), and butyrate is also currently in clinical trials for the treatment 
of CRC (Bolden et al., 2006). Hence, to better ascertain and understand the role of 
mortalin in mediating butyrate-induced cancer cell growth arrest and death; we 
decided to characterize its isoforms and subcellular expression in control and 
butyrate-treated HCT 116 cells.  
4.3.1. Characterisation of 5 mortalin isoforms with differential 
subcellular expression in HCT 116 
Using 2-D immunoblots, we were able to detect at least five isoforms of 
mortalin with estimated Mr of 74 kD in the HCT 116 mitochondrial fractions (Figure 
3.10). We refered to them as mortalin isoform d, a, b, c, and e, with pIs at 5.4, 5.5, 
5.6, 5.7, and 5.8, respectively. The identities of these isoforms were confirmed to be 
mortalin through MS/MS sequencing. The results were validated in three independent 
experimental batches, thus we are confident that these modified forms of mortalin 
were not artifacts introduced during sample preparation. Furthermore, we showed the 
presence of phosphorylated residues as a likely cause for the charge differences in the 
isoforms present in the mitochondrial fraction, through immunodetection (Figure 
3.13) and bioinformatic predictions (Figure 3.14; Table 3.4). 
Recently, Osorio et al. (2006) detected up to four differently charged mortalin 
isoforms in a horizontal trail on 2-DE gel (specific pIs not reported), from the 
hippocampi of patients with Alzheimer’s disease (AD). Currently, this is the highest 
number of mortalin isoforms reported in human. Our study detected at least five 
distinct mortalin isoforms (a, b, c, d, and e) through the enrichment of the 
mitochondria of HCT 116 cancer cells (Figure 3.10). These isoforms were 
subsequently found enriched in the HCT 116 nuclear fraction too (Figure 3.16). 
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Hence, at least one of the mortalin isoforms has been newly uncovered by our 
mitochondria enrichment strategy. This highlights the significance of subcellular 
fractionation, not only to address the differential subcellular expression of mortalin, 
but also to unmask its minor isoforms, which may turn up to be crucial targets of drug 
regulation. 
4.3.1.1. Mortalin was present most abundantly in HCT 116 
mitochondrial fractions 
hmot resides primarily in the mitochondria where it is indispensable for 
mitochondrial import, chaperoning, and quality control (Yaguchi et al., 2007). While 
its cDNA sequence bears substantial similarity with other members of the HSP70 
family, it carries an extra N-terminal, 46-residue mitochondrial targeting sequence at 
the amino terminus (Bhattacharyya et al., 1995). In vitro assays showed that this 
sequence is sufficient for efficient import of mortalin into isolated mitochondria in a 
process dependent on ∆ψm (Webster et al., 1994). Our immunoblot results showed the 
preferential enrichment of mortalin in the mitochondrial fractions of HCT 116, 
consistent with its specific targeting to the organelle, even in a transformed cancer cell 
line. 
Mortalin has also been found to have diverse binding partners and to be 
associated with many different protein complexes within mitochondria. Examples 
include TIM subunits (Yaguchi et al., 2007), HSP58 (Mizzen et al., 1991); HSP60 
(Wadhwa et al., 2005); VDAC (Schwarzer et al., 2002); as well as respiratory 
complexes (Kim et al., 2006a). The specificity of its interactions is significantly 
regulated by PTMs, such as phosphorylation by its own auto-kinase activity (Mizzen 
et al., 1991), or by other regulatory kinases like DNA-dependent protein kinase 
(DNA-PK) (Um et al., 2003). In our study, we noted that specific enrichment of all 5 
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mortalin isoforms in the HCT 116 mitochondrial fractions, relative to the whole-cell, 
nuclear and cytosolic fractions (Figure 3.11 and 3.16). Phosphorylated serine and 
tyrosine residues (pSer and pTyr) were also detected in most of the mitochondrial 
mortalin isoforms (Figure 3.13). These observations reflect mortalin’s primary role as 
a chaperone in the organelle, as well as the different post-translationally modified 
isoforms of the protein needed to perform the mulitple functions. 
4.3.1.2.  Different mortalin isoforms were found in different 
subcellular fractions in HCT 116 cells 
Besides being an essential housekeeping protein in the mitochondria, mortalin 
also resides in multiple extra-mitochondrial locations depending on the phenotype of 
the cell (Wadhwa et al., 1994). In fact, more than 30% of cellular mortalin is 
consistently found distributed in non-mitochondrial sites such as the ER, endocytic 
vesicles, plasma membrane, nuclear membrane and cytoplasm (Wadhwa et al., 2002). 
Mortalin binds to different partners at each of these sites and, in turn, performs 
different activities and functions (Figure 4.2). For instance, mortalin binds to 
fibroblast growth factor-I (FGF-1) to facilitate intracellular trafficking in the cytosol 
(Mizukoshi et al., 1999); while it also binds to glucose regulated protein 94 (GRP94) 
to act as a co-chaperone for newly synthesised proteins in the ER (Takano et al., 
2001). 
In mice, the differential distribution of mortalin proteins have been accounted 
by 2 different cDNA sequences — the mot-1 and mot-2 alleles (Deocaris et al., 2006). 
These two distinctly localized murine mortalin isoforms have also been shown to have 
contrasting functions; the pancytosolic mot-1 protein can induce cellular senescence 
in mouse embryonic fibroblast cells, NIH 3T3 (Wadhwa et al., 1993), while the 
perinuclear mot-2 protein can induce malignant transformation in the same cells (Kaul 
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et al., 1998).  However, cloning of mortalin cDNA from various human cell lines with 
different patterns of mortalin distribution, yielded only one sequence (HSPA9B or 
hmot) distinct from both mot-1 and mot-2 (Kaul et al., 2007). The single hmot protein 
encoded localises in the multiple subcellular compartments and carries transforming 
activity similar to murine mot-2 (Kaul et al., 1998). Hence, unlike in mice, the 
differential distribution of the mortalin in human, is likely to arise from other forms of 
regulation at the post mRNA levels, such as PTMs.  
Our observation of the differential expression of mortalin isoforms in the 
various subcellular fractions supports the possible regulation of mortalin subcellular 
localisation by specific PTMs. Mortalin isoforms d and e were preferentially present 
in the mitochondrial and nuclear fractions respectively, while the more abundant 
isoforms, a, b, and c, appeared to be more ubiquitously expressed (Figure 3.11). The 
most highly expressed mortalin isoform b was the main isoform found in the cytosolic 
fractions. Thus, this isoform was likely to be the most freely circulating form of the 








































Figure 4.2: Summary of the multiple subcellular sites, binding partners and 
functions of mortalin. Mortalin has been found to serve diverse functions in different 
compartments of the cell besides its basic role in mitochondrial preprotein import. Astericks ‘*’ 
denote the various sucellular localisations and associated functions of mortalin currently known. 
The mitochondrial mortalin is also essential for stress defense, structural maintenance in the 
organelle (Kaul et al., 2007), and has also been found to interact with proteins associated with 
apoptosis and ROS regulation, like p53 (Marchenko et al., 2000); p66Shc (Orsini et al., 2004); 
VDAC (Schwarzer et al., 2002) and the oxidation-reduction respiratory complexes (Kim et al., 
2006a). In the ER, mortalin has been shown to be a co-chaperone with GRP94 (Takano et al., 
2001). Also, cytosolic mortalin has been shown to interact with FGF-1 for intracellular trafficking 
(Mizukoshi et al., 1999), and carboxyl terminus of Hsc70-Interacting protein with ubiquitous E3-
ligase activity (CHIP), for proteasomal degradation activities (Kaul et al., 2007). Mortalin is also 
an activator of mevalonate pyruvate decarboxylase (MPD) in peroxisomes (Wadhwa et al., 
2003b), a factor for interleukin-1 receptor (IL-1) internalization in the plasma membrane 
(Wadhwa et al., 2002), as well as an inactivator of p53 via cytoplasmic retention at the perinuclear 
region (Wadhwa et al., 1998). Most of these functions, if not all, have direct prosurvival impact on 
the host cell. 
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4.3.1.3. pSer and pTyr residues were detected mainly in mortalin 
isoforms a, b, and c. 
The minor mortalin isoform e was of pI 5.8, which was closest to the 
theoretical pI, 5.87, of the unmodified mortalin protein (Figure 3.10). The rest of the 
mortalin isoforms detected in HCT 116 mitochondrial fractions were significantly 
more negatively charged than the unmodified precursor protein. Such deviations in 
charges were likely to be caused by PTMs that confer negative charges with minimal 
Mr change, such as phosphorylation. Many findings have indicated that hmot is a 
specific target for tyrosine and serine phosphorylation inducible via growth signals 
(Lim et al., 2003; Vandermoere et al., 2007), oxidative stress (Hadari et al., 1997), 
and DNA damage (Matsuoka et al., 2007). The recent AD tissue study by Osorio et 
al. (2006) found a similar pattern of mortalin isoforms, separated by charge 
differences in a horizontal trail across the gel. Using phosphostaining, they showed 
that the isoforms were differentially phophorylated according to apolipoprotein E 
(APOE) genotype. Studies also showed that such PTMs in mortalin regulate the 
multiple functional activities of the protein and lead to phenotypic alterations such as 
enhancement of growth, cell motility and resistance to apoptosis (Mizukoshi et al., 
2001; Lim et al., 2004). 
To delineate the PTM(s) responsible for the various mortalin isoforms in HCT 
116, we probed for pSer and pTyr among them. We detected pSer and pTyr in the 
highly abundant isoforms a, b, and c (Figure 3.13). The low degree of 
phosphorylation in e may be explained by it being closest to the unmodified precursor 
in pI. More in-depth studies need to be done to identify the specific phosphorylated 
residues in these isoforms. Thereafter, functional assays may be designed, possibly 
using site-directed mutagenesis to knock down specific phosphorylated isoforms of 
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mortalin, so as to determine if these isoforms contribute functionally to the highly 
proliferative and apoptosis-resistant nature of colon cancer cells. 
Ironically, no pSer and pTyr were detected in the most negatively charged 
isoform, d. Subsequent bioinformatic predictions demonstrated that amino acid 
residues, such as threonine, valine, leucine and isoleucine, may be phosphorylated 
instead to give rise to the acidic pI of d (Table 3.4). In fact, one of the few 
phosphorylation sites of mortalin, characterised to date, is threonine 62, which, 
together with serine 65, can regulate mortalin binding and super-activation of Mps1 
kinase during centrosome duplication and mitotic checkpoint response (Kanai et al., 
2007). However the detection of the heat-labile pThr is usually not easy, and would 
require additional chemical modification for stabilization and enrichment of the 
residues (de Hoog and Mann, 2004).  
4.3.1.4.  Mortalin was found more abundantly in HCT 116 nuclear 
fraction compared to the cytosolic fraction 
As noted by many studies, the subcellular expression of mortalin is highly 
dynamic and closely linked to the mortal phenotype of the cell. Immunostaining has 
shown that, while normal human cells (mortal) display uniform pancytoplasmic 
distribution of the protein, transformed cells (immortalised) exhibit a perinuclear 
distribution of mortalin (Wadhwa et al., 1995). Furthermore, these two patterns of 
distribution can interchange according to the loss and gain in cancer characteristics of 
the cell, making mortalin a reliable marker for malignancy and cancer regression in 
research (Wadhwa et al., 1995). In humans, the association of perinuclear mortalin 
with cancerous characteristics has been most commonly related to its ability to bind to 
the cytoplasmic domain of p53 and block the entry of the latter into the nucleus, as a 
result, suppressing the TF’s transactivation of growth-suppressive and pro-apoptotic 
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signals (Wadhwa et al., 1998). In fact, the use of truncated p53 peptides, which 
contain only the cytoplasmic domain of p53, has been proven effective in displacing 
the endogenous p53 from mortalin and restoring the tumour suppressive effects of the 
TF in human bone and breast cancer cells (Kaul et al., 2005).  
Consistent with the finding that nuclear-associated mortalin is a hallmark of 
malignancy; all five mortalin isoforms we detected were more abundantly present in 
the nuclear fraction of HCT 116 cancer cells as compared to the cytosolic fraction 
(Figure 3.15). Since HCT 116 carcinoma cells carry the wild-type p53 gene, despite 
transition of the adenoma-carcinoma sequence in CRC (Bunz et al. 1998), they are 
likely to have developed other ways to inhibit this crucial tumour suppressor. Our 
observations support the hypothesis that cytoplasmic sequestration of p53 by 
perinuclear mortalin is a likely mechanism by which HCT 116 suppresses the 
transcription-dependent effects of p53 and bypass its deactivation during cancer 
progression. This hypothesis can be validated through the co-immunolocalisation of 
p53 and mortalin in the cell, mortalin knockdown studies with ribozymes (Wadhwa et 
al., 2003a), as well as, the use of truncated p53 peptides to release the mortalin-bound 
p53, which, if present, would then suppress cancer cell growth in HCT 116. The 
activity of mortalin represents a novel mechanism of p53 suppression in cancer cells, 
without genetic and epigenetic regulation. 
4.3.1.5.  Two mortalin isoforms, d and e, were preferentially present in 
both the HCT 116 mitochondrial and nuclear fractions 
The two least abundant mortalin isoforms, d and e, were found specifically in 
both the HCT 116 mitochondrial and nuclear fractions, and not the untreated whole 
cell lysate and cytosolic fraction (Figure 3.11 and 3.16).  They were also significantly 
more enriched in the mitochondria (Figure 3.11). This may have further implications 
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for mortalin’s role in the physical association between the mitochondria and nuclei of 
cancer cells—a hypothesis proposed previously by Wadhwa et al. (2002). 
Even though mortalin is commonly known as the heat non-inducible HSP70, 
this is found to be only half-true. While its expression level remains the same after 
heat shock, immunostaining revealed that pancytosolic mortalin was redistributed to 
the perinuclear pattern reminiscent of the transformed phenotype (Kaul et al., 1993). 
This response to heat shock is likely to be cytoprotective, with parallels drawn to 
similar re-distributions of the mitochondrial organelles upon heat shock treatment in 
chicken embryo fibroblasts (Collier et al., 1993) and upon virus infection of 
mammalian cells (Murata et al., 2000). In addition, mortalin was also shown to be 
essential for the distribution of these organelles in yeast cells along the microtubule 
network (Kawal et al., 2001). As mentioned during Introduction, the distribution and 
morphology of mitochondria have also been directly related to the metabolic 
phenotype in cancer cells (Alirol and Martinou, 2006). It is thus reasonable to relate 
the differential staining patterns of mortalin in different human transformed cells to 
the alteration of mitochondrial distribution in these cells (Wadhwa et al., 2002). 
Therefore, the 2-DE resolution of mortalin isoforms that specifically link the 
nucleus and mitochondria of the cancer cell is relevant and warrants further research 
in future. Specific antibodies can be raised against the two mortalin isoforms, d and e, 
while confocal fluorescence microscopy or immunoelectron microscopy may be 
employed, to study the exact localisation of these isoforms, within the intact cell. In 
this way, we can determine if these isoforms are specifically co-localised in the nuclei 
and mitochondria, representing some kind of cross-talk or interaction exclusively 
between the two organelles. 
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4.3.2. Butyrate effects on the mortalin level in HCT 116 subcellular 
fractions 
The 1-DE profile of HCT 116 subcellular fractions reflected no significant 
regulation in the overall expression level of mortalin upon 24-hr, 5-mM butyrate 
treatment, in the whole cell lysates and various subcellular fractions (Figure 3.15). 
The only exception was the nuclear fraction, where the 74-kD mortalin band was 
significantly decreased in the treated sample. Hence it was unlikely for butyrate to 
have affected the general expression of mortalin through transcriptional repression, in 
which case, there would be an overall decrease of mortalin level, even in the whole 
cell lysate. It is more likely that butyrate targeted specific subunits of mortalin and 
regulated them through PTMs and translocation of isoforms within the cell.  
4.3.3. Differential regulation of HCT 116 mortalin isoforms by butyrate 
The high resolution achieved in the 2-DE profiles of mortalin expression in the 
various subcellular fractions allowed us to look specifically at the five different 
mortalin isoforms and their individual regulation by butyrate (Figure 3.12, 3.13, and 
3.16). To date, this is one the few large-scale and most detailed studies of mortalin, in 
terms of its various isoforms, subcellular locations and differential regulation in 
human. A similar study was published recently by Osorio et al. (2006) who observed 
the differential regulation of four mortalin isoforms in the brain tissue of AD patients 
by the APOE genotype, via 2-DE proteomics. They also performed phosphostaining 
to show the differential phosphorylation in these isoforms. However, they did not look 
into the specific subcellular locations of these isoforms. 
On the other hand, the latest study by Wadhwa’s research team documented 
the level of mortalin expression in a large variety of tumour tissues and cell lines 
(Wadhwa et al., 2006). Nevertheless, the individual regulation and localisation of the 
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various mortalin isoforms were not addressed in their extensive study. As previously 
discussed, and summarised in Figure 4.2, mortalin is a highly versatile protein 
performing diverse functions that are mostly dictated by its specific PTMs and 
subcellular locations in the human cell (Wadhwa et al., 2002). According to our 
knowledge, this is the first unbiased study using proteomics to look at the individual 
regulation and distribution of the various mortalin isoforms in human cancer. 
4.3.3.1. HCT 116 mortalin isoforms were regulated by butyrate only at 
specific subcellular levels 
Even though our 2-D immunoblots did not show any obvious regulation of the 
mortalin isoforms detected in the unfractionated HCT 116 whole cell lysate (Figure 
3.12), mortalin isoforms in the various individual subcellular fractions were 
significantly regulated upon 24-hr butyrate treatment (Figure 3.13 and 3.16). More 
precisely, all the mortalin isoforms detected in the mitochondrial, nuclear and 
cytosolic fractions, were found to be significantly down-regulated by butyrate. 
However, each mortalin isoform was found to be down-regulated to different extents 
in the different fractions (results summarised in Table 3.5). This implies that more 
than one mechanism may be involved in the suppression of mortalin isoforms by 
butyrate in the various subcellular compartments examined.  
The levels of mortalin isoforms a, b, and c were unchanged at the whole cell 
level (Figure 3.12). This indicates that their reduction in the various subcellular 
fractions were not likely to be due to extensive degradation or transcriptional 
repression (Figure 3.13 and 3.16). They were more likely to be sequestered or re-
distributed into other subcellular compartments, such as the ER or plasma membrane, 
in response to butyrate treatment. In this way, there would be no net decrease of these 
isoforms in the unfractionated whole cell lysate, as observed in our immunoassays.  
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Hence, butyrate down-regulated the CRC-overexpressed protein, mortalin, 
specifically only in the mitochondrial, nuclear and cytosolic subcellular fractions. 
This observation highlights the diverse roles mortalin may play in the various 
subcellular sites of human cancer cells, such that re-distribution of the protein, rather 
than overall down-regulation upon butyrate treatment, could possibly result in anti-
tumoural effects. In addition, this also emphasised the indispensable role of 2-DE 
subproteomics in addressing the subcellular distribution and differential expression of 
the various isoforms of multifunctional proteins, as exemplified by mortalin. 
4.3.3.2. Re-distribution of mortalin isoforms d and e was detectable 
upon prolonged butyrate treatment 
Upon 48-hr butyrate treatment, we observed the appearance of mortalin 
isoforms d and e in the HCT 116 whole cell lysate. These isoforms were previously 
observed only in the mitochondrial and nuclear fractions (Figure 3.12). At 72-hr post 
treatment, we observed the significant up-regulation of isoform e in the control cells, 
and isoform d in the treated cells. The reappearance of these isoforms, previously 
observed to be down-regulated in the mitochondrial and nuclear fractions, further 
supports the notion that the butyrate-regulated mortalin isoforms were re-distributed 
to other subcellular compartments, rather than destroyed or transcriptionally 
repressed, upon butyrate perturbation. Since the re-distribution of mortalin has been 
closely linked to cancer regression (Wadhwa et al., 1995), our results showed that 
butyrate is likely to modulate the cancer characteristics of HCT 116 cells through 
mortalin re-distribution. 
The isoforms d and e were noted to be lost or drastically reduced in the HCT 
116 mitochondrial and nuclear fractions within 24 hours of butyrate treatment. Yet, 
the corresponding increases of these isoforms in the whole cell lysates were not 
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detected until 48 hours of butyrate treatment. This delay may be explained by the 
sequestration of these less abundant isoforms of mortalin in an intermediate 
subcellular compartment, such that they were undetectable during the time lapse. To 
confirm this, further investigations of butyrate-induced translocation of mortalin may 
be done using immunofluorescence where the protein can be visualised in the intact 
cell at specific intervals of treatment so as to track the re-distribution of the protein 
with respect to the various organelles, in response to the drug. 
4.3.3.3. Mortalin isoform d was specifically associated with butyrate-
induced cell death 
Upon 72-hr butyrate treatment, a significant percentage (over 50%) of the 
HCT 116 cells was detached from the culture flask. The floating cells were shown to 
be apoptotic in morphology and to exhibit ladders of cleaved DNA, whereas the 
remaining adherent cells were still surviving, or in the earlier phases of apoptosis 
(Heerdt et al., 1994).  By harvesting them as separate populations, we were able to 
observe the difference in mortalin expression between them (Figure 3.12). A selective 
increase in isoform e was detected in the adherent population of butyrate-treated HCT 
116 cells. This phenomenon was similar to the control cells. On the other hand, the 
floating population displayed specific increase in isoform d. This was previously 
observed in the 72-hr treated cells that were harvested with floating and adherent cells 
combined. It is likely that isoform e corresponded to a less specific stress response 
upon prolonged incubation of the cells with or without butyrate, while isoform d 
constituted a more specific effect of butyrate prevalent in treated cells undergoing 
drug-induced apoptosis.  
As previously noted, isoform d, found exclusively in the HCT 116 
mitochondrial and nuclear fractions, may be specifically displaced by butyrate 
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treatment (Figure 3.16 and 3.17). The decrease of this isoform in these fractions and 
its corresponding increase in the crude whole cell lysate possibly reflect its 
translocation from the mitochondria and nucleus to other compartments of the cell.  
As discussed earlier, a major role of perinuclear mortalin in cancer cell 
survival is the retention of p53 in the cytoplasm, at the perinuclear position, such that 
the TF cannot enter the nucleus and lead to transactivation of other tumour 
suppressors and pro-apoptotic genes (Wadwa et al., 1998). Hence the translocation of 
the specific mortalin isoform d upon butyrate treatment, suggests the possibility of 
butyrate-induced removal of the perinuclear mortalin to relieve p53 sequestration 
from the nucleus. In this way, a significant amount of the TF may be released to 
activate anti-cancer signals in the cells. This proposed mechanism of butyrate action 
can be verified through the detection of mortalin-p53 complexes in the peri-nuclear 
region of HCT 116 cells and their regulation by butyrate, via immuofluorescence and 
co-immunoprecipitation in the nuclear fraction. 
4.3.3.4. Butyrate preferentially down-regulated mortalin isoform d  in 
HCT 116 mitochondrial fraction 
The mortalin isoform d was even more significantly reduced in the HCT 116 
mitochondrial fraction, compared to the nuclear fraction, such that it was no longer 
detectable at 24 hr post butyrate treatment (Figure 3.13). This is the first time a 
mortalin isoform in the mitochondria was specifically linked to cancer, as most cancer 
studies to date focused on the perinuclear mortalin which is a well-known hallmark of 
cellular immortality and malignancy (Wadhwa et al., 1995; Kaul et al., 2005).  
In fact, all five of the mortalin isoforms found in the mitochondrial fraction 
were down-regulated by butyrate, with isoform d being most obviously so (Figure 
3.13). Besides its role in carcinogenesis, hmot is essential in mitochondrial protein 
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import and folding, as well as a guardian against stress and apoptosis (Kaul et al., 
2007). Protein translocation into the mitochondria is driven by both ATP hydrolysis 
and an electrochemical H+ gradient across the inner membrane.  While cytosolic 
chaperone proteins like HSP70 maintain the precursor proteins in an unfolded state 
for translocation, mortalin residing at the matrix side of the inner membrane is 
responsible for binding to the preproteins and pulling them into the mitochondrial 
matrix (Mizzen et al., 1991). In fact, mortalin composes the only ATPase component 
of the TIM complex and is indispensable for the energy-dependent import mechanism 
(Yaguchi et al., 2007). Therefore, butyrate suppression of mortalin expression in the 
mitochondria can have profound impact on the mitochondrial function and survival of 
the cancer cell. 
 As previously discussed, a major consequence of butyrate perturbation of 
cancer cells is the induction of ROS production and oxidative stress, as noted by 
previous studies (Giardina and Inan, 1998) and our DIGE results. Mortalin appears to 
play a major role in ROS-triggered mitochondrial apoptosis. Firstly, mortalin a major 
target of ROS and highly prone to deactivation by ROS-induced PTMs like oxidation 
and carbonylation (Yaguchi et al., 2007). Such PTMs have been demonstrated to be 
capable of abrogating the vital chaperone function of mortalin, leading to protein 
misfolding and aggregation, and eventually mitochondrial damage and death 
(Yaguchi et al., 2007). Similar to our findings, mortalin was shown to be 
preferentially decreased in the mitochondrial fractions of the cellular model of 
Parkinson’s disease (PD), which was established through rotenone-induced oxidative 
stress (Jin et al, 2006).  
 Secondly, the mitochondrial mortalin has been found associated with the 
p66Shc protein which is a critical component of the apoptotic response to oxidative 
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stress (Orsini et al., 2004). Upon oxidative stress or other death signals, monomeric 
p66Shc has been noted to dissociate from mortalin, and to induce the collapse of ∆ψm 
as well as the release of cyt c (Orsini et al., 2004). Hence, this is another possible 
mechanism by which butyrate may kill cancer cells through the down-regulation of 
specific mortalin isoforms in the HCT 116 mitochondria. Nevertheless, the 
understanding of the true role played by mortalin, in particular the isoform d, in 
butyrate-induced cancer cell apoptosis would require delineation of the specific PTMs 
involved, and residues targeted. Appropriate functional studies can then be designed, 
possibly through the knock-out of this isoform via site-directed mutagenesis, or 
specific inhibition of its activity, to further characterize the function of isoform d in 
butyrate actions. 
 All in all, these associations substantiate the emerging paradigm that the 
survival of cancer cells is highly dependent on the mitochondrial functions, especially 
in terms of metabolism and apoptotic resistance (Kroemer, 2006). In relation to this, 
our study of butyrate-treated mitochondrial proteomics has yielded some preliminary 
results suggesting that butyrate specifically targets mitochondrial mortalin isoforms, 














4.3.4. Comparison of butyrate regulation of mortalin in HCT 116 and 
HT-29 
HT-29 cell line, previously established from a colon adenocarcinoma of a 
female patient, carries mutations in the APC gene but not the K-ras gene (Brattain et 
al., 1999). It is commonly used as a model for studying butyrate action in colon 
cancer cells (Heerdt and Augenlicht, 1991). Treatment of HT-29 with butyrate often 
gives rise to dual responses of apoptosis and differentiation in the cell population and 
drug sensitivity of the cells will decrease with prolonged treatment (Kucerova et al., 
2002). Previously, our laboratory has shown that HT-29 was significantly less 
sensitive than HCT 116 cells to 5-mM butyrate treatment; with the latter showing at 
least 7 times more apoptotic cells at 24-hr post treatment (Tan et al, 2002). The 
relative chemo-resistance of this cell-line was demonstrated to be conferred partly 
through the sustained accumulation of HSP27, a cytoprotective response to prolonged 
butyrate treatment at 72 hr. To investigate the possible role of mortalin as in 
determining chemosensitivity to butyrate actions in these cell lines, we next studied 
the effects of butyrate on the subcellular expression of mortalin in HT-29, in 
comparison to HCT 116. 
4.3.4.1. Extensive down-regulation of subcellular mortalin isoforms 
was associated with resistance to butyrate-induced apoptosis 
The 1-DE immunoblot showed a significant increase in mortalin in the whole 
cell lysates of HT-29 at 24 hr butyrate treatment (Figure 3.17). Interestingly, down-
regulation of mortalin by butyrate was observed to be more significant in the 
subcellular fractions of HT-29 than HCT 116, when HT-29 was supposedly more 
resistant to butyrate-induced apoptosis and growth arrest. The subsequent 2-DE 
analyses of mortalin expression revealed that the three major isoforms of mortalin (a, 
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b, and c) were significantly down-regulated in butyrate-treated HT-29 mitochondrial, 
nuclear and cytosolic fractions (Figure 3.18). This raised three possibilities for the 
role of mortalin in butyrate-mediated chemotherapy:-  
(i) The down-regulation of mortalin from the mitochondrial and nuclear fractions 
was protective rather than detrimental to the survival of the cancer cell. 
(ii)  HT-29 exhibits other defense mechanisms to counteract the decrease in 
mortalin which is supposed to be a guard against mitochondrial sress and 
cellular senescence (Kaul et al., 2007). 
(iii) The specific mortalin isoforms targeted by butyrate, rather than overall 
abundance of mortalin, are the determinants of chemo-sensitivity. 
In support of (i), recent findings have shown that mortalin and other 
mitochondrial stress proteins could actually be important “sensitizers” to certain 
forms of chemotherapy. For instance, the up-regulation of stress chaperones, mortalin 
and Pex19p, was shown to render a cell more susceptible to anti-cancer DNA 
demethylating agent, 5-Aza-2’ deoxycytidine (5AZA-dC) (Widodo et al., 2007). 
Upon the drug-mediated demethylation and expression of tumour suppressor genes, 
these chaperones serve to stabilise the newly synthesized proteins (Widodo et al., 
2007). This may apply to butyrate, an HDACi, which also induces the expression of 
previously silenced genes.  
On the other hand, butyrate may also behave like the drug, MKT-077; a 
mitochondrion-seeking dye which can bind to mortalin to inactivate its chaperone 
function and cause “stress-induced premature senescence (SIPS)” in the cancer cell 
(Deocaris et al., 2007). These potential roles of mortalin in butyrate treatment suggest 
that the overexpression of mortalin could be a possible route of chemosensitization, 
and can be tested through over-expression studies. 
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4.3.4.2. HT-29 expressed only trace levels of mortalin isoforms d and e 
In contrast to HCT 116 fractions, the mortalin isoforms d and e were hardly 
detectable in the mitochondrial and nuclear fractions of HT-29 cells (Figure 3.18). 
Since these isoforms were specifically linked to the effects of butyrate on HCT 116 
cells (Figure 3.16), their absence in HT-29 fractions could play a significant role in 
determining the latter’s resistance to butyrate. In particular, the isoform d was 
associated with butyrate-induced apoptosis in HCT 116 cells, and thus a possible key 
factor of the cells’ susceptibility to butyrate. 
The differential expression of various mortalin isoforms was possibly linked to 
the varying stress levels in the two cancer cell lines. Recently, it has been noted that 
DNA mismatch repair (MMR) status may influence the anti-neoplastic effects of 
butyrate. In particular, physiological concentrations of butyrate are likely to have 
more potent effects in CRC cell lines with deficient MMR. HCT 116 cell line, with a 
deletion in MLH1, has been found to display enhanced sensitivity to butyrate 
compared to MMR-proficient cells like HT-29 (Coxhead et al., 2005). Hence, HCT 
116 cells are conceivably under greater stress accrued from the frequent mutations 
potentiated by genomic instability, compared to the genetically more stable HT-29 
cells. Mortalin belongs to the class of HSPs which serve as safeguards to maintain 
homeostasis and integrity of protein interactions. These molecular chaperones are 
often induced amidst the stressful conditions of clonal selection during tumour 
progression. It is thus likely that mortalin is subjected to more modifications and 
enlisted in more diverse roles for the tumour preservation in HCT 116 cells compared 
to the less aggressive cell line of HT-29. For instance, protein kinases like ATM and 
ATR are known to selectively phosphorylate mortalin in response to DNA damage 
signals, possibly to enhance its protective functions (Matsuoka et al., 2007). Hence, 
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mortalin isoforms d and e were possibly products of the higher state of stress in HCT 
116. While isoform e appeared to promote survival during prolonged culture and 
butyrate treatment, isoform d was specifically associated with apoptotic cells and 
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5. CONCLUSION AND FUTURE DIRECTIONS 
In summary, our comparative proteomics study of the HCT 116 mitochondrial 
proteome revealed multiple mitochondrial targets and pathways involved in the 
chemotherapeutic effects of butyrate in cancer cells (Figure 5.1). These were possible 
downstream effectors of butyrate’s HDACi action as well as its modulation of the 
metabolism and apoptotic resistance in cancer cells. The induction of oxidative stress 
and mitochondrial dysfunction appeared to be the apparent collective outcomes of 
these changes, and could be the main modes of action through which butyrate exerts 
its anti-tumorigeneic effects through the HCT 116 mitochondria.  
Nevertheless, functional verifications are necessary to validate the significance 
of each of these biochemical changes in the chemotherapeutic effects of buytrate. It is 
important to remember that the cancer cell is highly adaptable and mutable in its 
genetic expression and protein composition. Hence, the chemotherapeutic effects of 
butyrate can potentially trigger off self-protective mechanisms of the cell. There is a 
need to distinguish the direct effects of butyrate from the defensive responses of the 
cell as well as possible less specific side-effects, so as to ensure safe and efficacious 
use of the drug in future. 
Mortalin is one of the mitochondrial proteins found to be significantly 
regulated by butyrate in the HCT 116 subproteomes. Our study also suggests that 
different mortalin isoforms played different roles in the course of butyrate’s anti-
cancer effects; while the presence of an isoform (d) in the mitochondria and nucleus 
might correlate with sensitivity to butyrate-induced apoptosis in HCT 116 cells, the 
extensive down-regulation of the other three major isoforms (a, b, and c) in the 
nucleus, mitochondria and cytosol, could correlate with chemoresistence to the same 
candidate drug, in HT-29 cells. 
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In order to better ascertain the role of the various mortalin isoforms, we need 
to identify them by their specific PTMs and understand how they were being 
regulated through these chemical alterations. Besides phosphorylation, there were also 
other known PTMs which could play a part in regulating mortalin functions by 
butyrate, such as oxidation (Yaguchi et al., 2007) and lysine acetylation (Kim et al., 
2006b). However these were not readily detectable on 2-DE gels.  
PTMs like phosphorylation, lead to a slight mass increment relative to the 
molecular weight of the unmodified amino acid sequence of the protein. Currently, 
MS/MS based approaches are ideal for the systematic determination of the PTMs 
through peptide mapping (finding the peptides which carry the differential PTMs 
upon sequence specific digestion by proteases like trypsin), as well as peptide 
sequencing (identifying specific residue carrying the modification within the peptide) 
(Mann and Jensen, 2003). Since the fraction of peptide bearing a specific PTM can be 
a small fraction of the total amount of peptide present in a sample, steps may be taken 
for the enrichment of the modified peptides, for example by affinity purification 
through the use of antibodies or special tags (de Hoog and Mann, 2004).  
By knowing the specific sites and types of PTM that give rise to the different 
mortalin isoforms regulated by butyrate, we can possibly perform site-directed 
mutagenesis of the specific amino acid residue(s) involved. This could possibly knock 
down the specific isoform and allow us to look into its effect on cell response to 
butyrate treatment. In this way, we can better understand the functional role these 
modifications play in butyrate regulation. In addition, it would be interesting to find 
out if butyrate directly acts on the molecular chaperone and affects its function. This 
can be done using stable isotope labeled butyrate (Boren et al., 2003) and the 
detection of the small molecule binding to mortalin in a pull-down assay. 
Conclusion and Future Directions 




Lastly, functional assays can also be performed to confirm the role of mortalin 
in butyrate-induced apoptosis. Specific targeting sequences can be expressed in the 
recombinant mortalin, so as to specifically target the protein to the organelle of 
interest. However, care needs to be taken to ensure no conformational interference is 
introduced by the tag. The use of fluorescence tags may also allow real time tracking 



















Figure 5.1: Summary of butyrate’s effects in HCT 116 mitochondrial 
proteome. Butyrate can work through HDAC inhibition (i) and altering the cancer cell 
metabolism (ii) to increase enzymes needed for metabolic activities like TCA cycle, fatty 
acid β-oxidation and glutamate production; ROS production; as well as translocation of 
death factors to the mitochondrial organelle (iiia). Conversely, it also causes a decline in 
proteins needed for OXPHOS, protein import, mtRNA translation and chaperoning in the 
organelle. These may then cross-talk with other modes of action of butyrate and culminate 
in growth arrest and killing of the cancer cells. 
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